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The brevianamides are a family of molecules produced by Penicillium and Aspergillius fungi. 
They have a wide range of biological activities and possess complex molecular structures. Despite 
numerous attempts over many decades, chemists have been unable to make many of these 
molecules in the laboratory. 
 
Mimicking the processes Nature uses to make a molecule can enable an exceptionally efficient 
chemical synthesis. We used the biological synthesis of the brevianamides as the strategic basis 
for our attempts to make them in the laboratory. While we don’t have access to the powerful 
biosynthetic machinery Nature uses to control chemical reactions, many complex transformations 
used in Nature reflect the innate chemical reactivity of the molecule. Our goal was to develop a 
biomimetic (inspired by Nature) chemical synthesis of the brevianamides and gain insight into the 
chemistry used by the fungus. 
 
This thesis describes our biomimetic synthetic investigations, which culminated in the synthesis 
of several of these complex molecules. These syntheses shed light on how these molecules are 
made in Nature and were enabled by a substantially improved synthesis of key intermediates, 










The brevianamides are a family of fungal derived prenylated indole alkaloids. Their range of 
complex structures are accompanied by a diverse array of biological activity. The brevianamides 
were the first reported examples of the wider bicyclo[2.2.2]diazaoctane class of natural products, 
which have been of continued interest due to their impressive polycyclic structures and the 
potential role of Diels–Alderase enzymes in their biogenesis. Despite prolonged synthetic attention, 
several important brevianamides have yet to succumb to total synthesis and many aspects of their 
biosynthesis remain unclear. This thesis describes our biomimetic synthetic studies towards these 
complex natural products, which has resulted in several short and efficient total syntheses. These 
syntheses have been enabled by a substantially improved synthesis of key intermediates, which 







Table of Contents 
Declaration....................................................................................................................................... i 
Acknowledgements ....................................................................................................................... iii 
Lay Summary .................................................................................................................................. v 
Abstract ......................................................................................................................................... vii 
Abbreviations ................................................................................................................................ xv 
Important Structural Motifs ................................................................................................... xviii 
Introduction ..................................................................................................................................... 1 
Introduction to the Brevianamides .............................................................................................. 1 
Isolation of the Brevianamide Alkaloids ..................................................................................... 3 
Identification of a Diels–Alderase in the Biosynthesis of the Monooxopiperazine Alkaloid 
Premalbrancheamide (35) ............................................................................................................ 8 
Brevianamide A (1) and B (2) ................................................................................................... 10 
Previous Syntheses of Brevianamide B (2) ............................................................................... 22 
Brevianamide X (16) and Y (17) ............................................................................................... 28 
Proposed Biosynthesis of Brevianamide X (16) and Y (17) ..................................................... 32 
Previous Syntheses of Notoamide B (32) and Versicolamide B (33) ....................................... 35 
Brevianamide J (20) and S (21) ................................................................................................. 39 
Aims – A Unified (Bio)synthetic Proposal for the Brevianamide Alkaloids ............................ 42 
Chapter 1: Synthesis of Dehydrodeoxy-brevianamide E (58) ....................................................... 45 
Synthetic Plan for Dehydrodeoxy-brevianamide E (58) ........................................................... 45 
Synthesis of Prenylated Indole 145 ........................................................................................... 48 
Model Studies Towards the Synthesis of N-acyl-enamine 148 ................................................. 50 
Hydrolysis of Methyl Ester 145 ................................................................................................ 52 
Synthesis of N-Acyl Enamine 148 ............................................................................................ 54 
Phthaloyl Deprotection to Give Dehydrodeoxy-brevianamide E (9) ........................................ 56 
Scaled Up Total Synthesis of Dehydrodeoxy-brevianamide E (9) ............................................ 57 
Chapter 2: Towards a Synthesis of Brevianamide J (20) and Brevianamide S (21) ..................... 59 
Oxidative Coupling of Enolate Equivalents .............................................................................. 59 
Oxidative Coupling Attempts with Dehydrodeoxy-brevianamide E (9) ................................... 62 
Indole Protection Attempts ........................................................................................................ 65 
Early Stage Coupling of Dehydro-proline 147 .......................................................................... 68 
Oxidation of Dehydrodeoxy-brevianamide E (9) – Radical Conditions ................................... 73 
Synthesis of Brevianamide K (10)............................................................................................. 74 
N-Acyl-enamine Oxidation of Dehydrodeoxy-brevianamide E (9) .......................................... 77 
Reductive Dimerisation of Compound 227 ............................................................................... 79 
Attempts Towards Total Synthesis of Brevianamide S (21) ..................................................... 82 
Chapter 3: Total Synthesis of Brevianamide X (16) and Y (17) ................................................... 87 
Total Synthesis of Brevianamide X (16) ................................................................................... 87 
x 
 
Total Synthesis of Brevianamide Y (17) .................................................................................. 91 
Chapter 4: Total Synthesis of Brevianamide A (1) ...................................................................... 97 
Synthesis of Dehydro-brevianamide E (71) ............................................................................. 97 
Investigations Towards Brevianamide A (1) .......................................................................... 103 
Optimisation of Brevianamide A (1) Synthesis ...................................................................... 115 
Scale Up – Completion of Brevianamide A (1) Synthesis ..................................................... 119 
Conclusions and Future Work .................................................................................................... 125 
Dehydrodeoxy-brevianamide E (9) ........................................................................................ 126 
Brevianamide J (20) and S (21) .............................................................................................. 127 
Brevianamide X (16) and Y (17) ............................................................................................ 130 
Brevianamide A (1) and B (2) ................................................................................................ 132 
Experimental ............................................................................................................................... 135 
General experimental conditions ............................................................................................ 135 
Total Synthesis of Brevianamide A (1) and B (2) ...................................................................... 137 
Experimental Procedure for Compound 143 .......................................................................... 137 
Experimental Procedure for Compound 145 .......................................................................... 138 
Experimental Procedure for Compound 164 .......................................................................... 139 
Experimental Procedure for Compound 148 .......................................................................... 140 
Experimental Procedure for Dehydrodeoxy-brevianamide E (9) ........................................... 142 
Experimental Procedure for Dehydro-brevianamide E (71) and Compounds dia-71 and 254
 ................................................................................................................................................ 143 
Experimental Procedure for (+)-Brevianamide A (1) and B (2) ............................................. 147 
Experimental Procedure for (–)-brevianamide A (1) and B (2) ............................................. 151 
Experimental Procedures for Reagents ....................................................................................... 152 
Experimental Procedure for Compound 147 .......................................................................... 152 
Experimental Procedure for 1,1-Dimethylallene 152 ............................................................. 153 
Experimental Procedure for B-prenyl-9-BBN 155 ................................................................. 154 
Experimental Procedure for t-BuOCl ..................................................................................... 155 
Experimental Procedures for Other Compounds ........................................................................ 156 
Experimental Procedure for Compound 149 .......................................................................... 156 
Alternative Experimental Procedure for Compound 143 ....................................................... 157 
Experimental Procedure for Compound 156 .......................................................................... 158 
Experimental Procedure for Compound 158 and 159 ............................................................ 159 
Experimental Procedure for Compound 161 .......................................................................... 162 
Experimental Procedure for Compound 182 .......................................................................... 163 
Experimental Procedure(s) for Compound 194 ...................................................................... 165 
Experiment 1 ....................................................................................................................... 165 
Experiment 2 ....................................................................................................................... 165 
Experimental Procedure for Compound 206 .......................................................................... 167 
Experimental Procedure for Compound 207 .......................................................................... 168 
xi 
 
Experimental Procedure for Compound 212 ........................................................................... 169 
Experimental Procedure for Compound 213 ........................................................................... 170 
Experimental Procedure for Compound 227 ........................................................................... 171 
Experimental Procedure for Compound 131 ........................................................................... 172 
Experimental Procedure for Brevianamide K (10) .................................................................. 173 
Experimental Procedure for Compound 239 ........................................................................... 174 
Experimental Procedure for Compounds 56 and 109 .............................................................. 175 
Experimental Procedure for Brevianamide X (16) .................................................................. 177 
Experimental Procedure for ‘Depyrano-sclerotiamide’ (235) ................................................. 178 
Experimental Procedure for Compounds 113 and dia-113 ..................................................... 179 
Experimental Procedure for Brevianamide Y (17) .................................................................. 181 
Experimental Procedure for Compounds ent-261 and ent-74 ................................................. 183 
Appendix 1: Previous Syntheses of Brevianamide B (2) ............................................................ 185 
Williams’ synthesis of (−)-brevianamide B (2) (1988) ........................................................... 185 
Williams’ first biomimetic synthesis of (±)-brevianamide B (2) (1998) ................................. 186 
Williams’ synthesis of (±)-brevianamide B (2) (2006) ........................................................... 187 
Williams’ second biomimetic synthesis of (±)-brevianamide B (2) (2007) ............................ 188 
Simpkins’ synthesis of (–)-brevianamide B (2) (2009) ........................................................... 190 
Scheerer’s first formal synthesis of (±)-brevianamide B (2) (2016) ....................................... 191 
Scheerer’s second formal synthesis of (±)-brevianamide B (2) (2017) ................................... 192 
Appendix 2: Chiral HPLC Chromatograms ................................................................................ 193 
Appendix 3: X-ray Crystal Structure (+)-Brevianamide A (1) ................................................... 199 
Appendix 4: Optimisation of Chromatography Conditions ........................................................ 201 
Appendix 5: NMR Spectra .......................................................................................................... 203 
1H NMR of Compound 143 (500 MHz, CDCl3) ..................................................................... 203 
13C NMR of Compound 143 (126 MHz, CDCl3) ................................................................... 203 
1H NMR of Compound 145 (600 MHz, CDCl3) ..................................................................... 204 
13C NMR of Compound 145 (151 MHz, CDCl3) .................................................................... 204 
1H NMR of Compound 164 (500 MHz, CD3OD) ................................................................... 205 
13C NMR of Compound 164 (126 MHz, CD3OD) .................................................................. 205 
1H NMR of Compound 148 (500 MHz, CD2Cl2) .................................................................... 206 
13C NMR of Compound 148 (151 MHz, CD2Cl2) ................................................................... 206 
1H NMR of Dehydrodeoxy-brevianamide E (9) (500 MHz, CDCl3) ...................................... 207 
13C NMR of Dehydrodeoxy-brevianamide E (9) (126 MHz, CDCl3) ..................................... 207 
1H NMR of Dehydro-brevianamide E (71) (500 MHz, CDCl3) .............................................. 208 
13C NMR of Dehydro-brevianamide E (71) (126 MHz, CDCl3) ............................................. 208 
1H NMR of Compound dia-71 (500 MHz, CDCl3) ................................................................. 209 
13C NMR of Compound dia-71 (126 MHz, CDCl3) ................................................................ 209 
1H NMR of Compound 254 (601 MHz, CDCl3) ..................................................................... 210 
xii 
 
13C NMR of Compound 254 (151 MHz, CDCl3) ................................................................... 210 
1H NMR of Brevianamide A (1) (500 MHz, CDCl3, ~3.0 mg/mL) ........................................ 211 
13C NMR of Brevianamide A (1) (126 MHz, CDCl3, ~3.0 mg/mL) ...................................... 211 
1H-1H COSY of Brevianamide A (1) (CDCl3) ....................................................................... 212 
1H-13C HSQC of Brevianamide A (1) (CDCl3) ...................................................................... 212 
1H-13C HMBC of Brevianamide A (1) (CDCl3) ..................................................................... 213 
1H-1H NOESY of Brevianamide A (1) (CDCl3)..................................................................... 213 
1H NMR of Brevianamide A (1) (500 MHz, CDCl3 - concentration dependence) ................ 214 
1H NMR of Brevianamide A (1) (500 MHz, (CD3)2SO) ........................................................ 215 
13C NMR of Brevianamide A (1) (126 MHz, (CD3)2SO) ....................................................... 215 
1H-1H COSY of Brevianamide A (1) ((CD3)2SO) .................................................................. 216 
1H-13C HSQC of Brevianamide A (1) ((CD3)2SO) ............................................................... 216 
1H-13C HMBC of Brevianamide A (1) ((CD3)2SO) ................................................................ 217 
1H-1H NOESY of Brevianamide A (1) ((CD3)2SO) ............................................................... 217 
1H NMR of Brevianamide B (2) (500 MHz, CDCl3) ............................................................. 218 
13C NMR of Brevianamide B (2) (126 MHz, CDCl3) ............................................................ 218 
1H NMR of Brevianamide B (2) (500 MHz, (CD3)2SO) ........................................................ 219 
13C NMR of Brevianamide B (2) (126 MHz, (CD3)2SO) ....................................................... 219 
1H-1H COSY of Brevianamide B (2) ((CD3)2SO) .................................................................. 220 
1H-13C HSQC of Brevianamide B (2) ((CD3)2SO) ................................................................. 220 
1H-13C HMBC of Brevianamide B (2) ((CD3)2SO) ................................................................ 221 
1H-1H NOESY of Brevianamide B (2) ((CD3)2SO) ............................................................... 221 
1H NMR of Compound 272 (500 MHz, (CD3)2SO) ............................................................... 222 
13C NMR of Compound 272 (126 MHz, (CD3)2SO) .............................................................. 222 
1H NMR of Compound 147 (500 MHz, CDCl3) .................................................................... 223 
13C NMR of Compound 147 (126 MHz, CDCl3) ................................................................... 223 
1H NMR of 3-Chloro-3-methyl-1-butyne 151 (500 MHz, CDCl3) ........................................ 224 
13C NMR of 3-Chloro-3-methyl-1-butyne 151 (101 MHz, CDCl3) ....................................... 224 
1H NMR of 1,1-Dimethylallene 152 (500 MHz, CDCl3) ....................................................... 225 
13C NMR of 1,1-Dimethylallene 152 (151 MHz, CDCl3) ...................................................... 225 
1H NMR of t-BuOCl (500 MHz, CDCl3) ............................................................................... 226 
13C NMR of t-BuOCl (126 MHz, CDCl3) .............................................................................. 226 
1H NMR of Compound 149 (400 MHz, (CD3)2SO) ............................................................... 227 
13C NMR of Compound 149 (126 MHz, (CD3)2SO) .............................................................. 227 
1H NMR of Compound 156 (500 MHz, CDCl3) .................................................................... 228 
13C NMR of Compound 156 (126 MHz, CDCl3) ................................................................... 228 
1H NMR of Compound 159 as a Major Constituent (500 MHz, CDCl3) .............................. 229 
13C NMR of Compound 159 as a Major Constituent (126 MHz, CDCl3) .............................. 229 
1H-1H COSY of Compound 159 as a Major Constituent ((CD3)2SO) .................................... 230 
xiii 
 
1H-13C HSQC of Compound 159 as a Major Constituent ((CD3)2SO) ................................... 230 
1H-13C HMBC of Compound 159 as a Major Constituent ((CD3)2SO) .................................. 231 
1H NMR of Compound 158 (600 MHz, CDCl3) ..................................................................... 232 
13C NMR of Compound 158 (151 MHz, CDCl3) .................................................................... 232 
1H NMR of Compound 161 (500 MHz, CD3OD) ................................................................... 233 
13C NMR of Compound 161 (126 MHz, CD3OD) .................................................................. 233 
1H NMR of Compound 182 (600 MHz, CD3CN) ................................................................... 234 
13C NMR of Compound 182 (126 MHz, CD3CN) .................................................................. 234 
1H-1H COSY of Compound 182 (CD3CN) ............................................................................. 235 
1H-13C HSQC of Compound 182 (CD3CN) ............................................................................ 235 
1H-13C HMBC of Compound 182 (CD3CN) ........................................................................... 236 
1H NMR of Compound 194 (500 MHz, CD3CN) ................................................................... 237 
13C NMR of Compound 194 (126 MHz, CD3CN) .................................................................. 237 
1H NMR of Compound 206 (500 MHz, CDCl3) ..................................................................... 238 
13C NMR of Compound 206 (126 MHz, CDCl3) .................................................................... 238 
1H NMR of Compound 207  (601 MHz, CHCl3) ..................................................................... 239 
13C NMR of Compound 207 (151 MHz, CDCl3) .................................................................... 239 
1H NMR of Compound 212 (500 MHz, CDCl3) ..................................................................... 240 
13C NMR of Compound 212 (126 MHz, CDCl3) .................................................................... 240 
1H NMR of Compound 213 (601 MHz, CDCl3) ..................................................................... 241 
13C NMR of Compound 213 (151 MHz, CDCl3) .................................................................... 241 
1H NMR of Compound 227 (500 MHz, CDCl3) ..................................................................... 242 
13C NMR of Compound 227 (126 MHz, CDCl3) .................................................................... 242 
1H NMR of Compound 131 (500 MHz, CDCl3) ..................................................................... 243 
13C NMR of Compound 131 (126 MHz, CDCl3) .................................................................... 243 
1H NMR of Brevianamide K (10) (500 MHz, CDCl3) ............................................................ 244 
13C NMR of Brevianamide K (10) (126 MHz, CDCl3) ........................................................... 244 
1H NMR of Compound 239 (500 MHz, CDCl3) ..................................................................... 245 
13C NMR of Compound 239 (126 MHz, CDCl3) .................................................................... 245 
1H NMR of Compound 56 (500 MHz, CDCl3) ....................................................................... 246 
13C NMR of Compound 56 (126 MHz, CDCl3) ...................................................................... 246 
1H NMR of Compound 109 (500 MHz, CDCl3) ..................................................................... 247 
13C NMR of Compound 109 (126 MHz, CDCl3) .................................................................... 247 
1H NMR of Brevianamide X (16) (500 MHz, (CD3)2SO) ....................................................... 248 
13C NMR of Brevianamide X (16) (126 MHz, (CD3)2SO)...................................................... 248 
1H-1H COSY of Brevianamide X (16) ((CD3)2SO) ................................................................. 249 
1H-13C HSQC of Brevianamide X (16) ((CD3)2SO) ................................................................ 249 
1H-13C HMBC of Brevianamide X (16) ((CD3)2SO) .............................................................. 250 
1H-1H NOESY of Brevianamide X (16) ((CD3)2SO) .............................................................. 250 
xiv 
 
1H NMR of Depyrano-sclerotiamide’ (235) (500 MHz, CDCl3) ........................................... 251 
13C NMR of Depyrano-sclerotiamide’ (235) (126 MHz, CDCl3) .......................................... 251 
1H NMR of Compound 113 (500 MHz, CDCl3) .................................................................... 252 
13C NMR of Compound 113 (126 MHz, CDCl3) ................................................................... 252 
1H NMR of Compound dia-113 (500 MHz, CDCl3) .............................................................. 253 
13C NMR of Compound dia-113 (126 MHz, CDCl3) ............................................................. 253 
1H NMR of Brevianamide Y (17) (601 MHz, (CD3)2SO) ...................................................... 254 
13C NMR of Brevianamide Y (17) (126 MHz, (CD3)2SO) ..................................................... 254 
1H-1H COSY of Brevianamide Y (17) ((CD3)2SO) ................................................................ 255 
1H-13C HSQC of Brevianamide Y (17) ((CD3)2SO) ............................................................... 255 
1H-13C HMBC of Brevianamide Y (17) ((CD3)2SO) .............................................................. 256 
1H-1H NOESY of Brevianamide Y (17) ((CD3)2SO) ............................................................. 256 
1H NMR of Compound 253 (500 MHz, (CD3)2SO) ............................................................... 257 
13C NMR of Compound 253 (126 MHz, (CD3)2SO) .............................................................. 257 
1H-1H COSY of Compound 253 ((CD3)2SO) ......................................................................... 258 
1H-13C HSQC of Compound 253 ((CD3)2SO) ........................................................................ 258 
1H-13C HMBC of Compound 253 ((CD3)2SO) ....................................................................... 259 
1H-1H NOESY of Compound 253 ((CD3)2SO) ...................................................................... 259 
1H NMR of Compound ent-261 (500 MHz, CDCl3) .............................................................. 260 
13C NMR of Compound ent-261 (126 MHz, CDCl3) ............................................................. 260 
1H NMR of Compound ent-74 (500 MHz, (CD3)2SO)........................................................... 261 
13C NMR of Compound ent-74 (126 MHz, (CD3)2SO) ......................................................... 261 













3 Å MS 3 Å molecular sieves 








BOPCl bis(2-oxo-3-oxazolidinyl)phosphinic chloride 
BP boiling point 
br. broad 
c  concentration in grams per 100 millilitres 
CAN ceric ammonium nitrate 
cat. catalytic 
COSY correlation spectroscopy 











DMP Dess–Martin periodinane 
DMSO dimethyl sulphoxide 
xvi 
 
e.e. enantiomeric excess 
e.r. enantiomeric ratio 
EI electron ionisation 




ESI electrospray ionisation 
ESI− electrospray ionisation (negative mode) 
ESI+ electrospray ionisation (positive mode) 
HATU 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
hept heptet 
HMBC heteronuclear multiple-bond correlation 
HMPA hexamethylphosphoramide 
HOBt hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSQC heteronuclear single-quantum correlation 
hν photochemical irradiation 
i- iso- 
IR infrared 




m/z mass to charge ratio 
m-CPBA meta-chloroperberzoic acid 
MHz megahertz 
MP melting point 
Ms methanesulfonyl 
n- normal- 
NADH 1,4-dihydronicotinamide adenine dinucleotide 








NMR nuclear magnetic resonance 
NOESY nuclear Overhauser effect spectroscopy 







ppm parts per million 
PPTS pyridinium para-toluenesulfonate 
quant. quantitative yield 
RBF round bottomed flask 
Rf retardation factor 
rt room temperature 







TLC thin layer chromatography 
TMS trimethylsilyl 
tR retention time 
Ts para-toluenesulfonyl 
UV ultraviolet 












Introduction to the Brevianamides 
 
The brevianamides are a class of non-ribosomal peptide derived prenylated indole alkaloids 
isolated from fungi of the genera Aspergillus and Penicillium.1 Brevianamides A–E (1–5) were 
the first to be isolated by Birch and Wright in 1969 (Scheme 1).2 Since then, more than 20 different 
brevianamides have been reported (Figure 1),3 with a number of total syntheses and biomimetic 
syntheses completed.4 Associated with the brevianamides are a large number of biosynthetically 
related natural products including the austamides, versicamides, stephacidins, versicolamides, 
marcfortines, notoamides, paraherquamides and norgeamides. 
 
 
Scheme 1: Brevianamide A–E (1–5) and biosynthesis of key biosynthetic intermediate 




Structurally the brevianamides can be identified by their common biosynthetic intermediate, 
deoxybrevianamide E (7), with its characteristic C2-reverse prenylated indole and 
diketopiperazine ring. In the more structurally complex brevianamides, these groups may have 
undergone significant rearrangement but their biosynthetic intermediacy is still evident. The 
biosynthesis of deoxybrevianamide E (7) begins with the cyclisation of the natural amino acids L-
Trp and L-Pro by the non-ribosomal peptide synthase, brevianamide F synthetase5a to form the 
diketopiperazine ring of brevianamide F (6). Brevianamide F (6) can then be reverse prenylated at 
C2 of the indole by a reverse prenyl transferase (encoded by the gene cdpC2PT)5b to give 
deoxybrevianamide E (7). Deoxybrevianamide E (7) is then either known (for brevianamides A 





Isolation of the Brevianamide Alkaloids 
 
A comprehensive and up to date list of all the named brevianamides are shown in Figure 1 and 
Figure 2. Between 1969–1974 Birch isolated the first brevianamides, A–F (1–6) from Penicillium 
brevicompactum.6 Shortly afterwards, Steyn isolated deoxybrevianamide E (7) and dehydrodeoxy-
brevianamide E (9) from Aspergillus ustus alongside the structurally related austamides (Figure 3, 
page 5).7 He also enabled the absolute structure of brevianamide A (1) to be confirmed by 
providing a sample of 5-bromo-brevianamide A for X-ray crystallography, to Coetzer.7b, 8 
 
Although the products were initially misassigned as oxindoles,9 Tsukamoto isolated brevianamide 
E (5) alongside with its diastereomer dia-brevianamide E (8) (1:1 d.r.) in feeding studies with a 
marine derived strain of Aspergillus sp. incorporating C11-[13C]-N16-[15N]-C17-[13C]-labelled 
deoxybrevianamide E (7).10 It is however possible that this diastereomeric mixture was an artefact 
of isolation, resulting from the known autoxidation of deoxybrevianamide E.4a, 11 Despite 
extensive investigation, we have been unable to find any mention of brevianamide G, H or I in the 
literature and so it is intriguing that these letters have been missed. Zhang isolated brevianamide 
J–R (10–12, 20, 22–26) from Aspergillus versicolor.3b, 12 Although they were named 
brevianamides, brevianamide L–P (22–26) (Figure 2) are structurally unrelated to the rest of the 
class. Brevianamide Q (11) and R (12) were isolated in racemic form, raising the possibility that 
they might be the products of non-enzymatic reactions of achiral brevianamide K (10) 
(hydration/methoxylation) or brevianamide V (15) (autoxidation). Brevianamide J (20) was noted 
for its impressive dimeric structure and Capon subsequently isolated a related dimer, brevianamide 
S (21) from Aspergillus versicolor, alongside brevianamides T, U & V (13–15).3c Brevianamide V 
(15) was isolated in scalemic form and Yepeng subsequently took the unusual step of naming the 
minor enantiomer of this mixture ‘brevianamide W’ (C12-R-15).3d In 2017 oxindole 
bicyclo[2.2.2]diazaoctane natural products brevianamide X (16) and brevianamide Y (17) were 
isolated from a deep-sea derived strain of Penicillium brevicompactum (DFFSCS025) by Qi.13 
Unfortunately, two more natural products were subsequently given the duplicate name 
‘brevianamide X’ (18 & 19) by Rateb14 and Sun.15 The first one, which we suggest should be 
re-named brevianamide X2 (18), was isolated from Aspergillus fumigatus, co-cultivated with the 
bacterium Streptomyces leeuwenhoekii C34 and appears to be a N-indole-hemiaminal-ether 
derivative of brevianamide F (6).14 The second one, (±)-brevianamide X3 (19) (our suggested 
name) was isolated in racemic form from epigenetically modified Aspergillus versicolor 
OUCMDZ-2738 and identified as the diastereomer of brevianamide U (14).15 The relative 
structure of (±)-brevianamide X2 (18) was assigned by X-ray crystallography, and showed a 
trans-relationship between the two hydroxyl groups. On the basis of this we have suggested 
4 
 




Figure 1: The brevianamide alkaloids.3b, 3c, 6-7, 9-10, 12-15 
5 
 
Although they have a diketopiperazine ring, brevianamides L–P (22–26) (Figure 2) are otherwise 
structurally unrelated to the other brevianamides and should not be included in this classification 
on the basis of structural or biosynthetic considerations. 
 
 
Figure 2: Structurally unrelated natural products also named brevianamides.3b, 12 
 
The austamides (27–30) are closely related to the brevianamides. Originally isolated by Steyn,7 
we have chosen to use the names given to them by Corey (Figure 3).16 They share the same 
defining structural features as the brevianamides (Scheme 1, page 1), reflecting the likely 
intermediacy of deoxybrevianamide E (7) in their biosynthesis. Based on purely 
structural/biosynthetic considerations they probably ought to be included in the brevianamide 
family as a subgroup identified by their characteristic C18-N10 linkage. 
 
 
Figure 3: The austamides.7 
 
There are also a large number of pyrano-indole analogues related to the brevianamides and 
austamides (Figure 4). These share some structural features with the brevianamides (Scheme 1, 
page 1) but are distinguished by an additional pyrano ring attached at the 6–7 positions of the 
indole ring. These related alkaloids include the stephacidins,17 notoamides,18 vericamides,19 
versicolamides,20 taichunamides,21,22 asperversiamide,23 norgeamides,24 amoenamides,25 
avrainvillamide26 and aspergamide.27 Many natural products in this family contain the 




Figure 4: Examples of pyrano-indole analogues of brevianamides and austamides.19-20, 25b 
 
There is also a large group of monooxopiperazine - bicyclo[2.2.2]diazaoctane natural products 
(Figure 5), where one of the carbonyls of the dioxopiperazine has been replaced by a methylene. 
Despite their structural similarities to the dioxopiperazines, these natural products are believed to 
be formed by distinct biosynthetic routes, without the intermediacy of deoxybrevianamide E (7).28 
Rather than being the products of late stage reduction of dioxopiperazine intermediates, the 
reduced state of the bicyclo[2.2.2]diazaoctane core is thought to result from early stage reduction.28  
 
A few monooxopiperazine natural products, such as paraherquamide F (38),29 have the 
pyrano-indoles discussed previously. However a wide range of indole substitutions are observed 
in this class of natural products, such as those displayed by paraherquamide A (39),30 
mangrovamide A (40),31 malbrancheamide (37)32 and peniciherquamide A (41)33 (Figure 5). 
Unsubstituted indoles such as those of (±)-premalbrancheamide (35) and penicimutamide D (36), 










Identification of a Diels–Alderase in the Biosynthesis of the Monooxopiperazine 
Alkaloid Premalbrancheamide (35) 
 
Williams recently demonstrated the involvement of a Diels–Alderase enzyme in the biosynthesis 
of the monooxopiperazine-bicyclo[2.2.2]diazaoctane premalbrancheamide (35) (Scheme 2).28 
Williams completed a biomimetic synthesis of (±)-premalbrancheamide (35) via acid catalysed 
rearrangement of enamide 42, and spontaneous hetero-Diels–Alder cyclisation. However, 
unexpectedly, enamide 42 underwent autoxidation in air to form an aromatic zwitterion 43. This 
could be reduced with NADPH or NADH to give (±)-premalbrancheamide (35) with 80–90% 
conversion, under physiologically plausible conditions, presumably via the same proposed 
hetero-Diels–Alder reaction. This reaction could be catalysed in vitro by the enzyme MalC (from 
Malbranchea aurantiaca) to give (+)-premalbrancheamide (35) enantioselectively when NADPH 
was used as the reductant (96% e.e.). Although, when NADH was used, the enantioselectivity was 
poor (26% e.e.).  
 
These observations demonstrate the ability of the enzyme MalC to act as a bifunctional reductase 
and Diels–Alderase, since it controls the stereochemical outcome of a hetero-Diels–Alder reaction 
of achiral intermediate 44. MalC is not unique, at least one homologous enzyme, PhqE (54% 
identity) has been identified, which is able to catalyse the same transformation. These results 
demonstrate that Diels–Alderases are involved in the biosynthesis of at least some of the 
monooxopiperazine-bicyclo[2.2.2]diazaoctanes, however they also show that enzyme catalysis is 
not required to account for product formation (only for stereocontrol). Although 
(+)-premalbrancheamide (35) ‘isolated from Malbranchea aurantiaca is optically pure,’28 the 
same natural product isolated from Penicillium purporogenum G59 is a scalemic mixture (e.r. 
56:44 (+)-35:(–)-35),34 inconsistent with a highly enantioselective Diels–Alderase (Scheme 2). 
While Diels–Alderases have been identified for a monooxopiperazine natural product, the 
evidence does not support them being universally involved and it is still unclear whether analogous 
enzymes are involved in the biosynthesis of the dioxopiperazines (e.g. the brevianamides). 
Alternative explanations for the observation of enantioenriched products should also be considered, 
including substrate controlled hetero-Diels–Alder reactions on enantiopure substrates, with simple 
substrate controlled diastereoselectivity (Scheme 14, Page 21) and enzymatic kinetic resolutions 
of (initially) racemic mixtures, which might produce advanced products (Scheme 23, Page 31) or 










Brevianamide A (1) and B (2) 
 
Brevianamide A (1) is a potent antifeedant against the insect larvae of Spodoptera frugiperda (fall 
armyworm) and Heliothis virescens (tobacco budworm),35 and appears to have low mammalian 
toxicity. Preliminary toxicity studies showed that brevianamide A was not toxic when fed or 
injected to mice.36 Mouse lungs intratracheally exposed to high doses of brevianamide A showed 
biomarkers associated with inflammatory response, however no significant weight changes or 
external signs of illness or respiratory distress were observed.37 
 
The production of brevianamide A  (1) and B (2) is associated with conidiation (asexual 
reproduction producing spores named conidia),38 and imparts a yellow-green fluorescence to the 
conidiophores of Penicillium brevicompactum (Figure 6).39 Campbell consistently measured a d.r. 
≳ 10:1 for these natural products once conidiation had been established and significant amounts 
of natural products were being produced.39 
 
 
Figure 6: ‘Diascopic (left) and epifluorescent (right) images of well-developed conidial heads of 
Penicillium brevicompactum.’39 
 
Brevianamide A (1) and B (2) are amongst only a handful of reported spiro-indoxyl 
bicyclo[2.2.2]diazaoctane natural products. The vast majority of bicyclo[2.2.2]diazaoctane 
alkaloids instead contain either the thermodynamically more stable oxindole, an indole, or a 
hydroxy-indolenine. Speramide A (45) was originally proposed to be an indoxyl,40 however was 
recently reassigned as hydroxy-indolenine taichunamide H (46).22, 25b Amoenamide B (31) appears 
to be the pyrano-analogue of brevianamide A (1) and was isolated in 2018 from Aspergillus 
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amoenus NRRL 35600.25b Notoamide O (47) has also been reported to possess an unusual 
hemi-acetal connected to a spiro-indoxyl moeity.41 However, the shift of the indoxyl carbonyl is 
substantially lower than similar indoxyl natural products, raising the possibility that its structure 
may have been misassigned. 
 
 
Scheme 3: Spiro-indoxyl bicyclo[2.2.2]diazaoctane natural products.22, 25b, 40-41 
 
In 1969 Birch first isolated brevianamides A, B, C, D and E (1–5) from Penicillium 
brevicompactum (Figure 7). Brevianamide A (1) and B (2) were the first reported natural products 
containing the remarkable bicyclo[2.2.2]diazaoctane core. However, 50 years after it was first 
isolated, no synthesis of brevianamide A (1) has been reported, despite extensive synthetic 
investigations, leading to numerous syntheses of its minor diastereomer brevianamide B (2).4a, 4d-
f, 11, 42 The bicyclo[2.2.2]diazaoctane cores of brevianamides A, B, C and D (1–4) all have an 
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anti-relationship between the methine C–H and amide N–H, in contrast to the syn-relationship of 
most other bicyclo[2.2.2]diazaoctane alkaloids (e.g. stephacidin A).43 
 
 
Figure 7: First brevianamides isolated by Birch.6d 
 
In initial studies, Birch found that brevianamide C (3) and D (4) were not observed when 
Penicillium brevicompactum was grown and extracted in the dark, suggesting that they are 
‘photochemical artefacts’ and were shown to be the photolysis products of brevianamide A (1).6b 
Brevianamide A (1) underwent photolysis to give an initial mixture of brevianamide A, B, C, and 
D (1–4) after 30 minutes, but only brevianamide C (3) and D (4) were observed after 7 hours 
(Scheme 4). Despite its observation in the early stages of brevianamide A (1) photolysis, 
brevianamide B (2) was still isolated when Penicillium brevicompactum was grown in the dark so 
it is not a ‘photochemical artefact.’ 
 
 
Scheme 4: Birch’s photolysis of brevianamide A (1).6b 
 
The major product of the photolysis reaction, brevianamide C (3) was also shown to undergo 
photocatalysed isomerisation to give an ‘equilibrium mixture’ of brevianamide C (3) and D (4).6b 
Despite Birch’s conclusion that brevianamide C (3) and D (4) are not the product of an enzymatic 
reaction, these compounds may still serve important biological function(s). Similarly to 
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brevianamide A (1), brevianamide D (4) shows insecticidal activity.35 The photolysis reaction of 
brevianamide A (1) may also play a role in biochemical signalling pathways, by acting as an 
indication of incident light. 
 
 
Scheme 5: Birch’s photocatalysed isomerisation of brevianamide C.6b 
 
Brevianamide B (2) was confirmed to be a diastereomer of brevianamide A (1) via interconversion. 
Reduction of brevianamide A (1) with NaBH4 followed by acidification gave an indole product 
named ‘deoxybrevianamide A’ (49).6a This could be oxidised in air to give the unnatural 
enantiomer of brevianamide B (2) as the only transformation product (Scheme 6).6b 
 
 
Scheme 6: Reduction and re-oxidation of brevianamide A (1).6a, 6b 
 
In biosynthetic studies, Birch demonstrated incorporation of labelled (±)-[methylene-14C]-
tryptophan, L-[5-3H]-proline, (±)-[2-14C]-mevalonic lactone and [2-14C]-acetate into brevianamide 
A (1) (Scheme 7). No incorporation was observed for [Me-14C]-methionine.2, 6c The amino acid 
incorporation implied the intermediacy of brevianamide F (cyclo-L-Trp-L-Pro - 6), which was 





Scheme 7: Birch's biosynthetic incorporation studies.2, 6c 
 
In 1970, while these biosynthetic investigations were ongoing, Sammes proposed that the 
bicyclo[2.2.2]diazaoctane core of brevianamide A (1)  was ‘formed by a [2+4] cycloaddition’ 
(Scheme 8).44 In support of this hypothesis he carried out supporting model studies, showing that 
dihydroxypyrazines 51 and 54 could undergo intermolecular [4+2] cycloadditions with suitable 
dienophiles, to form bicyclo[2.2.2]diazaoctane products 52 and 54. 
 
 
Scheme 8: Sammes' proposed hetero-Diels-Alder reaction, with supporting model studies.44 
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Based on Sammes’ proposed hetero-Diels–Alder reaction,44 and Birch’s biosynthetic 
incorporation studies, Williams’ developed an early biosynthetic proposal for brevianamide A (1)  
and B (2). Doexy-brevianamide E (7) had been isolated from Aspergillus ustus by Steyn7b and was 
presumed to be an intermediate based on Birch’s incorporation studies.6c Oxidation would give an 
aza-diene intermediate 55, capable of undergoing a Sammes-type hetero-Diels–Alder reaction. To 
account for the observed ratio of the natural products (≳10:1 d.r.),39 the resulting 
bicyclo[2.2.2]diazaoctane 56 would need to be generated in scalemic form (≳10:1 e.r.). An indole 
oxidase, showing complete R-selectivity for indole oxidation for both enantiomers of substrate 
would then give the observed mixture of ‘pseudo-enantiomeric’ diastereomers, brevianamides A 
(1) and B (2). 
 
 
Scheme 9: Williams' first generation biosynthetic proposal,45 based on Sammes’ proposed 
hetero-Diels–Alder reaction.44 
 
Williams’ first total synthesis of brevianamide B (2) allowed a chemical investigation of this 
hypothesis (Scheme 10. For all previous syntheses see Appendix 1, Page 185).4d, 4e, 42a Indole 57 
(prepared in 11 steps) underwent Boc protection and silyl ether cleavage to give alcohol 58, which 
was converted to Chloro-prenyl-diketopiperazine 59 using mesyl chloride. 
Chloro-prenyl-diketopiperazine 59 underwent SN2′ cyclisation under basic conditions, to give 
bicyclo[2.2.2]diazaoctane 60. Subsequent acid mediated cationic cyclisation and Boc deprotection 
gave product 61, the PMB-protected analogue of the proposed biosynthetic intermediate 56. 
16 
 
However, indole oxidation (Step 16, Scheme 10) gave complete diastereoselectivity for 
diastereomer 62, thus against that required for the proposed precursor of brevianamide A (2). 
Semi-pinacol rearrangement and deprotection of oxidation product 62 (Steps 17–18, Scheme 10) 
instead gave the unnatural enantiomer of brevianamide B (2). The same pattern of reactivity was 
confirmed for the proposed precursor of (+)-brevianamide A (1) , bicyclo[2.2.2]diazaoctane (–)-56 
(with deprotection preceding oxidation and rearrangement), giving ‘exclusively’ 
(–)-brevianamide B (2).45 
 
This 18-step synthesis of brevianamide B (2) accessed the minor natural diastereomer but was 
unable to prepare any trace of brevianamide A (1). The results also represent a challenge to 
Williams’ first generation biosynthetic proposal (Scheme 9, page 15), since the proposed 
enzymatic oxidation would have to overcome the innate selectivity of the substrate. These 
oxidations strongly favour oxidation of the indole from the convex face of the molecule (on the 
same side as the C–H methine of the bridgehead position). 
 
 





Biosynthetic incorporation studies conducted Williams and co-workers provided further evidence 
against Williams’ first generation biosynthetic proposal (Scheme 11).46 No incorporation of the 
proposed intermediate bicyclo[2.2.2]diazaoctane (±)-[C8-13C]-56 was observed, into either 
brevianamide A (1) or B (2). Labelled C8-[3H]-deoxybrevianamide E (7) was successfully 
incorporated into brevianamide A (1) and B (2) confirming its suspected role as an intermediate 
in their biosynthesis. C8-[3H]-Deoxybrevianamide E (7) was also incorporated into 
brevianamide E (5). However no incorporation of C8-[3H]-brevianamide E (5) into brevianamide 




Scheme 11: Williams' biosynthetic feeding studies.46 
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Based on these biosynthetic incorporation studies, Williams and co-workers proposed a second 
generation biosynthetic pathway (Scheme 12).46 In this proposal, stereoselective indole oxidation 
and semi-pinacol rearrangement would precede oxidation of the diketopiperazine ring and 
subsequent hetero-Diels–Alder cyclisation to give brevianamide A (1) and B (2). This hypothesis 
was supported by DFT calculations reported by Domingo, showing that the putative hetero-Diels–
Alder reaction favours brevianamide A (1) over brevianamide B (2) and significantly disfavours 
the other two syn-configured diastereomeric products (which have not been isolated).47 
 
Williams’ proposal could also account for the formation of brevianamide E (5), since 
hydroxy-indolenine intermediate 64 could undergo ring closure in competition with the proposed 
semi-pinacol rearrangement. However, this also represents a significant challenge to this 
hypothesis. In their early total synthesis of brevianamide E (5) Kametani and co-workers had 
oxidised deoxybrevianamide E (7) to brevianamide E (5) and dia-brevianamide E (8), however no 
indoxyl products were reported. Given that brevianamide E (5) had been determined to be a ‘shunt 
metabolite’ based on biosynthetic incorporation studies (Scheme 11), this cyclisation would likely 
need to be avoided. 
 
 




Attempts in the Williams group to carry out a biomimetic synthesis based on their second 
generation biosynthetic pathway were reported in Kathleen Halligan’s PhD thesis (Scheme 13).48 
To avoid ring closure and formation of brevianamide E (5) the diketopiperazine had been protected 
as a lactim ether 67. However, attempts to convert hydroxy-indolenine 67 to the corresponding 
indoxyl either gave rearrangement to oxindole 70 or indoxyl fragmentation product 69 via a 
presumed indoxyl intermediate 68. Unfortunately, no spectroscopic data were provided to allow 




Scheme 13: Halligan's attempted rearrangement of a hydroxy-indolenine to an indoxyl.48 
 
The final hetero-Diels–Alder reaction of Williams’ second-generation biosynthetic proposal is 
very appealing because it would allow substrate controlled diastereoselectivity to account for the 
observed ratio of brevianamide A (1) and B (2). In contrast, Williams’ first generation biosynthetic 
hypothesis invoked either a single poorly enantioselective Diels–Alderase enzyme, or a pair of 
Diels–Alderases with opposite enantioselectivities, to account for the observed ratio of 
brevianamide A (1) to B (2) (Scheme 9, page 15). However, the proposed order of preceding steps 
in the 2nd generation pathway presents a number of challenges. The biosynthesis needs to avoid 
the known disposition of deoxybrevianamide E (7) to cyclise to form ‘shunt metabolite’ 
brevianamide E (5) when oxidised and Halligan’s results show that fragmentation accompanies 
indoxyl rearrangement with the lactim ether analogue 67. 
 
Inspired by the hypotheses and results of Birch, Sammes and Williams, we have proposed an 
alternative biosynthetic pathway for brevianamide A (1) and B (2) (Scheme 14). It begins with the 
alternative starting material, dehydrodeoxy-brevianamide E (9), which is already at the correct 
oxidation state to undergo the hetero-Diels–Alder reaction later in the sequence. Indole oxidation 
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and cyclisation give dehydro-brevianamide E (71), in line with the innate reactivity of the substrate. 
Although brevianamide E (5) was not incorporated into brevianamide A (1) and B (2), this doesn’t 
rule out the intermediacy of its analogue, dehydro-brevianamide E (71), when generated in this 
particular order of steps. Reversible ring opening of the hydroxy-pyrroloindole ring could enable 
a semi-pinacol rearrangement to give indoxyl intermediate 73. With the diketopiperazine already 
at the correct oxidation state, this could then undergo rapid tautomerisation and Sammes-type 
hetero-Diels–Alder reaction to give brevianamide A (1) and B (2). Enabling these reactions to 
occur rapidly could allow them to out-compete the type of fragmentation observed by Halligan 
(Scheme 13, page 19). 
 
To validate this biosynthetic proposal, we planned to carry out a short and efficient biomimetic 
synthesis of brevianamide A (1) and B (2) via our proposed biosynthetic intermediates, 
dehydrodeoxy-brevianamide E (9) and dehydro-brevianamide E (71). Our synthetic investigations 









Previous Syntheses of Brevianamide B (2) 
 
In addition to Williams’ original 18-step synthesis of (–)-brevianamide B (2) (Scheme 10, page 
16) a further 5 syntheses of brevianamide B (2) have been reported, proceeding in 9–15 steps (for 
all previous syntheses see Appendix 1, Page 185). However, none of these syntheses have been 
able isolate any trace of brevianamide A (1). All reported syntheses carry out a late stage oxidation 
of bicyclo[2.2.2]diazaoctane 56 (or protected analogues), followed by base mediated semi-pinacol 
rearrangement (Scheme 15) and none have been able to overcome the inherent diastereoselectivity 
of the oxidation to access brevianamide A (1). 
 
 
Scheme 15: General conditions for conversion of indole 56 into indoxyl brevianamide B (2). 
 
Shortly after Williams’ initial synthesis of (–)-brevianamide B (2), he reported a 12-step 
biomimetic synthesis of racemic material (Scheme 16)4f, 42b based on his first generation 
biosynthetic proposal (Scheme 9, page 15. For all previous syntheses see Appendix 1, Page 185). 
The synthesis started from the epi-deoxybrevianamide E (75) prepared in 6 steps, using a sequence 
reported in Kametani’s early synthesis of brevianamide E (5).4a, 11 Epi-deoxybrevianamide E (75) 
was converted to the lactim ether and oxidized with DDQ to give azadiene 77. Exposure of 
azadiene 77 to KOH gave racemic bicyclo[2.2.2]diazaoctane 78 which was proposed to occur via 
an intramolecular hetero-Diels–Alder cycloaddition analogous to that suggested in Williams’ first 
generation biosynthetic proposal. Bicyclo[2.2.2]diazaoctane 78 underwent the same late stage 
oxidation/semi-pinacol rearrangement common to all of these syntheses (Scheme 15), followed by 
deprotection to give racemic brevianamide B (2). While providing experimental validation for the 
Sammes type hetero-Diels–Alder reactions proposed in the biosyntheses of these molecules and 
accessing brevianamide B (2) in a significantly reduced step count, this biomimetic synthesis 
mirrored a biosynthetic proposal which has been all but ruled out on the basis of incorporation 





Scheme 16: Williams’ first biomimetic synthesis of (±)-brevianamide B (2) (1998).4a, 4f, 11, 42b 
 
Williams reported another 12-step, synthesis of racemic brevianamide B (2), again using an 
intramolecular hetero-Diels-Alder reaction (Scheme 17. For all previous syntheses see Appendix 
1, Page 185).42c Treatment of compound 80 (accessed in 7 steps) with AlCl3 gave racemic 
bicyclo[2.2.2]diazaoctane 81 with a high degree of diastereoselectivity. The indole moiety was 
installed via a Fisher indole synthesis to give racemic indole 56. Late stage oxidation/semi-pinacol 
rearrangement gave racemic brevianamide B (2). 
 
 





Scheme 18: Williams' 2nd biomimetic synthesis of (±)-brevianamide B (2) (2007).42c, 42e, 42f 
Williams’ second biomimetic synthesis of (±)-brevianamide B (2) was completed in 14 steps 
(Scheme 18. For all previous syntheses see Appendix 1, Page 185).42e This synthesis demonstrated 
the ability of dehydrodeoxy-brevianamide E (9) to undergo tautomerisation and hetero-Diels–
Alder directly to bicyclo[2.2.2]diazaoctane (±)-56, without the need for prior conversion to the 
lactim ether. From compound (±)-56 the synthesis of brevianamide B (2) was completed with the 
oxidation/semi-pinacol conditions reported in Williams 2006 synthesis.42c This synthesis also 
forms the basis of the first total synthesis of brevianamide Y (17). Oxidation of compound (±)-56 
with Davis’-oxaziridine gave a product (±)-74 which was initially misassigned as oxindole 
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(±)-brevianamide Y (17), despite matching the structure of the penultimate intermediate in the 
synthesis of (±)-brevianamide B (2). However, this error was subsequently corrected and it was 
shown that hydroxy-indolenine (±)-74 could undergo acid mediated rearrangement to give 
oxindole (±)-brevianamide Y (17).42f 
 
Simpkins’ synthesis of (−)-brevianamide B (2) is the shortest reported to date (Scheme 19. For all 
previous syntheses see Appendix 1, Page 185).42g, 42h At 9 steps, it halves the step-count of 
Williams’ original 18-step synthesis of (−)-brevianamide B (2), the only other enantioselective 
synthesis. Strategically it mirrors Williams’ original synthesis very closely. The 
bicyclo[2.2.2]diazaoctane core was constructed in a one-step cationic cyclisation cascade from 
alcohol 89 (Step 5 - Scheme 19) which bears close resemblance to Williams’ SN2′ 
cyclisation/cationic cyclisation sequence (Steps 14 & 15 - Scheme 10, Page 16). The indoxyl was 








Scheme 20: Scheerer’s first formal synthesis of (±)-brevianamide B (2) (2016).49 
 
More recently, Scheerer completed two formal syntheses of (±)-brevianamide B (2) (Scheme 20 
& Scheme 21. For all previous syntheses see Appendix 1, Page 185). Both syntheses started from 
azadiene 94, prepared in 4 steps from proline methyl ester,50 and used intermolecular hetero-Diels–
Alder reactions to construct the bicyclo[2.2.2]diazaoctane core of brevianamide B (2). Scheerer’s 
first formal synthesis (Scheme 20) used methyl 2-nitroacrylate (95) as the dienophile, which 
initially gave a mixture of regioisomers, (±)-96 and (±)-97. Elimination with DBU, followed by 
hydrogenation (Steps 6 & 7, Scheme 20) gave ester (±)-100, which was converted to intermediate 
56 by sequential: methyl-Grignard addition, lactim-ether deprotection and cationic cyclisation/Boc 
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deprotection (Steps 6, 9 & 10, Scheme 20). Combined with Williams’ oxidation/semi-pinacol 
sequence (Steps 11 & 12, Scheme 17; Steps 13 & 14, Scheme 18) this represents a relatively short 
12-step formal synthesis of (±)-brevianamide B (2). 
 
Scheerer’s second formal synthesis used maleic anhydride (103) as an alternative dienophile, to 
achieve a diastereoselective intermolecular hetero-Diels–Alder reaction (Step 5, Scheme 21).42e, 
42i However, the additional steps necessary to achieve selective decarboxylation of anhydride 








Brevianamide X (16) and Y (17) 
 
Brevianamide X (16) and Y (17) where first isolated by Qi and co-workers in 2017 from the deep-
sea fungal strain of Penicillium brevicompactum – DFFSDC025.13 Structurally they both possess 
a bicyclo[2.2.2]diazaoctane ring system and a spiro-oxindole heterocycle. Brevianamide X (16) 
and Y (17) differ with regard to the stereochemistry around the bicyclo[2.2.2]diazaoctane core. 
Brevianamide X (16) has a syn-relationship between the methine C-H and amide N-H, whereas in 
brevianamide Y (17) these have an anti-relationship. 
 
 
Figure 8: Brevianamide X (16) and Y (17).13 
 
The isolation chemists noticed that brevianamide Y (17) was similar to the known natural product 
versicolamide B (33). They have the same structure as except versicolamide B (33) has a pyran 
ring attached to the oxindole (Figure 9). The absolute stereochemistry of (+)-brevianamide Y (17) 
matches that of (+)-versicolamide B (33), isolated from Aspergillus amoenus20 (previously 
Aspergillus versicolor NRRL 35600)43 and is opposite to that of (−)-versicolamide B (33) isolated 
from Aspergillus sp.51  
 
Brevianamide X (16) lacks the pyran ring of notoamide B (32), but the structures are otherwise 
identical. The absolute stereochemistry of (+)-brevianamide X (16) matches that of 
(+)-notoamide B (32) isolated from Aspergillus amoenus20 and is opposite to that of (−)-notoamide 
B (32) isolated from Aspergillus sp.18 Overall, the absolute stereochemistries of brevianamide Y 
(17) and X (16) match those of versicolamide B (33) and notoamide B (32) isolated from 






Figure 9: Structural similarities between brevianamide Y (17) and versicolamide B (33), and 
brevianamide X (16) and notoamide B (32). 
 
The structural similarity of the Penicillium natural products brevianamide X (16) and Y (17) to 
natural products found in Aspergillus raises the interesting question of whether they are derived 
from homologous biochemistry (diverging from the biochemistry of a common ancestor) or 
convergent biochemistry to construct similar structures. Convergent evolution might have been 
driven by a particularly useful structural motif or reflect the innate reactivity of the substrates. 
Brevianamide X (16) and Y (17) have only recently been isolated, so little has been determined 
about their biosynthesis. However, the biosyntheses of their pyrano analogues, notoamide B (32) 
and versicolamide B (33) might be examples of homologous biochemistry and even if not, are 
examples of (bio)chemically feasible, analogous pathways. 
 
The ‘enantiodivergent’ biosynthesis of notoamide B (32) and versicolamide B (33) is remarkable. 
Notoamide S (106) has been suggested as a common intermediate in the biosynthesis of both 
natural products. Its proposed role in the biosynthesis is supported by feeding studies in 
Aspergillus amoenus (previously Aspergillus versicolor NRRL 35600)43 where labelled notoamide 
S (106) was incorporated into versicolamide B (33), stephacidin A (48) and notoamide B (32).52 
On the basis of these results, Williams suggested that notoamide S (106) is incorporated into syn- 
and anti- bicyclo[2.2.2]diazaoctanes, stephacidin A (48) and 6-epi-stephacidin A (107), 
presumably via an intramolecular hetero-Diels–Alder cyclisation (Scheme 22 & Scheme 23).43 
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The syn-bicyclo[2.2.2]diazaoctane, stephacidin A (48), appears to be produced as antipodal single 
enantiomers in A. ameonus and A. protuberus.43 Feeding of racemic C11-[13C]-C17-[13C]-labelled 
(±)-stephacidin A (48) to A. ameonus and A. protuberus showed incorporation of the endogenous 
enantiomer of stephacidin A (48) into the corresponding enantiomer of notoamide B (32), with 
accumulation of the exogenous enantiomer (Scheme 22 & Scheme 23).9 
 
 
Scheme 22: Williams’ proposed biosynthesis of notoamide B (32) and versicolamide B (33) in A. 
protuberus.43 
 
The anti-bicyclo[2.2.2]diazaoctane, 6-epi-stephacidin A (107), appears to be produced as a single 
enantiomer in A. protuberus, and oxidised to give the corresponding enantiomer of versicolamide 
B (33) (Scheme 22).43 In contrast, 6-epi-stephacidin A (107) is isolated from A. amoenus as a 
scalemic mixture (Scheme 23).43  This observation is consistent with an initial synthesis of racemic 
6-epi-stephacidin A (107), followed by an enzymatic, oxidative, kinetic resolution, giving 






Scheme 23: Williams’ proposed biosynthesis of notoamide B (32) and versicolamide B (33) in A. 





Proposed Biosynthesis of Brevianamide X (16) and Y (17) 
 
By analogy with Williams’ proposed biosyntheses of notoamide B (32) and versicolamide B (33) 
(Scheme 22 & Scheme 23), a proposed biosynthesis of brevianamide X (16) and Y (17) is 
presented in Scheme 24. We propose that dehydrodeoxy-brevianamide E (9) tautomerises to give 
an azadiene intermediate 55, which undergoes a hetero-Diels–Alder reaction to give a mixture of 
diastereoisomeric syn- and anti- bicyclo[2.2.2]diazaoctanes 109 and 56. These then undergo 
oxidation to hydroxy-indolenines 108 and 74. Subsequent semi-pinacol rearrangement would then 
give brevianamide Y (17) and brevianamide X (16). 
 
 
Scheme 24: Our biosynthetic proposal for brevianamide X (16) and Y (17), inspired by Williams’ 
biosynthetic proposals for notoamide B (32) and versicolamide B (33) (see Scheme 22, page 30 & 
Scheme 23, page 31). 
 
Although it is possible that a Diels–Alderase (analogous to that reported for monooxopiperazine 
premalbrancheamide (35) - Scheme 2, page 9) is involved in the biosynthesis of (+)-brevianamide 
X (16) and (+)-brevianamide Y (17), the enantioselectivity observed in their biosynthesis could 
also be explained in other ways. An initial substrate controlled, synthesis of racemic 
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bicyclo[2.2.2]diazaoctanes 109 and 56 via achiral azadiene 55 could be followed by an oxidative 
enzymatic kinetic resolution similar to that observed in the biosynthesis of versicolamide B (33) 
in Aspergillus amoenus (Scheme 23). 
 
 
Scheme 25: Our alternative biosynthetic proposal for brevianamide Y (17), inspired by Williams' 
proposed biosynthesis of versicolamide B (33) (see Scheme 88, page 93 for Williams’ related 
biomimetic synthesis).53 
 
Alternatively, a substrate controlled hetero-Diels–Alder reaction of oxindole 113 would allow 
formation of a single enantiomer of (+)-brevianamide Y (17) without requiring a Diels–Alderase 
(Scheme 25). Oxindole 113 could be formed by oxidation and rearrangement of known natural 
product dehydrodeoxy-brevianamide E (9), potentially via intermediate dehydro-brevianamide E 
(71) which we have proposed to be an intermediate in the biosynthesis of brevianamide A (1) and 
34 
 
B (2) (Scheme 14, Page 21). The proposed hetero-Diels–Alder reaction in this biosynthetic 
proposal is analogous to that presented in Williams’ proposed biosynthesis of versicolamide B (33) 
(Scheme 25).53 The chemical feasibility of Williams’ proposed hetero-Diels–Alder reaction has 
been demonstrated by biomimetic synthesis (Scheme 88, Page 93). Although the isolation of likely 
intermediates suggest an alternative biosynthesis for versicolamide B (33) (Scheme 22, Page 30 & 
Scheme 23, 31), multiple biosynthetic routes might be active and routes could vary between 
organisms. There is also every possibility that the biosynthesis of brevianamide Y (17) could differ 






Previous Syntheses of Notoamide B (32) and Versicolamide B (33) 
 
Two syntheses of brevianamide Y (17) have been reported. Williams and co-workers have 
completed a 14-step synthesis of racemic material (previously shown in Scheme 18, Page 24),42c, 
42e, 42f and Qin and co-workers completed an 18 step, enantioselective synthesis (Scheme 86, Page 
92).54 These syntheses are discussed in more detail in Chapter 3 (page 87). No synthesis of 
brevianamide X (16) has been reported. However, numerous syntheses of the pyrano-analogues 
notoamide B (32) and versicolamide B (33) have been reported. Three total syntheses of 
notoamide B (32) have been reported, proceeding in 16–18 steps (Scheme 26, Scheme 28 & 
Scheme 29).42h, 55 Two total syntheses of versicolamide B (33) have been reported, proceeding in 
16–18 steps (Scheme 28 & Scheme 88, Page 93).53, 56 
 
 
Scheme 26: Williams’ stereoselective synthesis of (+)-notoamide B (32) (2007)55a 
 
In 2007, Williams’ completed an 18 step, stereoselective synthesis of (+)-notoamide B (32). 
Chloro-prenyl-diketopiperazine 115 (prepared in 14 steps) underwent SN2′ cyclisation under basic 
conditions to form bicyclo[2.2.2]diazaoctane 116 under conditions similar to those reported in 
Williams’ first synthesis of  (–)-brevianamide B (2) (Step 14, Scheme 10, Page 16). Subsequent 
cyclisation was achieved using Pd mediated conditions, originally developed by Trost and 
Fortunak (Step 16, Scheme 26).57 Lactim ether hydrolysis was achieved by carrying out an acidic 
workup, followed by removal of the Boc protecting group in MeCN, using microwave heating 
(Step 17, Scheme 26) to give the natural product (–)-stephacidin A (48). Diastereoselective 
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oxidation of (–)-stephacidin A (48) with Davis’-oxaziridine was accompanied by spontaneous 
rearrangement to give oxindole (+)-notoamide B (32). 
 
There are some notable differences between the oxidation chemistry of pyrano-indoles and their 
depyrano-analogues (Scheme 27). Pyrano-indole substrates (117) tend to readily rearrange to 
pyrano-oxindoles (118) upon oxidation (see Scheme 26, Scheme 28 & Scheme 88, Page 93 for 
examples), however the depyrano-analogues (119) tend to oxidise to hydroxy-indolenines (120) 
initially and tend to require more forcing conditions to facilitate the rearrangement to oxindoles 
(121) (see Scheme 18, Page 24 & Scheme 83, Page 89 for examples). This difference in reactivity 
appears to have contributed to numerous miss-assignments of 
hydroxy-indolenines/hydroxy-pyrroloindoles as oxindoles in the literature.10, 42f 
 
 
Scheme 27: General oxidation chemistry of pyrano-indole vs depyrano-indole substrates. 
 
In the same year, Williams’ completed an 18 step, biomimetic synthesis of racemic (±)-notoamide 
B (32),55b which was subsequently extended to enable an 18-step synthesis of (±)-versicolamide B 
(33) (Scheme 28).56  Base mediated rearrangement and hetero-Diels–Alder cyclisation of lactim 
ether 122, gave bicyclo[2.2.2]diazaoctanes 123 and 124 as a mixture of diastereomers. Lactim 
ether hydrolysis of the syn-diastereomer 124 gave (±)-stephacidin A (48), which was oxidised with 
Davis’-oxaziridine to give oxindole (±)-notoamide B (32), as seen in Williams’ stereoselective 
synthesis (Scheme 26). The same steps could be applied in the opposite order to the 





Scheme 28: Williams' biomimetic synthesis of (±)-notoamide B (32) (2007),55b and 
(±)-versicolamide B (33) (2008).56  
 
In 2013 Simpkins reported an unexpected 16-step synthesis of scalemic (+)-notoamide B (32) 
(Scheme 29). Thioether 127 (prepared in 13 steps) underwent a reductive radical cyclisation 
cascade to form a mixture of diastereomeric bicyclo[2.2.2]diazaoctanes. A mixture of epimers 129 
was subjected to Boc-deprotection conditions, followed by oxidation with catalytic SeO2 to give 
scalemic (+)-notoamide B (32) as the unexpected product of the oxidation, rather than 
avrainvillamide (126), which was the expected product based on the literature. Baran had 
previously reported oxidation of a similar mixture of diastereomeric indolines 125 to give 
avrainvillamide (126) using the same SeO2 conditions.
58 Simpkins attributed the difference in 
reactivity to the use of a different diastereomeric mixture of starting materials, however the relative 
stereochemistry of the major diastereomer of Simpkins’ mixture should match that of one of the 
diastereomers of Baran’s ‘inconsequential mixture of diastereomers,’58 making this result highly 





Scheme 29: Simpkins’ unexpected synthesis of (+)-notoamide B (32) via a radical cyclisation 





Brevianamide J (20) and S (21) 
 
Brevianamide J (20) and S (21) are dimeric natural products isolated from Aspergillus versicolor. 
These dimers were the initial reason that the ‘Lawrence group’ became interested in this family of 
alkaloids, given its longstanding interest in the total synthesis of dimeric natural products.59 
Brevianamide J (20) and S (21) appear to be formed by oxidative coupling of a simpler monomer 
and are the only known natural products of their structural class. Brevianamide J (20), isolated in 
2009 by Zhang and co-workers,3b is a chiral molecule with a reported optical rotation of 
[α]𝐷
20 +45.0 (c 0.10, acetone), indicating that brevianamide J (20) is enantioenriched if not 
enantiopure. Zhang and co-workers did not however comment on or assign absolute 
stereochemistry to brevianamide J (20). Brevianamide S (21), which is achiral, was isolated shortly 
afterwards in 2012 by Capon and co-workers and found to exhibit antibacterial activity towards 
Bacillus Calmette–Guérin (a screening surrogate for Mycobacterium tuberculosis).3c  
 
 
Scheme 30: Brevianamide J (20),3b and S (21).3c 
 
When they reported the isolations of brevianamide J (20) and S (21), Zhang3b and Capon3c each 
independently proposed that these dimers were formed by the oxidative coupling of brevianamide 
K (10). Zhang’s proposed dimerisation of brevianamide K (10) to give brevianamides J (20) 
necessarily involves a regioselective and enantioselective oxidation/hydration, therefore 
necessitating enzyme control. We therefore propose an alternative hypothesis (Scheme 31) which 
avoids the need for enzyme stereocontrol, where the biosynthetic monomer is instead the natural 
product dehydrodeoxy-brevianamide E (9). This substrate would have simpler regioselectivity. 
The initial oxidative coupling product 131 could still undergo dehydrogenation to give 
brevianamide S (21). However, the stereocenters retained from the starting material could 
potentially control a diastereoselective hydration to give enantioenriched brevianamide J (20) after 





Scheme 31: Proposed biosyntheses of brevianamide J (20),3b and brevianamide S (21).3c 
 
A proposed mechanism for the oxidative coupling of dehydrodeoxy-brevianamide E (9) is shown 
in Scheme 32. Electron abstraction from the N-acyl-enamine of dehydrodeoxy-brevianamide E (9) 
would give the radical cation 133. Radical addition to another unit of dehydrodeoxy-brevianamide 
E (9) would give the stabilised capto-dative radical 134. This could undergo protonation and 
further oxidation to give the iminium 135. Deprotonation would give our proposed intermediate 





Scheme 32: Proposed mechanism for the oxidative coupling of dehydrodeoxy-brevianamide E (9) 





Aims – A Unified (Bio)synthetic Proposal for the Brevianamide Alkaloids 
 
The role of deoxybrevianamide E (7) as an intermediate in the biosynthesis of the brevianamides 
has been well established. However, our consideration of the biosynthesis of the complex 
brevianamides (A (1), B (2), X (16), Y (17), J (20) and S (21)) suggests that the dehydro-analogue, 
dehydrodeoxy-brevianamide E (9) might also be a common intermediate in their biosynthesis 
(Scheme 33). We hoped to use biomimetic chemical synthesis to investigate the chemical 
feasibility of this biosynthetic network. 
 
 
Scheme 33: Unified biosynthetic proposal for the complex brevianamide alkaloids. 
 
Dehydrodeoxy-brevianamide E (9) is the lynchpin intermediate in our plan to carry out a unified 
biomimetic synthesis of the brevianamide alkaloids. To achieve this goal, we needed to develop: 
 
1. A short, scalable synthesis of dehydrodeoxy-brevianamide E (9) (Chapter 1). 
43 
 
2. A thorough understanding of the oxidation chemistry of dehydrodeoxy-brevianamide E (9) 
to allow us to synthesise dimers, brevianamide J (20) and S (21) (Chapter 2). 
3. An understanding of the hetero-Diels–Alder reaction and the oxindole moiety, to allow us 
to synthesise brevianamide X (16) and Y (17) (Chapter 3). 
4. Conditions to validate our proposed hydroxy-pyrroloindole ring opening/ 
indoxyl-rearrangement/tautomerisation/hetero-Diels–Alder cascade to synthesise 







Chapter 1: Synthesis of Dehydrodeoxy-brevianamide E (58) 
 
Synthetic Plan for Dehydrodeoxy-brevianamide E (58) 
 
 
Scheme 34: William’s synthesis of dehydrodeoxy-brevianamide E (9),42e, 60 via Boc-protected 
amino acid 82.46 
To carry out our planned investigations we needed access to significant quantities of the natural 
product, dehydrodeoxy-brevianamide E (9). Racemic dehydrodeoxy-brevianamide E (9) has 
previously been prepared by Williams and co-workers.42e, 60 Their synthesis started with an 8-step 
synthesis of racemic Boc-protected amino acid 82 (Scheme 34), the synthesis of which had 
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previously been reported by the group.46 Boc-protected amino acid 82 was then converted into 
racemic (±)-dehydrodeoxy-brevianamide E (9) by a 4-step sequence of: amide coupling, amine 
deprotection, lactam ring closure and Mitsunobu-type dehydration. Overall their synthesis 
required 12 steps, with 8% overall yield, and was completed on <100 mg scale. We hoped to 
significantly reduce the step-count of this synthesis in order to develop a practical and readily 
scalable synthesis. 
 
A short and enantioselective synthesis of the Boc-protected amino acid intermediate 82, used in 
Williams synthesis, had been reported by Danishefsky and co-workers in 1999, proceeding in only 
5 steps from commercially available starting materials (Scheme 35).4g Their novel alkylation 
procedure (Step 2 - Scheme 35) enabled the direct reverse prenylation of protected tryptophan, 
avoiding the need for indole construction (cf. Steps 2 & 3 - Scheme 34). Combining Danishefsky’s 
and Williams’ procedures we could theoretically synthesise enantioenriched dehydrodeoxy-




Scheme 35: Danishefsky’s improved synthesis of Boc-protected amino acid 82.4g 
 
Firstly, we hoped to save two steps by avoiding the extraneous deprotection-reprotection sequence 
in Danishefsky’s synthesis (Steps 3 & 4 - Scheme 35). Instead we planned to directly hydrolyse 
ester 145 to give acid 146. Secondly, Williams’ synthesis required a distinct dehydration step to 
convert alcohol 83 into dehydrodeoxy-brevianamide E (9) (Step 12 - Scheme 34). We planned to 
avoid this by generating the N-acyl-enamine functionality directly by coupling dehydro-proline 
147 with acid 146, in a direct imine acylation. Finally, phthaloyl deprotection and lactam ring 
closure of N-acyl-enamine 148 would give access to the target natural product dehydrodeoxy-
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brevianamide E (9). To achieve this sequence we planned to carry out a well precedented phthaloyl 
de-protection of N-acyl-enamine 148 using hydrazine.4g, 61 Subsequent reflux under basic 
conditions had commonly been used for similar lactamisations in the literature.4h, 27a, 42e However, 
it was hoped that hydrazine would be sufficiently basic to allow both of these transformations to 
be carried out in a single step, further streamlining the synthesis. Similar single step hydrazine 
phthaloyl deprotection/ring closing reactions have been reported, albeit with poor yield.62 If 
successful, the planned synthesis would give us access to enantioenriched dehydrodeoxy-
brevianamide E (9) in between 5–6 steps, a significant reduction over literature approaches and a 
more practical route for preparing large quantities of material for further study. 
 
 





Synthesis of Prenylated Indole 145 
 
Our synthetic plan involved following Danishefsky’s4g procedure to synthesise prenylated indole 
145 from protected tryptophan 143. Danishefsky’s paper didn’t report a procedure for the 
protection of L-Trp to protected tryptophan 143, so we based our initial protection on reports from 
elsewhere in the literature.63 Refluxing L-Trp with phthalic anhydride in pyridine gave crude acid 
149,63a which was esterified without further purification to give protected tryptophan 143 in good 
yield using acetyl chloride in methanol.63b This sequence could be scaled up to give multi-gram 
quantities of protected tryptophan 143 in good yield. 
 
 




The reverse prenylation of protected tryptophan 143 required reagents which were not 
commercially available on the scale required. Thus, t-BuOCl was synthesised from t-BuOH using 
an acidic solution of sodium hypochlorite.64 1,1-Dimethylallene 152 was prepared by reacting 
propargyl chloride 151 (itself prepared on large scale from propargyl alcohol 150) with activated 
zinc to give an organozinc species which was subsequently protonated by the solvent to give 1,1-
dimethylallene 152.65 1,1-Dimethylallene 152 was hydroborated with 9-BBN (153) to give a 
solution of B-prenyl-9-BBN 144,66 which was used directly in the reverse prenylation. The first 
step of the reverse prenylation, t-BuOCl mediated indole oxidation of protected tryptophan 143, 
generated 3-chloroindolenine intermediate 154. This intermediate subsequently reacted with 




Model Studies Towards the Synthesis of N-acyl-enamine 148  
 
Our synthetic plan involved the coupling of the known imine 14767 to acid 146 with deprotonation 
of the resulting iminium ion giving the N-acyl-enamide 148 (Scheme 38). Initially we repeated 
Schmalz’68 oxidation and subsequent one pot coupling with methyl chloroformate to familiarise 
ourselves with this chemistry. Although we achieved a significantly lower yield of carbamate 156 
than reported by Schmalz (32% vs 90%), we attribute this to difficulty we experienced during 
chromatographic purification. The fact that we were able to synthesise the product was nonetheless 
promising. We then attempted to isolate their proposed intermediate, imine 147, after the first 
step.68 We were unable to achieve satisfactory purification by flash column chromatography. 
However, distillation under reduced pressure yielded imine 147 in good yield and on multi-gram 
scale. 
 
Next, we carried out a series of model studies to see under which conditions we might be able to 
synthesise N-acyl-enamine 148 from imine 147.  Conventional carbodiimide activation of acid 
149,69 – a simplified analogue of acid 146 lacking the reverse prenyl group –  proved unsuccessful. 
After a series of experiments, varying the number of equivalents of base, rate of addition of imine 
147 and the addition of HOBt additive we were unable to identify any of our desired product from 
these reactions. 
 
Following concern that carbodiimide coupling conditions did not generate a sufficiently reactive 
electrophile, we switched to using oxalyl chloride with catalytic DMF
70 to activate acid 149 as its 
acyl chloride 157. Slow addition of imine 147 and pyridine gave a crude product containing a 1:1 
ratio of major products. The first of these was tentatively identified as N-acyl-enamine 159 as it 
was co-isolated alongside a minor impurity (the presence of which complicated unequivocal 
characterisation). The second major product was identified as spiro-indolenine 158. The 
spiro-indolenine side product 158 is proposed to result from a 6-endo-trig ring cyclisation between 
the indole C3 and the N-acyl-iminium of intermediate 160. The results of this model study 
suggested that we were able to perform the desired coupling to give N-acyl-enamine 148 and gave 
us confidence to apply similar coupling conditions in the later stages of our synthesis. Indeed, it 
was envisaged that the presence of the reverse prenyl group at C2 in our intended substrate 146 








Hydrolysis of Methyl Ester 145 
 
With a proof of concept from our model studies, we wanted to hydrolyse methyl ester 145 to allow 
us to apply this chemistry directly to acid 146. We expected this to be fairly straight forward, 
especially given that the saponification of methyl ester 145 with LiOH had previously been 
reported by Ley and co-workers.61b However, attempts to repeat this chemistry yielded 
di-carboxylic acid 161, wherein the phthalimide ring had been cleaved (Scheme 39). Potassium 
carbonate in aqueous methanol,71 was also unsuccessful, yielding an unidentified mixture of 
products. In hindsight, the phthaloyl ring opening is consistent with the known sensitivity of the 
phthalimide group to ‘nucleophilic reagents, which in the case of mild aqueous base results in ring 
opening’.72 The sensitivity of the phthaloyl group might also explain why related syntheses 
swapped amide protecting groups with this substrate, replacing it with a Boc (see Step 3–4, Scheme 
35, page 46),4g trityl,4h or 2-trimethylsilylethoxycarbonyl groups.61b 
 
 
Scheme 39: Saponification of ester 145. 
 
In an attempt to avoid these deprotection-reprotection steps we decided not to sidestep this issue 
of chemoselectivity and instead focussed our attention on investigating SN2-type demethylation 
conditions.73 Lithium iodide has been widely used for the selective cleavage of methyl esters.74 
Fisher and co-workers have developed the use of lithium iodide for the dealkylation of esters 
containing an amide carbonyl group γ to the ester carbonyl group and demonstrated that these 




When we attempted de-alkylation of methyl ester 145 using Fisher’s conditions (LiI in EtOAc) we 
were able to synthesise lithium carboxylate 161 with high crude recovery. However, the purity of 
the carboxylate 161 was lower than desired (Scheme 40). The reaction mixture was observed to 
go dark brown (the colour was lost upon washing with aqueous sodium thiosulphate) indicating 




Scheme 40: SN2-type demethylation of ester 145, inspired by Fischer.
73 
 
Since purification of the carboxylate 161 was considered impractical, we instead attempted to 
synthesise carboxylate 161 more cleanly using LiCl in DMF.76 Encouraged by the formation of a 
small amount of product after 3 h at 110 °C the temperature was increased to 140 °C. At this 
temperature, the reaction proceeded well, however a small amount of starting material was still 
present after 6 h. To minimise this, the reaction was heated at an external temperature of 160 °C 
overnight, which gave a remarkably clean reaction, giving carboxylate 161 in essentially 
quantitative yield. The reaction was readily scaled to give 23 g of crude carboxylate.  
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Synthesis of N-Acyl Enamine 148 
 
With carboxylate 161 in hand we hoped to apply the results of our model studies to enable a 
synthesis of N-acyl-enamine 148. Lithium carboxylate 161 was activated as the acyl chloride using 
the oxalyl chloride with catalytic DMF
70 system which had proved successful during our model 
studies. We attempted the synthesis of the acyl chloride in anhydrous CD2Cl2, and analysis of the 
reaction mixture by 1H NMR spectroscopy showed a mixture of new products, which were 
tentatively assigned as the acyl chloride 165 contaminated with the corresponding anhydride 166, 
in a 20:1 ratio (Scheme 41). The crude mixture was fairly stable; the 1H NMR spectrum of the 
mixture did not change significantly when stored under inert atmosphere overnight. 
 
 
Scheme 41: Activation of lithium carboxylate 161 as the acyl chloride. 
 
Attempts to couple the acyl chloride with imine 147 showed consumption of the acyl chloride 
intermediate 165 by NMR spectroscopy, however the minor product of the acyl chloride synthesis 
166 did not appear to react. An early screen of bases also showed that NEt3 gave a cleaner reaction 
than pyridine, so this was used throughout the remainder of our investigations. After multiple 
repetitions, the reaction proved unreliable, with the putative anhydride 166 sometimes representing 
a major product of the overall reaction. Associated with this, acid 146 appeared to form during 
column chromatography, complicating purification. 
 
 
Scheme 42: Early attempts to synthesise N-acyl-enamine 148. 
 
In an attempt to avoid this, we tried changing the order of addition. Rather than adding oxalyl 
chloride and DMF to lithium carboxylate 161, we instead slowly added carboxylate 161 to a 
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premixed solution of oxalyl chloride and DMF. This gave a much cleaner reaction and allowed us 
to synthesise and purify N-acyl enamine 148 in good yield (Scheme 43). 
 
 
Scheme 43: Synthesis of N-acyl-enamine 148. 
 
With these optimised conditions we were delighted to observe the formation of our desired N-acyl 
enamine product 148 unaccompanied by the competing intramolecular indole ring closure we had 
observed in the model system (Scheme 38, page 51). The additional steric bulk of the reverse 
prenyl group on the indole appears to have disfavoured intramolecular ring closing sufficiently to 




Phthaloyl Deprotection to Give Dehydrodeoxy-brevianamide E (9) 
 
Having optimised the coupling to give us N-acyl-enamine 148 we next turned our attention to the 
phthaloyl deprotection. Traditionally this is carried out using hydrazine as a nucleophile.4g, 72 
When we attempted the reaction with hydrazine62 we were happy to observe that the desired 
deprotection was accompanied by ring closure to form the cyclic diketopiperazine ring of 
dehydrodeoxy-brevianamide E (9) in one step (Scheme 44). Unfortunately the yield for the 
reaction was poor, which was in part due to amide bond cleavage by the strongly nucleophilic 




Scheme 44: Phthaloyl deprotection and cyclisation to give dehydrodeoxy-brevianamide E (9) 
using hydrazine. 
 
Attempts to use alternative nucleophiles such as, ethylene diamine78, methylamine79 (N 15.19, SN 
0.68, MeCN),77  hydroxylamine (N 12.80, SN 0.63, MeCN),
77  ethanolamine,80 phenylhydrazine,81 
all gave similarly poor results.  Eventually we tried using methanolic ammonia, a significantly 
milder nucleophile (N 11.39, SN 0.69, MeCN),
77 which finally gave a reliable, clean reaction. This 
was readily scalable and allowed us to access dehydrodeoxy-brevianamide E (9) in 84% yield, in 
a single step from N-acyl enamine 148. 
 
 
Scheme 45: Phthaloyl deprotection and cyclisation to give dehydrodeoxy-brevianamide E (9) 




Scaled Up Total Synthesis of Dehydrodeoxy-brevianamide E (9) 
 
With the key reactions for the synthesis of dehydrodeoxy-brevianamide E (9) optimised, the next 
goal was to scale up the synthesis of our natural product monomer dehydrodeoxy-brevianamide E 
(9) and provide large quantities of material for further studies (Scheme 46). We started by 
preparing compound 143 using commercially available tryptophan methyl ester 168 as our starting 
material. From this material we were able to prepare bis-protected tryptophan 143 in a single step 
by a simple phthaloyl protection.82 This alternate starting material allowed us to shave a step from 
our previous synthetic route and conveniently, the crude product was sufficiently pure to be used 
without additional purification.  
 
 
Scheme 46: Scaled up total synthesis of dehydrodeoxy-brevianamide E (9). 
 
Using this material we were able to scale up Danishefsky’s reverse prenylation conditions,4g giving 
prenylated indole 145 on 21 g scale, with 69% yield over the two steps. While repeating the final 
3 steps of the synthesis, Dr Nick Green, a PDRA in the Lawrence group, found that these steps 
could be telescoped. We subsequently scaled up the final 3 steps of the synthesis, giving access to 
dehydrodeoxy-brevianamide E (9) with 49% yield over these 3 steps. The scaled-up synthesis of 
dehydrodeoxy-brevianamide E (9) was completed on 8.5 g scale, with 34% overall yield, and 
required just two chromatographic purifications. With a longest linear sequence of 5 steps from 
commercially available starting materials, our total synthesis of dehydrodeoxy-brevianamide E (9) 
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represents a significant improvement on the literature. It more than halves the step count of 
Williams’ previous 12-step synthesis,42e, 60,83 and is a 4-step reduction on a formal 9-step 





Chapter 2: Towards a Synthesis of Brevianamide J (20) and 
Brevianamide S (21) 
 
Oxidative Coupling of Enolate Equivalents 
 
We were planning to investigate a biomimetic oxidative N-acyl-enamine homo-coupling reaction 
to access brevianamide J (20) and S (21) (Scheme 48). Precedent for similar reactions was 
therefore important to this project. The oxidative coupling of enolates has been widely used to 
form 1,4-dicarbonyls. The range of specific enolate equivalents coupled includes lithium enolates, 
silyl enol ethers and enamines.84 A general approach involves conversion of the substrate into an 
enolate equivalent, followed by addition of an oxidant to give the desired coupling (Scheme 47). 
 
 
Scheme 47: General mechanism for oxidative coupling of enolate equivalents.84 
 
Until 2010 the scope of oxidative enamine homo coupling was limited to vinylogous amides,85 
such as compound 169, of which a number of examples had been reported.86 With these substrates 
it is proposed that the initially formed radical cation can be readily deprotonated to form a doubly 
capto-stabilised radical, such as intermediate 170 (Scheme 48).86b This electron poor radical can 
then undergo radical addition to the electron rich site of another unit of vinylogous amide. 
Subsequent cyclisation generally yields the pyrrole, however the synthesis of a dimeric 
tetrahydrofuran ring system - similar to that of brevianamide J (20) - has also been reported for 
substrates where pyrrole ring formation is not possible. In Poulton’s work, a range of example 
vinylogous amides 172 were oxidised in the presence of water to form tetrahydrofuran ring 
systems 173.86f Poulton’s results suggest that an analogous tetrahydrofuran ring forming reaction 
might be possible with dehydrodeoxy-brevianamide E (9), since pyrrole ring formation is 





Scheme 48: Oxidative coupling of vinylagous amides.86b, 86f 
 
In 2010 Jia and co-workers published a paper where they described the oxidative coupling of 
simple enamines 176, formed in situ from aldehydes 174 and amines 175, to give symmetrical 
pyrroles 178.85  Jia proposed a mechanism for these reactions very similar to that which we have 
proposed for the oxidative coupling of dehydrodeoxy-brevianamide E (9). Jia’s results provide 
crucially important precedent for the oxidative coupling of simple enamines, rather than just 
vinylogous amides. However, whether these results would translate to our more electron deficient 
N-acyl-enamine substrates dehydrodeoxy-brevianamide E (9) and brevianamide K (10) remained 









Oxidative Coupling Attempts with Dehydrodeoxy-brevianamide E (9)  
 
With one of our proposed biosynthetic monomers in hand, we began by trying to oxidatively 
couple monomer dehydrodeoxy-brevianamide E (9) to form dimer 131 (Scheme 49). We treated 
dehydrodeoxy-brevianamide E (9) with a range of different single electron oxidants and saw no 
significant reaction with AgOTf or FeCl3 under any of the conditions tested. However, Cu(OTf)2 
and CAN both gave the same major product when the reaction was carried out in MeCN. The 
oxidation was highly sensitive to the polarity of the solvent system. When aqueous MeCN was 
used as the solvent system the reactions became much slower, with only a little product formed 
with CAN and no reaction observed with Cu(OTf)2. Attempts to use excess CAN to speed up the 
reaction in aqueous MeCN gave rapid decomposition, with no clear products formed.  In EtOH, 
CAN reacted to give product(s) but no reaction was observed for Cu(OTf)2. 
 
 
Scheme 49: Oxidative coupling of dehydrodeoxy-brevianamide E (9) to give unsymmetrical dimer 
182. 
Of Cu(OTf)2 and CAN, Cu(OTf)2 is the milder oxidant (E°′(Cu(OTf)2 in MeCN) = 0.40, E°′(Ce(IV) 
in H2O) = 0.88),
87 and was thus expected to give a cleaner reaction, so we scaled up the reaction 
using this oxidant88  to allow us to isolate sufficient product for characterisation (Scheme 49). We 
were unable to purify the product by flash column chromatography or reverse phase HPLC. 
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However, after extensive analysis of the NMR data for the mixture, we were able to tentatively 
identify the major product as unsymmetrical dimer 182 (see page 163 for analysis). 
 
 
Scheme 50: Literature examples of indole oxidative couplings.89 
 
This product shows oxidative indole coupling rather than the desired oxidation of the 
N-acyl-enamine moiety. While C3–C3 indole oxidative couplings such as the copper (II) coupling 
of 3-ethyl-indole reported by Tsuji and co-workers are common (Scheme 50),89 reflecting the 
tendency of the indole to oxidise primarily at the C3 position (see Scheme 63 & Scheme 64, Page 
72–72), C3-C6 couplings are rare (see Scheme 50 for examples). Some C3-C6 dimer 187 was 
observed by Takayama and co-workers when 1,2,3,4-tetrahydrocarbazole 185 was oxidised with 
PIDA, however C3-C3 dimer 186 still represented the major product of the reaction.90 Surprisingly, 
PIFA oxidation of the same substrate gave almost exclusively C3-C6 dimer 187. The same 
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oxidation could also be achieved by anodic oxidation to give the same C3-C6 coupled dimer 187.91 
We suspect that the steric bulk of the C2-reverse-prenyl group in our substrate prevents C3-C3 
coupling. Instead our substrate undergoes C3-C6 coupling, consistent with Sarpong’s 
investigations of indole halogenation, which suggest that C6 is the second most oxidisable position 





Indole Protection Attempts 
 
The electron rich nature of the indole seemed to be leading to indole oxidation as opposed to 
N-acyl-enamine oxidation. To circumvent this, we planned to investigate whether electron 
withdrawing protecting groups on the indole nitrogen might disfavour indole oxidation sufficiently 
to enable the desired coupling. 
 
 
Scheme 51: Boc protection of dehydrodeoxy-brevianamide E (9) inspired by Sodeoka's 
conditions.93 
 
There was good precedent in the literature for indole protection in preference to amides. For 
example, Sodeoka was able to achieve quantitative Boc protection of indole 189 without any 
competing amide protection (Scheme 51).93 When the ‘amide’ was part of a diketopiperazine ring 
(i.e. a lactam) there were greater issues of chemoselectivity (Scheme 51).93 Indole protection was 
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still favoured over amide protection, with the reaction giving a mixture of mono-protected indole 
192 and bis-protected product 193. However, when we tried similar protection conditions,93 we 
saw clean lactam protection without any sign of the desired indole protection by NMR analysis of 
the crude reaction mixture (Scheme 51). Extending the reaction time, increasing the equivalents 
of reagent and catalyst and heating the reaction,94 didn’t give any observable indole protection. 
The differences in chemoselectivity observed for this protection compared to the literature is 
presumably due to the steric bulk of the reverse prenyl group, at the C2-position of the indole. 
 
Although we were unable to observe indole protection with simple nucleophilic catalysis, we 
hoped to be able to achieve protection under basic conditions. Martin has reported indole 
protection, with a quaternary carbon group at the 2-position of the indole, using sodium hydride 
as a strong base to activate the indole (Scheme 52).95 
 
 
Scheme 52: Martin’s indole protection conditions.95 
 
Based on the DMSO pKa values for indole (21.0)96 and the 6 membered lactam δ-valerolactam 
198 (26.6)97 reported by Bordwell (Scheme 53), we expected basic conditions to favour 




Scheme 53: pKa value of indole and lactam.96-97 
 
However, when we attempted Boc protection of our substrate under Martin’s basic conditions, 
using sodium hydride, we again observed clean amide protection without any sign of indole 
protection (Scheme 54). The fact that we were still unable to observe any indole protection, under 
these more forcing conditions, demonstrates the clear steric influence of the reverse prenyl group 
on the reactivity of our substrate. It’s possible that the restricted rotation of the quaternary 
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substituent at the 2-position of Martin’s indole substrate 196 reduced its steric influence enough 
to enable the type of protection we were unable to observe. The crude material from both of our 
indole protection attempts was combined and columned to give Boc-protected lactam 194 for 
characterisation in a 50% average yield across the two reactions. 
 
 
Scheme 54: Attempted Boc protection of indole with sodium hydride. 
 
Our attempts to achieve indole protection with a range of different protecting groups proved 
unsuccessful, even under forcing conditions. Upon further investigation of the literature, it became 
apparent that indole protection with an adjacent reverse prenyl group (or analogue) was a known 
challenge. In his early landmark synthesis of austamide (27), Kishi had been forced to develop a 
new protecting group for the indolic nitrogen for this challenging protection.98 In his paper, Kishi 
noted the greater reactivity of the diketopiperazine nitrogen towards intermolecular alkylation, and 
consequently was forced to protect the N–H of the diketopiperazine prior to indole protection. 
Treating indole 199 with 2-chloroethyl chloromethyl ether 200 with KH as a base gave them 
protected indole 201 in 50% yield (Scheme 55). Unfortunately, Kishi’s protecting group wasn’t 
expected to be sufficiently electron withdrawing to significantly attenuate indole oxidation. For 
this reason and because of progress in other areas of the project, further efforts towards indole 
protection were not deemed to be an immediate priority. 
 
 




Early Stage Coupling of Dehydro-proline 147 
 
Given the failure of our single electron oxidative coupling attempts to give the desired dimer(s) an 
alternative approach was considered. Rather than late-stage oxidative coupling of complex 
monomer dehydrodeoxy-brevianamide E (9), we instead envisioned an early-stage oxidative 
coupling of imine 147. This would be followed by a double coupling with acyl chloride 165 to 
give complex dimer 203. Finally, we planned to apply our methanolic-ammonia conditions to 
affect a deprotection and cyclisation to give our initial dimeric target 131. 
 
 
Scheme 56: Synthetic plan based on early stage coupling of dehydro-proline 147. 
 
In the literature there were numerous examples of deprotonation α to an imine, oxime or 
hydrazones, followed by oxidative coupling, generally using a halogen as the terminal oxidant. 99 
For example, Kaiser and Wiegrebe used n-BuLi to deprotonate oxime 204, followed by I2 as an 
oxidant to access dimer 205 in a one-pot procedure (Scheme 57).99a 
 
 




Attempts to apply the same conditions to our imine substrate 147 gave a complex mixture, 
including the double addition product 206 in 5% yield, but without any sign of dimer (Scheme 58). 
 
 
Scheme 58: Attempt to apply Kaiser and Wiegrebe’s oxidative coupling conditions to imine 147. 
 
To avoid nucleophilic addition of base to the ester, we attempted to carry out the reaction using 
LDA as a non-nucleophilic base, starting the reaction at −78 ºC and slowly warming to room 
temperature.100 Under these conditions we were able to isolate a dimeric product, imine 207, in 5% 
yield. However, dimer 207 was the result of an unexpected unsymmetrical dimerisation rather than 
the desired symmetrical dimerisation (Scheme 59). 
 
 
Scheme 59: oxidative coupling of imine 147. 
 
One possible mechanism is presented in Scheme 60. The planned reaction required deprotonation 
α to the carbon of the imine. Instead it appears that deprotonation occurred at the carbon, α to the 
nitrogen of the imine, to give an imine-enolate intermediate 209. Oxidation by iodine, followed by 





Scheme 60: Proposed mechanism for oxidative coupling of imine 147. 
 
Based on the failure of a one-pot approach for oxidatively coupling imine 147, we considered an 
alternative synthetic sequence (Scheme 61). Instead of deprotonating imine 147 and then carrying 
out an oxidative coupling using halogen, we instead planned to carry out an oxidation with a 
halogen oxidant, followed by reductive coupling to form the dimer. 
 
 
Scheme 61: Alternative synthetic plan for coupling imine 147. 
 
Attempts to oxidise imine 147 with sulfuryl chloride101 appeared to give overoxidation. NBS gave 
poor results, however with NCS the reaction proceeded cleanly when monitored by NMR 
spectroscopy to give mono-chlorinated 212 in 57% yield after chromatography (Scheme 61). We 
planned to trial reductive coupling conditions using this material, however, due to progress in other 
areas of the project this line of investigation was put on hold. 
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Oxidation Chemistry of Dehydrodeoxy-brevianamide E (9) – 2 Electron 
Conditions 
 
In our investigations so far, attempts to carry out an oxidative coupling of dehydrodeoxy-
brevianamide E (9) under single electron conditions had proved unsuccessful, giving instead an 
unsymmetrical dimer. However, we hadn’t yet investigated the oxidation chemistry of 
brevianamide K (10), the other proposed biosynthetic precursor to brevianamide S (21) and 
brevianamide J (20). We hoped to synthesise brevianamide K (10) by dehydrogenation of 
dehydrodeoxy-brevianamide E (9). We were also hopeful that oxidation of dehydrodeoxy-
brevianamide E (9) under non-single electron conditions might also give us a route through to the 
dimer brevianamide S (21). We were therefore keen to explore a wide range of different oxidation 
conditions to explore the innate reactivity of the substrate. 
 
 
Scheme 62: investigations into the oxidation chemistry of dehydrodeoxy-brevianamide E (9). 
 
An initial screen of oxidants on dehydrodeoxy-brevianamide E (9) – conducted by Dr Nick Green, 
a PDRA in the Lawrence group – using a range of different oxygen-based oxidants, consistently 
showed chemoselective oxidation of the indole, accompanied by ring closure, to give a mixture of 
diastereomeric hydroxy-pyrroloindoles 71 and dia-71. The reaction with Davis’-oxaziridine,20 was 
fairly clean, but showed almost no stereoselectivity, giving an approximately 1:1 d.r. of hydroxy-
pyrroloindoles 71 and dia-71 (Scheme 63). Attempts to oxidise dehydrodeoxy-brevianamide E (9) 
with DMDO102 and singlet oxygen,4a gave similar results, with low diastereoselectivities. However, 
oxidation with m-CPBA gave the same major products with improved diastereoselectivity, 
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alongside an unexpected fragmentation product. Further investigations into these conditions are 
discussed in detail in Chapter 4 (Page 97). 
 
 
Scheme 63: Nick Green’s Davis’-oxaziridine oxidation of dehydrodeoxy-brevianamide E (9). 
 
When dehydrodeoxy-brevianamide E (9) was oxidised with halogens,103 chemoselective indole 
oxidation was observed. However, with halogen oxidants, indole oxidation was not accompanied 
by ring closure as it had been with oxygen oxidants. Instead of forming ring closed pyrroloindoles, 
oxidation with halogens instead gave halo-indolenines. For example, oxidation of dehydrodeoxy-
brevianamide E (9) with NBS gave halo-indolenine 213 – prepared by Dr Nick Green – in 57% 
yield as a mixture of diastereomers (Scheme 64). Similar reactivity was observed qualitatively in 
test reactions with iodine and chlorine-based oxidants. 
 
 
Scheme 64: Indole oxidation with NBS. 
 
With bromo-indolenine substrate 213 in hand, we expected to be able to carry out an E2 
elimination under basic conditions to give access to brevianamide K (10). However, we were 
unable to observe elimination under any of the conditions tested. Treating bromo-indolenine 213 
with DBU caused slow decomposition at room temperature.104 Attempts to use weaker bases also 
proved unsuccessful. For example, refluxing with Li2CO3,
105 or Ag2CO3 in DMF, gave no reaction 
and neither did refluxing in neat NEt3,
103 or pyridine.106 Given our inability to eliminate 
bromo-indolenine 213 we considered alternative strategies for oxidising dehydrodeoxy-
brevianamide E (9) to brevianamide K (10).  
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Oxidation of Dehydrodeoxy-brevianamide E (9) – Radical Conditions 
 
Radical oxidation was considered as an approach to achieve different chemoselectivity. Under 
radical conditions, we expected to avoid oxidation of the indole in favour of the diketopiperazine 
C–H methine. Hydrogen abstraction at this position would give a stabilised capto-dative radical 
intermediate. 
 
Scheme 65: Kishi’s synthesis of (±)-hydratoaustamide (30) by radical autoxidation.98 
 
In Kishi’s original synthesis of austamide he applied this approach to carry out a radical 
autoxidation of 214 under an atmosphere of oxygen to chemoselectively oxidise at a single methine 
position of the diketopiperazine (Scheme 65).98 Corey subsequently applied these same conditions 
in an improved synthesis of austamide.16 
 
Scheme 66: Synthesis of brevianamide K (10) under radical halogenation conditions. 
 
Although Kishi’s autoxidation conditions proved unsuccessful on our substrate, carrying out a 
similar oxidation with NCS instead of oxygen as the terminal oxidant, gave small amounts of 
brevianamide K (10). However, even after extensive optimisation brevianamide K (10) could only 
be accessed in 22% yield based on NMR analysis using an internal standard (Scheme 66). 
Brevianamide K (10) was always isolated alongside oxindole 113 which was the major product of 
the reaction unless it was carried out over activated molecular sieves. Even with molecular sieves 
the hydration product 113 was isolated in 8% yield.  
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Synthesis of Brevianamide K (10) 
 
Mukaiyama had first developed the use of chloro-sulfinimidoyl reagent 216 to oxidise alcohols to 
the corresponding aldehydes/ketones (Scheme 67).107 Similar conditions had also been applied to 
the oxidation of amines,108 and N-sulfonyl-amines.109 
 
 
Scheme 67: First use of Mukaiyama's chloro-sulfinimidoyl oxidising reagent (216).107a 
 
Although we were unable to find any reports of Mukaiyama’s chloro-sulfinimidoyl reagent (216) 
being applied to directly oxidise an amide, Matsuo had used it to carry out dehydrogenations on 
carbamates (Scheme 68).110 In contrast to Mukaiyama’s milder conditions Matsuo used n-BuLi, 
presumably as a strong base to deprotonate the carbamate and utilise the nucleophilicity of the 
conjugate base. We hoped to be able to apply a similar approach to dehydrogenate dehydrodeoxy-
brevianamide E (9) using the reactivity of the amide moiety. 
 
 
Scheme 68: Matsuo's application of Mukaiyama's dehydrogenation conditions, with their 
proposed mechanism.110b  
 
Applying Matsuo’s strongly basic conditions to our substrate proved unsuccessful. However, using 
DBU as a base instead of n-BuLi, as reported in Mukaiyama’s original paper,107a gave 
brevianamide K (10) in 12% yield alongside 68% recovered starting material, based on NMR 
analysis using an internal standard  (Scheme 69). The reaction initially appeared to proceed rapidly 
by TLC at −78 °C, but after allowing the reaction to warm to room temperature and leaving for 3 
days the reaction still had not gone to completion, even with excess reagent. The reaction 
proceeded cleanly but appeared to be stalling. We attributed this to an unwanted side reaction 
between DBU and the chloro-sulfinimidoyl reagent 216. DBU was expected to be more 
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nucleophilic than the amide under these conditions and with α-hydrogen atoms, could potentially 
undergo a competing dehydrogenation. Consumption of the reagents (DBU and Mukaiyama’s 
chloro-sulfinimidoyl reagent 216) in the absence of substrate has previously been observed by 
Mukaiyama.107b Therefore, Barton’s base 221 was trialled as an alternative to DBU. It doesn’t 
have a hydrogen atom α to the most basic/nucleophilic position so wasn’t expected to undergo 
competing dehydrogenation. As a guanidine base it also is also a slightly stronger base than DBU. 
Under these conditions the reaction didn’t stall and brevianamide K (10) was isolated in 56% yield 
(Scheme 69). This represents the first reported total synthesis of brevianamide K (10), with a 
longest linear sequence of 6 steps. 
 
 
Scheme 69: Dehydrogenation of dehydrodeoxy-brevianamide E (9) using Mukaiyama's 
chloro-sulfinimidoyl reagent 216 to prepare brevianamide K (10). 
 
With brevianamide K (10) in hand we were able to test oxidative coupling conditions on this 
substrate. Applying the same CuII(OTf)2 conditions we previously used to oxidatively dimerise 
dehydrodeoxy-brevianamide E (9), we were unable to observe any dimeric product (Scheme 70). 
Instead oxidative fragmentation product, aldehyde 222,66 was the major product observed in the 
crude. A proposed mechanism is presented in Scheme 70. Initial indole oxidation would give a 
stabilised radical(cation) intermediate, stabilised by extensive delocalisation, and capto-datively 
by the lactam groups of the diketopiperazine ring. This radical(cation) would therefore be expected 
to persist until it could undergo a second single electron oxidation rather than undergoing radical 
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addition (to form a less stable radical intermediate). Subsequent hydration and fragmentation 
would then give aldehyde 222 as the product of the reaction. 
 
 





N-Acyl-enamine Oxidation of Dehydrodeoxy-brevianamide E (9) 
 
Having prepared brevianamide K (10) we investigated alternative conditions for 
pre-functionalising our monomer in preparation for a dimerisation reaction. This work was 
conducted in conjunction with Dr Nick Green. 
 
 
Table 1: Optimisation of N-acyl-enamine oxidation. All reactions carried out at room temperature 
in N,N-dimethylformamide-d7 overnight. 
 equivalents equivalents 
 NIS TFA 227a. 
a 1 0.02 41% 
b 1.3 0.02 25% 
c 1 1 32% 
d 1.3 1 17% 
a. NMR yields, using an internal standard. 
 
Previous oxidations of dehydrodeoxy-brevianamide E (9) with halogen-based oxidants had 
consistently given indole oxidation (Scheme 64, page 72), unless carried out under radical 
conditions (Scheme 66, page 73). However, Dr Green found that halo-indolenines were prone to 
decomposition, which could be prevented by adding a few drops of NEt3 prior to concentration 
and storage. Decomposition appeared to be associated with polar solvent, and acidic (or at least 
non-basic) conditions. Based on these observations we explored halogenations in polar solvents. 
Halogenation using NBS or NIS in alcohol solvents (e.g. CD3OD, t-BuOH) appeared to give 
halogenation, accompanied by incorporation of one equivalent of solvent. Inspired by these results, 
Dr Green tried oxidising dehydrodeoxy-brevianamide E (9) with NIS in DMF, which gave direct 
access to compound 227, a promising intermediate for dimerisation studies. Initial attempts to 
repeat the reaction, however, gave unreliable results. Following purification of reagents (see 
experimental for details) and further optimisation of the reaction (Table 1) we were able to scale 





Scheme 71: Optimised N-acyl-enamine oxidation of dehydrodeoxy-brevianamide E (9) in polar 
solvent. 
 
Mechanistically we propose that the change in chemoselectivity in acidified polar solvent is the 
result of the reaction being able to funnel through to the thermodynamically favoured product 
under these conditions. We still expect that indole oxidation would be kinetically favoured, 
however protonation of the intermediate halo-indolenine, followed by an SN2 reaction at iodine by 
trace iodide in solution could reasonably regenerate molecular iodine as an active oxidant. N-acyl-
enamine oxidation would then give access to the observed product 227, which is expected to be 
thermodynamically favoured over the halo-indolenine 228 due to its undisrupted aromatic indole. 
A similar mechanistic proposal and pattern of reactivity was reported by Sarpong whilst this work 
was ongoing (Scheme 72).92 Initial oxidation of the indole could be followed by rearrangement at 
elevated temperature (or under Lewis acid catalysis), with regeneration of aromaticity, to give the 
6-haloindole product under thermodynamic control. 
 
 





Reductive Dimerisation of Compound 227 
 
With pre-functionalised monomer 227 in hand, we next set about developing reductive coupling 
conditions. Attempts to use Baldwin’s reductive coupling agent111 CoICl(PPh3)3 under 
Movassaghi’s conditions,112 gave no reaction at room temperature. Heating monomer 227 with 
excess Cu(I) thiophene-2-carboxylate,113 gave dimer 131 as a minor product, alongside 
proto-dehalogenation product dehydrodeoxy-brevianamide E (9) as the major product (Scheme 
73). These Ullmann-type conditions – originally developed by Dr Nick Green – were promising, 
successfully giving some reductive coupling product. However, further optimisation was required 
to give the desired selectivity and improve the yield.  
 
 
Scheme 73: Synthesis of dimer 131 under Nick Green’s Ullmann type conditions.
113 
 
A rational optimisation of this Ullmann-type coupling was complicated by controversy regarding 
the mechanism, which is ‘still not known with certainty.’114 Generally two main mechanisms are 
proposed. The suggested radical mechanism involves initial single electron transfer, followed by 
radical-radical coupling (Scheme 74).114 Within this mechanistic framework, the 
proto-dehalogenation observed would be the result of competing hydrogen abstraction by the 
radical intermediate.  
 
The suggested ionic mechanism (Scheme 74), involves an initial oxidative addition to form a Cu(II) 
intermediate 234 using Cu(0) as the reductant - which corresponds to a Cu(III) intermediate with 
our Cu(I) reductant. This would need to undergo reduction to Cu(I) species 235 before it could 
undergo further oxidative addition to another unit of monomer and subsequent reductive 
elimination. Assuming this type of mechanism, the basicity of the initial Cu(III) intermediate 





Scheme 74: Mondall’s proposed general mechanisms for Ullmann reactions.114 
 
Inspired by conditions reported by Ploypradith and co-workers,115 a modification of the reaction 
conditions were considered. Assuming an ionic Ullmann mechanism, proto-dehalogenation would 
most likely occur via protonation of an initial Cu(III) intermediate. We thought that the competing 
reduction could be favoured over proto-dehalogenation by using Ploypradith’s conditions, with 
excess of Cu(0) as the terminal reductant and a lower equivalency of Cu(I) 
thiophene-2-carboxylate (Scheme 75). Using Ploypradith’s conditions we were able to access 
dimer 131 as the major product of the reaction in an improved 2:1 crude ratio (131:9). Based on 
our hypothesis we tried further reducing the amount of Cu(I) thiophene-2-carboxylate, from 2 
equivalents to catalytic quantities of 10 mol%. Under these conditions we saw good 











Attempts Towards Total Synthesis of Brevianamide S (21)  
 
With dimer 131 in hand we expected that simply applying our amide-dehydrogenation conditions 
(Scheme 69, Page 75) would give us direct access to brevianamide S (21). However, when we 
attempted these conditions, we saw no reaction, with only starting material recovered (Scheme 76). 
The dimeric starting material was poorly solubility in CH2Cl2 so we had tried the reaction with 
(CH2Cl)2, although we do not think this can account for the lack of reaction.  
 
 
Scheme 76: Attempted dehydrogenation of dimer 131. 
 
Instead, we propose that additional delocalisation enabled by the dimer linkage significantly 
reduces the acidity of the diketopiperazine amide. A nitrogen atom on the other side of the dimer 
can donate into the carbonyl of the amide, reducing its acidity (Scheme 37). Mixing lactam 
dehydrodeoxy-brevianamide E (9) with Barton’s base 221 hadn’t shown any visible change 
relative to the 1H NMR spectrum of pure dehydrodeoxy-brevianamide E (9). Suggesting that, 
while the conjugate base was accessible, the equilibrium significantly disfavoured deprotonation 
of the amide. It is therefore likely that a decrease in the acidity of the amide could make the 
conjugate base inaccessible and prevent the reaction from proceeding. 
 
 




To sidestep our inability to dehydrogenate dimer 131, we attempted to change the order of steps. 
We were able to apply our dehydrogenation conditions to compound 227 to give the alternative 
monomer 239 in 35% yield by analysis using an NMR internal standard, with 13% isolated yield 
after multiple rounds of chromatography (Scheme 78). 
 
 
Scheme 78: Dehydrogenation of compound 227 to give monomer 239. 
 
When a reductive coupling of compound 239 was attempted using unoptimised Ullmann-type 
conditions we did not observe dimer brevianamide S (21). Instead the major product of the reaction 
was aldehyde 222 (Scheme 79). Using a Cu(I) species as our reductant, reductive 
coupling/proto-dehalogenation of substrate 239 would generate a Cu(II) species as a side-product. 
Previously, when we had treated brevianamide K (10) with Cu(II) oxidant, we had observed 
oxidative fragmentation to give the same aldehyde product 222 (see Scheme 70, page 76). 
 
 




To avoid this oxidative fragmentation we then applied our optimised conditions (Scheme 75), 
using only catalytic Cu(I), with excess Cu(0) as the terminal oxidant, to minimise the formation 
of Cu(II) and disfavour proto-dehalogenation. Under these conditions, some fragmentation 
product was still observed, but it was relatively minor. Brevianamide K (10) was a major product 
of the reaction, which is the result of proto-dehalogenation. This obscured all regions of the 1H 
NMR spectrum where peaks for brevianamide S (21) had been reported in CD3OD,
3c with the 
exception of a single peak reported at δ = 3.13, dd (9.6, 9.0 Hz) ppm. In this region we observed a 
matching peak with δ = 3.14, app. t (~9.3 Hz) ppm, suggesting we had formed brevianamide S (21) 
(Figure 10). 
 
Scheme 80: Attempt to couple compound 239 with excess Cu(0). 
 
Unfortunately, due to the small scale of this test reaction we were unable to record a sufficiently 
intense 13C NMR spectrum of the crude for comparison to literature values and the material 
corresponding to the peak of interest was lost during purification attempts. Nonetheless, these 
results suggest that we may have prepared brevianamide S (21) for the first time, a promising lead 













Chapter 3: Total Synthesis of Brevianamide X (16) and Y 
(17) 
 
Total Synthesis of Brevianamide X (16) 
 
 
Scheme 81: Preparation of bicyclo[2.2.2]diazaoctanes 56 and 109. 
 
We began our synthesis of brevianamide X (16) by repeating Williams synthesis of syn and anti 
bicyclo[2.2.2]diazaoctane Diels–Alder adducts 109 and 56.42e When we attempted the reaction at 
room temperature we consistently observed a significant amount of recovered starting material. In 
an attempt to push the reaction to completion we heated the reaction to 40 ºC, however this led to 
a reduction in stereocontrol, giving only 3:2 d.r. (whereas lower temperatures gave a 2:1 d.r.) and 
there was still some starting material present in the crude. 
 
Initially, chromatographic purification proved challenging, however following optimisation of the 
solvent system, a CHCl3/MeCN based solvent system was found to give good separation. This 
could be explained by the high α solvatochromic parameters of these solvents (α(CHCl3) ≈ 0.44, 
α(MeCN) = 0.19),116 representing their ‘hydrogen bond acidity’,117 and enabling significant 
differential interactions between the Lewis-basic amide groups of the two stereoisomers. With this 





Scheme 82: Synthetic plan for the synthesis of brevianamide X (16), inspired by the work of 
Williams and co-workers.4e, 42b, 42c, 42e, 42f  
 
From substrate 109 we planned to oxidise it to hydroxy-indolenine 108, followed by acid catalysed 
rearrangement to give the oxindole and complete the total synthesis of brevianamide X (16) 
(Scheme 82). The planned oxidation was well precedented. Related oxidations by Williams and 
co-workers on the diastereomer of our substrate (reaction 1 - Scheme 82),42c, 42e the PMB protected 
analogue of our substrate (reaction 2 - Scheme 82),4e and the lactim ether analogue of our substrate 
(reaction 3 - Scheme 82),42b all with practically perfect diastereoselectivity. Williams had also 
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reported acid catalysed rearrangements of the diastereomer of our planned hydroxy-indolenine 
intermediate 74, to give the related oxindole product brevianamide Y (17) (reaction 4 - Scheme 
82).42f 
 
Applying the planned 2-step sequence - diastereoselective oxidation and acid catalysed 
rearrangement - to the syn-Diels–Alder adduct 109 proved successful and gave us access to 
racemic brevianamide X (16) in 50% yield over the two steps (Scheme 83). This represents the 
first total synthesis of this natural product and proceeds in only 8 steps. While the final stages of 
this synthesis draw heavily from the work of Williams and co-workers, this synthesis allowed us 
to develop greater familiarity with bicyclo[2.2.2]diazaoctane chemistry, which we later applied to 
more challenging targets (see Chapter 4, Page 97). 
 
 
Scheme 83: Our synthesis of brevianamide X (16). 
 
We were interested in modifying this synthesis to enable an enantioselective synthesis of 
brevianamide X (16), by carrying out an oxidative kinetic resolution of indole 109 to give 
enantioenriched hydroxy-indolenine 108. Attempts to use chiral oxaziridine 
(−)-(8,8-dichlorocamphorsulfonyl)oxaziridine 234 as an oxidant gave a slow reaction after TFA 
was added. To our surprise the oxidation gave doubly oxidised hydroxy-oxindole 235 alongside 
recovered starting material, without any sign of mono-oxidised product. No significant enantio-
induction was observed however the structure of the unexpected product was very interesting. We 
had inadvertently synthesised the depyrano-analogue of the known natural product sclerotiamide 
(236).118 This unexpected and complex transformation is an impressive example of how the innate 
reactivity of these substrates will often give rise to structural motifs observed in natural products. 
Attempts to apply the same conditions to dehydrodeoxy-brevianamide E (9) gave no reaction 
(Scheme 84), suggesting that the specific structure of indole 109, with its fused 
bicyclo[2.2.2]diazaoctane core might be significant for this reaction and that this isn’t simply a 









Total Synthesis of Brevianamide Y (17) 
 
Williams had previously synthesised racemic (±)-brevianamide Y (17) from 
hydroxy-diketopiperazine 84, prepared in 11 steps (Scheme 34, page 45).42e, 42f Dehydration of 
hydroxy-diketopiperazine 84 under Mitsunobu-type conditions, followed by in situ 
tautomerization and hetero-Diels–Alder gave diastereomeric syn and anti 
bicyclo[2.2.2]diazaoctanes (±)-109 and (±)-56. Oxidation of the minor anti-diastereomer with 
Davis’-oxaziridine gave hydroxy-indolenine 74, which was initially miss-assigned as 
brevianamide Y (17). However, in a subsequent correction hydroxy-indolenine (±)-74 was 
rearranged to oxindole (±)-brevianamide Y (17) under acidic conditions.42f Overall this represents 
a 14-step synthesis of racemic (±)-brevianamide Y (17). 
 
 
Scheme 85: Williams' synthesis of brevianamide Y (17).42e 
 
Qin had also previously completed an 18-step synthesis of (–)-brevianamide Y (17) (Scheme 86).54 
The key step was a late stage hetero-Diels–Alder reaction, however accessing the precursor 
required a large number of steps and further steps were required to install the carbonyl of the 





Scheme 86: Qin's synthesis of ent-brevianamide Y (17).54 
 
Williams’ total synthesis of the related natural product versicolamide B (33), the pyrano-analogue 
of brevianamide Y (17), inspired us to consider an improved strategy based on a late-stage 
hetero-Diels–Alder reaction. The starting material 239 had been made in 11 steps, although the 
exact details of this synthetic sequence are not clearly detailed in the paper, nor references cited.24, 
119 This was coupled to a hydroxy-proline derivative 240 to give amide 241 as a mixture of 








Scheme 88: Completion of Williams’ synthesis of (+) and (-)-versicolamide B (33).53 
 
Hydroxy-diketopiperazine diastereomers 242 and 243 were independently oxidised to 
diastereomeric mixtures of oxindoles using Davis’-oxaziridine (Scheme 88).53 The diastereomeric 
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oxindole products were then separated and dehydrated under Mitsunobu-type conditions, before 
undergoing tautomerisation and hetero-Diels–Alder reactions to give either (+) or (−) 
versicolamide B (33) alongside their minor diastereomers (+) or (−) taichunamide E (252).21 The 
stereochemical outcome for each reaction was controlled by the oxindole stereocenter, with the 
other stereocenter being ablated during the course of the reaction. Despite its length (16 steps), 
and complications resulting from the use of racemic starting material, this synthesis provides a 
good model for an improved synthesis of brevianamide Y (17), based on a late stage 
oxindole-controlled hetero-Diels–Alder reaction. 
 
With our plan to synthesise brevianamide Y (17) based on a late-stage, hetero-Diels–Alder reaction, 
we began by developing a diastereoselective oxidation of dehydrodeoxy-brevianamide E (9) to the 
corresponding oxindole. We had previously observed oxindole 113 as a side product, associated 
with trace moisture, in the NCS oxidation of dehydrodeoxy-brevianamide E (9) to form 
brevianamide K (10) (Scheme 66, page 73). After a brief screen of conditions, we determined that 
NCS in MeOH, with catalytic TFA and a little added water gave the cleanest oxidation. Reactions 
in CDCl3 gave less clean results and reactions with NIS as the oxidant were unreliable, giving an 
entirely different set of products when the reaction was carried out in CD3OD with catalytic TFA. 
Our optimised conditions gave diastereomeric oxindoles 113 and dia-113 which were readily 
separated by flash chromatography, using a MeCN/CHCl3 solvent system, to give pure 
diastereomers in 76% combined yield with 5:3 d.r. Treating the major diastereomer 113 to 
Williams’ basic-rearrangement/hetero-Diels–Alder conditions,42e gave brevianamide Y (17) as the 
major product of the reaction, alongside its diastereomer 253 (the depyrano-analogue of 
taichunamide E (252). The poor yield for this reaction is attributed to difficulties with purification. 
 
 
Scheme 89: Our synthesis of brevianamide Y (17). 
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Overall, our synthesis of brevianamide Y (17) was completed in a longest linear sequence of  7 
steps, halving the step count of Williams’ 14-step racemic synthesis (Scheme 85, page 91) and 
more than halving Qin’s 18 steps (Scheme 86, page 92). In contrast to Williams’ synthesis of 
racemic brevianamide Y (17), carrying out the hetero-Diels–Alder reaction as the final step of the 
synthesis allowed the initial stereocenter of dehydrodeoxy-brevianamide E (9), to influence the 
stereochemical outcome of the indole oxidation in a point-to-point chirality transfer. The 
stereochemistry of the oxindole was then able to control the stereochemistry of the final 
hetero-Diels–Alder reaction, in which the initial stereocenter is ablated. In principle this should 
have allowed us to prepare enantioenriched material, however accurate determination of its optical 
rotation has so far been precluded by lack of material and the low intensity of the optical rotation 
reported for this material (literature: [𝛂]𝑫
𝟐𝟓 +11.5 (c 0.2, MeOH), literature (enantiomer): [𝛂]𝑫
𝟐𝟎 –
12.6 (c 0.10, CH2Cl2)).
13, 54a A future scaled-up synthesis is planned to provide more material for 
this purpose and to enable us to resolve the difficulties associated with purification. This will also 






Chapter 4: Total Synthesis of Brevianamide A (1) 
 
Synthesis of Dehydro-brevianamide E (71) 
 
Based on a modification of Williams’ biosynthetic hypothesis, we were interested in investigating 
oxidations which might give access to an indoxyl intermediate 73, which was expected to act as 
biosynthetic precursor to brevianamide A (1). 
 
 
Scheme 90: Synthetic plan for brevianamide A (1). 
 
An initial screen of oxidants on dehydrodeoxy-brevianamide E (9) was conducted by Dr Nick 
Green, a PDRA in the Lawrence group. A wide range of different oxygen based oxidants such as 
DMDO,102 Davis’-oxaziridine,20 and singlet oxygen,4a gave chemoselective oxidation of the indole 
which was accompanied by ring closure to give a mixture of diastereomers 71 and dia-71 without 
any indoxyl product observed. The reaction with Davis’-oxaziridine was fairly clean, but gave 
almost no stereoselectivity, giving an approximately 1:1 mixture of hydroxy-pyrroloindoles 71 
and dia-71 (Scheme 91). However, oxidation with m-CPBA gave hydroxy-pyrroloindoles 71 and 
dia-71 with improved diastereoselectivity, alongside a side product. 
 
 
Scheme 91: Nick Green’s Davis’-oxaziridine oxidation of dehydrodeoxy-brevianamide E (9). 
 
The side product was initially suspected to be an indoxyl on the basis of a carbonyl 13C NMR shift 
(δ = 201.2 ppm) consistent with an indoxyl heterocycle (see Scheme 3, Page 11 for examples). In 
order to determine the structure of the side product, and confirm the diastereoselectivity observed 
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by Dr Green, we repeated the oxidation, using a slight excess of m-CPBA (Scheme 92).120 These 
conditions gave hydroxy-pyrroloindoles 71 and dia-dE, isolated with 51% overall yield and 2:1 
d.r. along with 9% recovered starting material and 20% of the side product, which was able to be 
identified as oxidative fragmentation product 254 upon closer analysis. 
 
 
Scheme 92: Oxidation of dehydrodeoxy-brevianamide E (9) with 1.2 eq m-CPBA. 
 
The double oxidation product is the dehydrogenated, depyrano-analogue of known natural product 
amoenamide A (255), first isolated from Aspergillus amoenus NRRL 35600 in 2017.25a  
 
 
Scheme 93: Structural similarity between oxidative fragmentation product 254 and amoenamide A 
(255). 
 
This unexpected side product is formed by oxidative fragmentation, possibly via 
hydroxy-indolenine intermediate 72. Addition of m-CPBA, followed by fragmentation would give 
the double oxidation product 254 (Scheme 94). This second oxidation/fragmentation sequence is 
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likely to occur prior to ring closure to form hydroxy-pyrroloindole 71 and therefore these reactions 
are expected to be in competition. Ring closure could potentially be reversible under these 
conditions, but the fact that starting material was recovered despite the use of excess oxidant, 
indicates that the oxidative fragmentation pathway is fast enough to be kinetically competitive 
during the course of the reaction and isn’t merely the result of over oxidation resulting from excess 
oxidant. Based on this proposed mechanism, we hypothesised that that slow addition of m-CPBA 
would limit the concentration of hydroxy-indolenine intermediate 72 during the course of the 
reaction and thereby reduce the rate of oxidative fragmentation. Slow addition of a single 
equivalent of m-CBPA gave significantly less double oxidation product 254 and a lower proportion 
of recovered starting material (Scheme 95). We attempted to optimise the reaction to achieve better 
diastereoselectivity by testing a range of milder conditions. However, running the reaction at −40 
ºC didn’t significantly increase diastereoselectivity and gave a large amount of recovered starting 
material. Given that we had seen little diastereoselectivity with oxidants other than m-CPBA, we 
then attempted to screen a range of alternative peracids and peracid analogues.  
 
 
Scheme 94: Proposed mechanism for oxidative fragmentation. 
 
Peracetic acid and perbenzoic acid were generated in situ, inspired by conditions reported by 
Sarpong and co-workers,121 due to limited commercial availability/long lead times. However, both 
sets of conditions gave large amounts of recovered starting material without improved 
diastereoselectivity. Attempts to carry out the oxidation using in situ generated peroxyimidic 
acids,122 gave either no reaction with peroxyacetimidic acid123 or mostly recovered starting 
material with the more reactive peroxy-trichloroacetimidic acid,122 again, without any 
improvement in diastereoselectivity. Alternative peracids had failed to give improved 
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diastereoselectivity, so we chose to scale up the reaction with m-CPBA due to its relative simplicity 
and ease of use. 
 
Scaling up the oxidation, we added just over 1 equivalent of m-CPBA slowly to minimise double 
oxidation (Scheme 95). The reaction gave 2.80 g of hydroxy-indolenines 71 and dia-71 with 3:2 
isolated d.r. (crude d.r. 9:5) with 67% combined yield, alongside 7% recovered starting material 
and a mixture of double oxidation product 254 (5%) and oxindole 113 (4%). On smaller scales, 71 
and dia-71 had been separable by preparative TLC without significant optimisation, however on 
large scale, separation of the diastereomers by flash chromatography proved exceptionally 
challenging. Developing optimised conditions for the separation was therefore essential. 
 
 
Scheme 95: Large scale oxidation to give dehydrodeoxy-brevianamide E (71). 
 
MeCN, THF, i-PrOH and acetone gave little to no separation. Selectivity group II solvents (such 
as Et2O, i-Pr2O)
124 proved the most promising. They are characterised by their relatively high β 
solvatochromic parameters (β(Et2O) = 0.47, β(i-Pr2O) = 0.49),
116 representing their 
‘hydrogen-bond basicity’117 alongside otherwise low polarity parameters. EtOAc (selectivity 
group VIa)124 also gave modest selectivity, presumably due to its relatively high β parameter, 
β(EtOAc) = 0.45, (see Appendix 4, Page 201, for full table of Rf data).
116 A relatively high 
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‘hydrogen-bond basicity’ (in an otherwise relatively non-polar solvent) would be expected to give 
good differential interactions between the hydroxyl groups of the two diastereomers, and is a 
potential explanation for the good selectivity observed with these solvents. 
 
 
Of the solvents tested, i-Pr2O was associated with the best selectivity, however, use of this solvent 
presented a few challenges. Neat i-Pr2O gave an almost baseline Rf, so dilution with a more polar 
solvent was necessary. Mixed EtOAc/i-Pr2O solvent systems were usable, however, the mix gave 
lower selectivity and the large proportion of i-Pr2O used was linked to poor dissolution of the 
sample, associated with streaking. i-Pr2O has a remarkably low Hildebrand solubility parameter, 
δ(i-Pr2O) = 7.1, lower even than n-Hexane, δ(n-Hexane) = ~7.5,
125 making it an exceptionally poor 
solvent for dissolving even modestly polar substrates. To overcome this, we tried swapping EtOAc, 
δ(EtOAc) = 8.9, with CH2Cl2, δ(CH2Cl2) = 9.6, which has a substantially lower eluotropic strength, 
allowing us to use a higher proportion in our solvent mixture. 
 
To our surprise, mixed i-Pr2O/DCM solvent systems showed co-operative elution, with higher Rf 
values observed for mixed solvent systems than for either pure solvent (Graph 1). Rf values had 
their maximum at around 7:3 DCM/i-Pr2O at 0.15/0.09 for the two diastereomers. This remarkable 
solvent system was used as the basis for our optimised separation. Despite the high concentration 
of CH2Cl2 and good solubility of the substrates, some streaking was still observed, and attempts 
to supress this with additives (NEt3/i-PrOH) reduced separation without significantly sharpening 
spots by TLC. Streaking is often associated with hydrogen bonding from hydroxyl groups, 
however the rationale for our solvent system was to leverage differential hydrogen bonding with 
the hydroxyl groups of our molecule to achieve selectivity, so some amount of streaking was 
perhaps unavoidable. Optimised chromatography conditions gave 34% (1.43g) pure major 
diastereomer 71 after the first column and a total of 37% (1.54 g) after the second. The second 
column also gave 11% (0.454 g) pure minor diastereomer dia-71, as well as many mixed fractions 






















Investigations Towards Brevianamide A (1) 
 
 
Scheme 96: Precedent for base catalysed rearrangement of hydroxy-indolenines to form 
indoxyls.42b, 98,4e, 42c, 42e 
 
Based on the clear predisposition of dehydrodeoxy-brevianamide E (9) to oxidise to give fused 
hydroxy-pyrroloindoles 71 and dia-dE, under a wide range of different conditions and our inability 
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to observe either hydroxy-indolenine 72 or indoxyl 73, we concluded that the fused 
hydroxy-pyrroloindole 71 was the most likely biosynthetic precursor to brevianamide A (1). There 
was already a fair amount of precedent to suggest that this transformation might be feasible under 
basic conditions. In his early 1979 synthesis of Austamide,98 Kishi had developed conditions for 
the rearrangement of a hydroxy-indolenine intermediate 258 to an indoxyl 259 under basic 
conditions via a ‘type IV’126 semi-pinacol rearrangement (Scheme 96). Williams subsequently 
applied similar conditions numerous times to carry out rearrangements of hydroxy-indolenines to 
indoxyls en route to brevianamide B (2) (Scheme 96).42b,4e, 42c, 42e We had already applied a base 
mediated rearrangement/hetero-Diels–Alder sequence to prepare bicyclo[2.2.2]diazaoctanes: 109, 
56, 253 and brevianamide Y (17) (Scheme 97). The conditions previously used for each of the two 
planned transformations – base catalysed bicyclo[2.2.2]diazaoctanes formation and rearrangement 
to the indoxyl – were remarkably similar, and we hoped they could occur sequentially in an in situ 
cascade from dehydro-brevianamide E (71). 
 
 
Scheme 97: Previous applications of base catalysed rearrangement/Diels–Alder sequence in this 
work. 
 
For this approach to work, the hydroxy-pyrroloindole ring of compound 71 would need to readily 
open under basic conditions. This would enable a pre-equilibrium, where hydroxy-indolenine 72 
generated in situ could react either with rearrangement to indoxyl 73, followed by rearrangement 
to azadiene 66 and Diels–Alder reaction to give brevianamide A (1) (Route (1), Scheme 98) or 






Scheme 98: Potential routes for cascade forming brevianamide A (1) under basic conditions. 
Our first attempts to synthesise brevianamide A (1) started using Kishi’s methanolic  methoxide 
approach,98 under conditions reported by Williams.4e This gave hydroxy-indolenine 261 as the 
major product of the reaction, alongside brevianamide A (1), with brevianamide B (2) a minor 
product, which initially proved challenging to purify due to its generally poor solubility6b (Scheme 
99). Trace amounts of brevianamide Y (17) were also observed in one sample of brevianamide B 
(2) after numerous purification attempts. However, it’s unclear if this was formed during the 
reaction, during the acidic workup, or during chromatography. 
 
 




Scheme 100: Conversion of dehydro-brevianamide E (71) to oxindole 113 under acidic conditions. 
 
These initial results suggested that the 5 membered pyrroloindole ring of dehydro-brevianamide E 
(71) was fairly labile. We therefore expected that we might be able to carry out an acid mediated 
rearrangement of dehydro-brevianamide E (71) to give an oxindole product. Heating dehydro-
brevianamide E (71) with trifluoroacetic acid in deuterated methanol showed slow conversion to 
oxindole 113, without any sign of the diastereomer dia-113 (Scheme 100). 
 
 
Scheme 101: Proposed mechanisms for conversion of dehydro-brevianamide E (71) to oxindole 
113. 
 
The complete stereoselectivity observed for this transformation implies a stereospecific (or highly 
stereoselective) mechanism. Two possible stereospecific mechanisms are presented in Scheme 101. 
The first mechanism, Route (1), proceeds without dissociation of the hydroxyl group, with the 
initial stereochemistry of the hydroxyl centre controlling the stereochemical outcome of the 
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reaction to give oxindole C3-S-113. By contrast the second mechanism, Route (2), (suggested by 
Jacqueline Tan in personal correspondence) involves initial dehydration, with the stereochemistry 
of the reverse-prenyl group controlling the stereochemical outcome of the reaction and giving a 
different diastereomer of oxindole C3-R-113. 
 
To limit the amount of the valuable major diastereomer dehydro-brevianamide E (71) we needed 
to use for our optimisations we chose to continue by using the minor diastereomer dia-71 as a 
model system. Assuming that minor differences in the equilibrium for the initial ring opening 
wouldn’t significantly affect the remainder of the reaction, the main difference between the two 
starting materials was that they were expected to give opposite enantiomers of product. The 
diastereomer dia-71 was therefore expected to act as an almost perfect model system for dehydro-
brevianamide E (71). 
 
Treating dia-71 with aqueous KOH in MeOH42e (Scheme 102) gave ent-brevianamide A (1) and 
ent-brevianamide B (2) in 65% combined yield with 3.1:1 d.r. alongside 10% hydroxy-indolenine 
ent-261. It appears that introducing water to the reaction conditions reduced the quantity of 
hydroxy-indolenine product relative to brevianamide A (1). With anhydrous methoxide in 
methanol, hydroxy-indolenine 261 had been the major product (Scheme 99, page 105), whereas 
under these aqueous conditions, hydroxy-indolenine ent-261 was a minor product. 
 
 
Scheme 102: Brevianamide A (1) synthesis - aqueous potassium hydroxide in methanol. 
 
Treating hydroxy-pyrroloindole dia-71 with weaker base gave hydroxy-indolenine 
bicyclo[2.2.2]diazaoctane products ent-261 and ent-74 as a mixture of diastereomers, with almost 
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complete chemoselectivity, with only trace amounts of brevianamide A (1) visible in the 1H NMR 
spectrum of the crude product. 
 
 
Scheme 103: Selective synthesis of hydroxy-indolenine bicyclo[2.2.2]diazaoctanes ent-261 and 
ent-74. 
 
These results led us to consider the hypothesis that these hydroxy-indolenines were intermediates 
en route to brevianamide A (1) and brevianamide B (2) (Scheme 104) under the more forcing 
conditions previously used.  
 
 
Scheme 104: Mechanistic proposal - hydroxy-indolenines 261 and 74 as precursors to 
brevianamide A (1) and B (2). 
 
Based on this hypothesis, we hoped that, using potassium carbonate under more forcing conditions, 
the mixture of hydroxy-indolenines would funnel through to indoxyls brevianamide A (1) and 
brevianamide B (2). Applying the previously aqueous methanolic potassium carbonate conditions 
to dehydro-brevianamide E (71) and heating to reflux still gave hydroxy-indolenine product 261 
rather than brevianamide A (1). However, under these conditions the diastereomer 74 was no 
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longer observed. Hydroxy-indolenine 261 appears to be stable under these reaction conditions, 
whereas its diastereomer 74 is consumed. 
 
 
Scheme 105: Attempted synthesis of brevianamide A (1), with aqueous methanolic potassium 
carbonate under reflux. 
 
The rearrangement of hydroxy-indolenine 74 under basic conditions is a known transformation 
(Scheme 106),24a, 61 so this result was unsurprising, but the relative stability of the diastereomer 
261 was remarkable and merited further investigation. 
 
 
Scheme 106: William's rearrangement of hydroxy-indolenine 74 to brevianamide B (2).24a, 61 
 
Resubjection of ent-261 to the conditions previously used to synthesise brevianamide A (1) 
(Scheme 102, page 48) gave exclusively recovered starting material, with no ent-brevianamide A 
(1) observed (Scheme 107). This strongly suggests that hydroxy-indolenine 261 is not a precursor 
to brevianamide A (2), but rather an alternative product formed by a different mechanistic route. 
 
 




To rule out the possibility that hydroxy-indolenine 261 was formed from brevianamide A (1), we 
resubjected brevianamide A (1) to anhydrous methanolic conditions previously used to synthesise 
it (Scheme 99, page 105). We saw no reaction under these conditions, which gave exclusively 
recovered starting material, with no formation of hydroxy-indolenine 261 (Scheme 108). 
 
 
Scheme 108: Resubjection of brevianamide A (1) to reaction conditions. 
 
Based on these results an improved mechanism for the formation of brevianamide A (1) and 
hydroxy-indolenine 261 was suggested (Scheme 109). It’s clear that hydroxy-indolenine 261 is 
not an intermediate to brevianamide A (1) nor brevianamide A (1) to compound 261. 
Brevianamide A (1) and hydroxy-indolenine 261 seem to be formed from two competing reactions, 
which can be favoured depending on the reaction conditions. When the weak base potassium 
carbonate was used (Scheme 103, page 108; Scheme 105, page 109) Route (2) dominated, forming 
hydroxy-indolenine 261 as the main product, with only trace brevianamide A (1) observed. With 
stronger bases such as NaOMe or NaOH, both routes contributed significantly, with anhydrous 
conditions (Scheme 99, page 105) slightly favouring formation of hydroxy-indolenine 261 and 





Scheme 109: Updated mechanistic proposal for formation of brevianamide A (1) and hydroxy-
indolenine 261. 
 
The remarkable stability of hydroxy-indolenine 261 was further demonstrated by its stability under 
acidic conditions (Scheme 110). 
 
 
Scheme 110: Attempted acid catalysed rearrangement of hydroxy-indolenine 261 to oxindole. 
 
When treated to the same conditions by Williams’ and co-workers, hydroxy-indolenine 74 had 
undergone rearrangement to oxindole brevianamide Y (17)42f (Scheme 111) and we had applied 
similar conditions in our synthesis of brevianamide X (16) (Scheme 83, page 89). However, 






Scheme 111: Williams’s acidic rearrangement of hydroxy-indolenine 74 to oxindole 
brevianamide Y (17).42f 
 
The remarkable stability of hydroxy-indolenine 261 could potentially be due to internal hydrogen 
bonding between the hydroxyl group and the N–H of the lactam (Figure 11). This would be 
expected to substantially increase the thermodynamic stability of the substrate. 
 
 
Figure 11: Possible internal hydrogen bonding in 261. 
 
Like brevianamide A (1), B (2) and Y (17), hydroxy-indolenine 261 has an anti-relationship 
between the methine C–H and amide N–H of its bicyclo[2.2.2]diazaoctane core. The hydroxyl 
group of the hydroxy-indolenine is also anti with respect to the C–H methine of the core. This 
relationship would make it very challenging to synthesise or biosynthesise via oxidation of a 
bicyclo[2.2.2]diazaoctane substrate such as 56. Laboratory oxidation of bicyclo[2.2.2]diazaoctane 
indoles has consistently given exclusive syn oxidation (Scheme 112).42c, 42e Oxidation from the 
convex face of the molecule – past the C–H methine – is sterically favoured and probably accounts 
for the high degree of selectivity observed for these oxidations. 
 
 




Figure 12: Natural product analogues of hydroxy-indolenine 261.23 
 
Hydroxy-indolenine 261 has several natural product analogues, which share its relative 
stereochemistry around the bicyclo[2.2.2]diazaoctane core and with respect to the 
hydroxy-indolenine (Figure 12). Asperversiamide A (267)23 and taichunamide A (268)21,22 have 
both been isolated from Aspergillus versicolor. Both enantiomers of notoamide U (269) have been 
isolated; (−) from Aspergillus amoenus NRRL 3560025a and (+) from Aspergillus taichungensis.34 
Penicimutamide D (36) has also been isolated from a diethyl sulfate mutant of the marine-derived 
fungus Penicillium purpurogenum G59.34 Given that the formation of these natural products via the 
oxidation of a bicyclo[2.2.2]diazaoctane indole would be contrary to the innate diastereoselectivity 
of the substrate, it is likely that their biosynthesis instead mirrors the synthesis of hydroxy-
indolenine 261 described in this work (Scheme 103, page 108), by a sequence of ring opening, 
tautomerisation and hetero-Diels–Alder from a hydroxy-pyrrolo-indolenine intermediate (e.g. 
Route (2), Scheme 109, Page 111). As well as presenting a model for their likely biosynthesis, our 
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synthesis potentially presents a general synthetic approach to this group of natural products, which 
would be challenging to synthesise by alternative means. 
 
Taichunamide H (46) was co-isolated with taichunamide A (268) from Aspergillus versicolor22 
and the related N-oxide aspergamide A (270) was isolated from Aspergillus ochracheus.27 
Together these natural products pose some interesting biosynthetic questions. They possess the 
same anti relationship between the methine C–H of the bicyclo[2.2.2]diazaoctane core and 
hydroxy group of the hydroxy-indolenine as 261, which would be difficult to form via late stage 
oxidation. However, the syn relationship between the C–H methine and the N–H of the 
bicyclo[2.2.2]diazaoctane core would be difficult to form via a late stage Diels–Alder reaction. 
Although Diels–Alder reactions of indole precursors tend to somewhat favour formation of 
syn-Diels–Alder adducts, (Scheme 81, page 87) indoxyl and oxindole precursors give exclusively 
anti products and from our studies, the same trend appears to apply to hydroxy-indolenines. During 
our syntheses of hydroxy-indolenine bicyclo[2.2.2]diazaoctane 261 we were never able to observe 
any syn-Diels–Alder adducts. 
 
 





Optimisation of Brevianamide A (1) Synthesis 
 
 
Scheme 113: Optimisation of brevianamide A (1) synthesis, yields based on NMR analysis of the 
crude product in (CD3)SO using ethylene carbonate an internal standard. 
 
Table 2: Brevianamide A (1) optimisation: temperature, base screen, methanolic vs aqueous 
conditions. 
  Concentration  Temperature  Result 
 Base  (M) Solvent  (°C) Time ent-1 ent-2 ent-261 
a KOH 1 4:1 H2O/MeOH 65 50 min 37% 7.0% 11% 
b KOH 1 H2O rt 4 h 49% 4.8% 1.5% 
c NaOH 1 H2O rt 4 h 43% 4.3% 1.1% 
d LiOH 1 H2O rt 4 h 60% 6.0% 1.7% 
e KOH 1 H2O 0–8 6 h 47% 5.3% 1.3% 
 
Based on our updated mechanistic proposal for the formation of brevianamide A (1) and hydroxy-
indolenine 261 (Scheme 109, page 111) we set about trying to optimise the reaction in favour of 
brevianamide A (1). Using our aqueous-methanolic KOH conditions as a baseline (Table 2, entry 
a – see Scheme 102, page 107), we set about optimising the reaction to achieve the best possible 
yield and selectivity for brevianamide A (1). Based on our observation that aqueous conditions 
had disfavoured the formation of brevianamide A (1), we attempted the reaction in the complete 
absence of organic solvent (Table 2, entry b). To our delight, the reaction not only worked, but 
could be carried out at room temperature to give a significantly improved yield of brevianamide A 
(1). This swap to aqueous conditions almost eliminated the formation of hydroxy-indolenine 
product 261, going from 11% to <2%. Interestingly the diastereomeric ratio of brevianamide A (1) 
to brevianamide B (2) also improved substantially, from ~5:1 (Table 2, entry b) to ~10:1 – which 
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matches the ratio isolated from fungal samples.39 This observation could be explained by the 
suppression of the hydroxy-indolenine forming pathway (Scheme 103, page 108), indicated by the 
huge reduction in formation of hydroxy-indolenine 261. This pathway has substantially lower 
diastereoselectivity (d.r. ~3:1 261:74, Scheme 103, page 108) and since the minor diastereomer, 
hydroxy-indolenine 74 readily converts to brevianamide B (2) (Scheme 106, page 109),24a, 61 
supression of this pathway would substantially improve the brevianamide A (1) to brevianamide 
B (2) ratio. Next, we compared alternative bases (Table 2, entry b–c). NaOH gave somewhat worse 
yield than KOH, however using LiOH substantially improved the yield without adversely affecting 
the selectivity of the reaction. We were also able to carry out the reaction at reduced temperature 
with KOH (Table 2, entry e) however this had little impact on the reaction. 
 
Next, we explored the effect of reaction time on the yield (Table 3, entry a–b) and found that 
longer reaction times substantially reduced the yield of the reaction. The reaction itself appears to 
proceed almost instantaneously, with the limiting factor being the slow dissolution of the starting 
material. Although we had observed significant improvements in selectivity by removing methanol 
from the reaction, we tested the addition of a smaller quantity of MeOH to aid dissolution, however 
this didn’t significantly affect the outcome of the reaction (Table 3, entry c). 
 
Table 3: Brevianamide A (1) optimisation: effect of time, effect of trace MeOH. 
  Concentration  Temperature  Result 
 Base  (M) Solvent  (°C) Time ent-1 ent-2 ent-261 
a LiOH 1 H2O rt 18 h 26% 4.4% 1.3% 
b LiOH 1 H2O rt 30 min  65% 5.4% 1.3% 
c LiOH 1 20:1 H2O/MeOH rt 20 min 63% 4.6% 1.9% 
 
An investigation into the strength of base showed that strongly basic conditions (pH>14) were 
required for highly chemoselective formation of brevianamide A (1) and B (2). No reaction was 
observed in the absence of base (Table 4, entry a). Under aqueous methanolic conditions, K2CO3 
had previously given highly chemoselective formation of hydroxy-indolenines 261 and 74, in good 
yield, at room temperature, (Scheme 103, page 108). However, under aqueous conditions in the 
absence of methanol (Table 4, entry b) the reaction proceeded slowly and required heating to give 
a complex mixture containing hydroxy-indolenine 261 and brevianamide A (1), in low yield. 
Under similar conditions, K3PO4 gave a complex mixture containing less hydroxy-indolenine 261 




Varying the concentration of LiOH from 0.1 M to 5 M (Table 4, entry d–g), the 0.1 M reaction 
required a longer reaction time, gave a lower yield of brevianamide A (1) and gave substantially 
more hydroxy-indolenine 261. The 1 M conditions appeared to be optimal, although increasing 
the concentration to 2–5 M didn’t substantially reduce the yield of the reaction and reduced 
hydroxy-indolenine 261 formation to <0.5%. We had previously tried using saturated KOH under 
methanolic conditions (Table 4, entry h). Under these conditions an initial product was formed, 
which had previously been seen to slowly convert back to brevianamide A (1) in DMSO (Scheme 
114, Page 118), consistent with Birch’s observations with respect to the hydrolysis and 
regeneration of brevianamide A (1).6a Acidification of the reaction mixture and slow concentration 
under a flow of N2 gave brevianamide A (1) in 54% yield. We suggest that these strongly basic 
conditions lead to alkaline lactam hydrolysis of brevianamide A (1), to give compound 271, which 
is capable of ring closure back to brevianamide A (1) under a range of conditions (Scheme 114, 
Page 118). This hydrolysis reaction might also account for the reduction in yield associated with 
longer reaction times (Table 3, entry a). 
 
Table 4: Brevianamide A (1) optimisation: strength and concentration of base. *entry h was 
acidified (HCl aq.) and concentrated under a flow of N2 overnight before recording yields. 
  Concentration  Temperature  Result 
 Base  (M) Solvent  (°C) Time ent-1 ent-2 ent-261 
a none - H2O rt overnight - - - 
b K2CO3 1 H2O rt/70 days/5 h 8.0% 2.0% 12% 
c K3PO4 1 H2O rt/70 days/5 h  8.4% 2.1% 3.6% 
d LiOH 0.1 H2O rt 18 h 45% 7.4% 17% 
e LiOH 1 H2O rt 30 min  65% 5.4% 1.3% 
f LiOH 2 H2O rt 40 min 56% 4.7% 0.5% 
g LiOH 5 H2O rt 20 min 58% 5.2% 0.2% 
h* KOH saturated 4:1 H2O/MeOH rt 40 min 54% 2.9% - 
 
We also tested the effect of varying the concentration of starting material dia-71 (Table 5, entry a-
b) however this didn’t have a large effect on the yield. 
 
Table 5: Brevianamide A (1) optimisation: concentration of substrate (varying amount of solvent). 
  Concentration  Temperature  Result 
 Base  (M) Solvent  (°C) Time ent-1 ent-2 ent-261 
a LiOH 1 H2O (20 mL) rt 17 min 55% 5.1% 1.3% 




Overall, aqueous conditions with sufficient strong base appear to be optimal, and consistently gave 
a d.r. of between 12:1–10:1, brevianamide A (1): brevianamide B (2) while forming very little 
hydroxy-indolenine 261 (<2%). LiOH was identified as the optimal base of those tested and it was 
beneficial to keep reaction times as low as practical while still allowing enough time for complete 
dissolution of the starting material (~30 min). Extending the reaction time was associated with 










Scale Up – Completion of Brevianamide A (1) Synthesis 
 
We chose to scale up the synthesis using dia-71 to prepare the unnatural enantiomer, 
(−)-brevianamide A (1), prior to committing material to synthesising the natural enantiomer 
(+)-brevianamide A (1). Based on our reaction optimisation attempts, 1 M aqueous LiOH was 
expected to give the most reliable and high yielding reaction. Longer reaction times had been 
shown to harm the outcome of the reaction, so just enough time was allowed to affect full 
dissolution of the starting material under these reaction conditions.  
 
The hydroxy-indolenine starting materials dehydro-brevianamide E (71) and dia-71 are insoluble 
in water. However, brevianamide A (1) showed some solubility in water; a saturated solution in 
D2O gave a bright yellow sample after filtration, with a weak NMR spectrum consistent with 
brevianamide A (1). This aqueous sample appeared foamy when shaken, suggesting brevianamide 
A (1) might be able to act as a detergent, which could aid solubilisation of the starting material 
during the reaction. The solubility and potential detergent effect of brevianamide A (1) could also 
be substantially increased by the basic conditions used for the reaction. Under these scaled up 
aqueous conditions, only trace hydroxy-indolenine 261 was observed, and we were able to purify 




Scheme 115: optimised synthesis of unnatural enantiomers, (–)-brevianamide A (1) and 
(–)-brevianamide B (2). 
 
A minor indole fragmentation side product was also isolated, hydroxy-oxindole 272. The 
formation of an indole fragmentation product bears some similarities to the indoxyl fragmentation 
observed by Halligan while working in Williams’ lab, which was reported to give indoxyl 69 as 




Scheme 116: Indoxyl fragmentation reported by Kathleen Halligan (Williams group).48 
 
A proposed mechanism for our observed fragmentation is shown in Scheme 117. Following 
rearrangement to the indoxyl (Scheme 109, page 111), deprotonation α to the lactam would give 
an enolate 273 which could undergo retro-Michael fragmentation. Subsequent protonation would 
give Halligan’s reported indoxyl product 69. However, under our conditions this was not observed 
and instead appears to have undergone a subsequent autoxidation at the central C–H of the indoxyl. 
Initial hydrogen abstraction at this position would give a highly stabilised capto-dative radical 
intermediate, potentially explaining the rapidity of the observed oxidation. Finally 
hydroxy-indoxyl 275 appears to have undergone base mediated rearrangement to the 
corresponding hydroxy-oxindole 272, presumably driven by the greater thermodynamic stability 
associated with oxindoles over indoxyls.127 Its possible that the difference in fragmentation 
products observed between our two sets of conditions is due to our reaction being carried out under 
an aerobic atmosphere. Unfortunately, no characterisation data was reported for Halligan’s product 
to facilitate direct comparison. 
 
 
Scheme 117: Proposed mechanism for indoxyl fragmentation and autoxidation. 
Applying our optimised conditions to the major diastereomer dehydro-brevianamide E (71) and 
scaling up the reaction allowed us to purify 750 mg of the natural enantiomer (+)-brevianamide A 





Scheme 118: Optimised synthesis of (+)-brevianamide A (1) and (+)-brevianamide B (2). 
 
The absolute structure of (+)-brevianamide A (1) (the natural enantiomer)6a was confirmed by 
X-ray crystallography. The crystal structure was solved by Dr Gary Nichol at the University of 
Edinburgh. Brevianamide A (1) crystallised from CHCl3 (by vapour diffusion of Et2O) with one 
molecule of solvent of crystallisation, consistent with the crystallisation reported by Birch.6a 
 
 
Figure 14: X-ray structure of brevianamide A (1). 
 
Overall, these results complete the first total synthesis of brevianamide A (1), as well as 
representing the shortest reported synthesis of the minor natural diastereomer, brevianamide B (2) 
(for all previous syntheses see Appendix 1, Page 185).4d-f, 42b, 42c, 42e, 42g, 42i The synthesis required 
a longest linear sequence of only 7 steps, with only 4 chromatographic purifications. Our results 
support our proposed biosynthesis for brevianamide A (1) and B (2) (Scheme 119). 
 
Our results support the surprising conclusion that that hydroxy-pyrroloindole 
dehydro-brevianamide E (71) acts as a key intermediate in the biosynthesis of brevianamide A (1) 
and B (2), despite the fact that the saturated analogue, brevianamide E (5) had previously been 
determined to be a ‘shunt metabolite’ by biosynthetic feeding studies.46 Previous attempts to mimic 
Williams’ proposed route had used protecting groups to prevent ring closure and formation of 
pyrrolo-indole brevianamide E (5). However, our studies show that pyrrolo-indole formation does 
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not need to be avoided if the (bio)synthesis proceeds via the alternative intermediate 
dehydro-brevianamide E (71). 
 
 
Scheme 119: Proposed biosynthesis of brevianamide A (1) and B (2). 
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 Our results support Halligan’s observation,48 that the free indoxyl is unstable and prone to 
fragmentation. This requires it to undergo the hetero-Diels–Alder reaction quickly to form the 
stable products brevianamide A (1) and brevianamide B (2) – consistent with the cascade from 
dehydro-brevianamide E (71) in our synthesis and proposed biosynthesis. This also represents 
evidence against Williams’ proposed biosynthesis,46 which requires indoxyl intermediate 65 to be 
formed prior to oxidation and subsequent hetero-Diels–Alder cycloaddition. Our 
dehydro-pyrrolo-indole substrate dehydro-brevianamide E (71) is already at the correct oxidation 
state to undergo the hetero-Diels–Alder reaction, allowing it to rapidly funnel through to the 








Conclusions and Future Work 
 
We originally proposed that the alkaloid dehydrodeoxy-brevianamide E (9) is a common 
intermediate in the biosynthesis of the complex brevianamides (A (1), B (2), X (16), Y (17), J (20) 
and S (21)). We have used biomimetic chemical synthesis to investigate the chemical feasibility 
of our proposed biosynthetic network. We were able to complete an improved synthesis of 
dehydrodeoxy-brevianamide E (9) and used this material to complete biomimetic syntheses of 
brevianamide A (1), B (2), X (16) and Y (17). Attempts to synthesise brevianamide J (20) and S 
(21) are still ongoing. 
 
 
Scheme 120: Biomimetic synthesis of brevianamide A (1), B (2), X (16) and Y (17) via 





Dehydrodeoxy-brevianamide E (9) 
 
In Chapter 1 we developed a new synthetic route to our proposed biosynthetic intermediate 
dehydrodeoxy-brevianamide E (9). With a longest linear sequence of 5 steps from commercially 
available starting materials, our total synthesis of dehydrodeoxy-brevianamide E (9) represents a 
significant improvement on the literature (Scheme 112). It more than halves the step count of 
Williams’ previous 12-step synthesis,42e, 60,83 and is a 4-step reduction on a formal 9-step 
combination of Williams’42e, 60 and Danishefsky’s4g reported chemistry. This improved synthesis 
(Scheme 121) was enabled by developing SN2-type demethylation conditions (Step 3), applying a 
direct imine acylation (Step 4), and using gentle ammoniacal phthaloyl deprotection/lactam 
cyclisation conditions (Step 5). 
 
 





Brevianamide J (20) and S (21) 
 
In Chapter 2 we investigated the oxidative chemistry of dehydrodeoxy-brevianamide E (9) in order 
to complete a total synthesis of the dimeric alkaloids brevianamide J (20) and S (21). Our original 
biosynthetic hypothesis was that the dimers were formed via oxidative coupling of dehydrodeoxy-
brevianamide E (9). Chemical oxidative coupling instead gave unsymmetrical indole coupled 
dimer 192 (Scheme 122), suggesting that our proposed coupling requires enzymatic control or is 
in fact incorrect. 
 
 
Scheme 122: Oxidative coupling of dehydrodeoxy-brevianamide E (9). 
 
The majority of oxidation conditions tested on dehydrodeoxy-brevianamide E (9) led to indole 
oxidation. However, an extensive investigation of the oxidation chemistry of dehydrodeoxy-
brevianamide E (9) allowed Dr Nick Green (a PDRA working in the Lawrence group) to 
successfully oxidise the N-acyl-enamine moiety to give iodo-N-acyl-enamine 227 (Scheme 123). 
Reductive coupling of iodo-N-acyl-enamine 227 by Dr Nick Green under Ullmann type conditions 
gave access to dimer 131. My investigation of the dehydrogenation of dehydrodeoxy-





Scheme 123: Investigations towards a total synthesis of brevianamide J (20) and S (21). 
 
I discovered that dehydrodeoxy-brevianamide E (9) could be efficiently dehydrogenated using 
Mukaiyama’s chloro-sulfinimidoyl reagent 216 under modified conditions, completing the first 
total synthesis of brevianamide K (10) in 6 steps. Attempts to apply these conditions to dimer 131 
proved unsuccessful, but iodo-N-acyl-enamine 227 underwent dehydrogenation to give monomer 
239. Reductive coupling of monomer 239 under modified Ullmann-type conditions suggested 
formation of brevianamide S (21) based on analysis of the NMR spectrum of the crude product. 
Unfortunately, initial attempts to purify brevianamide S (21) from this small-scale reaction proved 
unsuccessful. Nonetheless, these results suggest that we may have prepared brevianamide S (21) 
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for the first time, a promising lead in our attempts to develop a practical synthesis of this natural 
product. 
 
Further optimisation and scale up of this final reductive coupling will hopefully allow us to prepare 
practical quantities of brevianamide S (21), completing an 8-step total synthesis (Scheme 124). 
Next, we would attempt to synthesis brevianamide J (20) either by hydration of brevianamide S 
(21) or hydration, followed by dehydrogenation from alternative dimeric precursor 131. 
 
 




Brevianamide X (16) and Y (17) 
 
In Chapter 3 we completed the first total synthesis of (±)-brevianamide X (16), in 8 steps from 
commercially available starting materials. From dehydrodeoxy-brevianamide E (9), we initially 
used Williams’ conditions to achieve tautomerisation and a Sammes-type hetero-Diels-Alder 
cycloaddition (Step 6 - Scheme 125),42e, 60 followed by oxidation and acid mediated rearrangement 
to give oxindole brevianamide X (16) (Steps 7 & 8 - Scheme 125). 
 
 
Scheme 125: Total synthesis of brevianamide X (16). 
 
We also completed an improved synthesis of brevianamide Y (17), in 7 steps from commercially 
available starting materials (Scheme 126). This synthesis represents a significant improvement on 
the literature, halving the step count of Williams’ previous 14-step synthesis,42f and Qin’s 18-step 
synthesis.54 Dehydrodeoxy-brevianamide E (9) underwent chemoselective and diastereoselective 
oxidation to give oxindole 113 (Step 6 - Scheme 126). Oxindole 113 underwent tautomerisation 
and a Sammes-type hetero-Diels-Alder cycloaddition to give brevianamide Y (17) alongside its 
diastereomer dia-113. In future work, we plan to scale up this synthesis, to allow us to resolve 
issues associated with the purification of brevianamide Y (17) and isolate sufficient material to 
accurately measure its optical rotation and confirm the absolute stereochemistry of the product 









Brevianamide A (1) and B (2) 
 
In Chapter 4 we completed the first total synthesis of brevianamide A (1), 50 years after it was 
first isolated,6d as well as the shortest reported synthesis of its diastereomer brevianamide B (2) 
(Scheme 127. For all previous syntheses of brevianamide B (2), see Appendix 1, Page 185). An 
initial diastereoselective oxidation with m-CPBA (Step 6 - Scheme 127) gave 
hydroxy-pyrroloindole 71. When this was subjected to aqueous base (Step 7 - Scheme 127), it 
underwent a hydroxy-pyrroloindole ring opening/indoxyl-rearrangement/tautomerisation/ 
hetero-Diels–Alder cascade to give diastereomeric natural products (+)-brevianamide A (1) and 
(+)-brevianamide B (2) in a ratio (d.r. 12:1) consistent with that isolated from the organism (d.r. ≳ 
10:1).39  
 
These results demonstrate the chemical feasibility of our proposed biosynthesis of (+)-
brevianamide A (1) and (+)-brevianamide B (2) (Scheme 127). Furthermore, the close match 
between the d.r. observed from this chemical reaction and isolation from the natural source 
suggests that the final hetero-Diels–Alder reaction of the cascade proceeds with substrate-
controlled stereoselectivity. Enzyme catalysed reactions tend to be highly stereoselective so it 
would be a remarkable if an enzyme catalysed the Diels–Alder reaction without significantly 
affecting the stereochemical outcome.  While we have demonstrated its chemical feasibility, 
further investigation is required to confirm our proposed biosynthesis in vivo. Synthesis of labelled 
dehydrodeoxy-brevianamide E (9) and dehydro-brevianamide E (71) would allow us to conduct 
biosynthetic feeding studies to explore the involvement of these proposed biosynthetic 
intermediates. Brevianamide A (1) possesses insecticidal activity.35 Having accessed substantial 
quantities (of both enantiomers) of brevianamide A (1) and with a readily scalable synthesis, we 
are interested in exploring its biological activity further. Exploring its antifeedant mode of action 





Scheme 127: Biomimetic total synthesis of brevianamide A (1) and B (2). 
 
While optimising the synthesis of brevianamide A (1) we observed substantial variation in the 
chemoselectivity depending on the strength of base and solvent used. When treated with 
methanolic K2CO3, hydroxy-pyrroloindole dia-71 gave almost exclusively hydroxy-indolenine 
products ent-261 and ent-74 instead of brevianamide A (1) and B (2) (Scheme 128). We are 
currently collaborating with Dr Fernanda Duarte’s group to try to explain this change in selectivity 
using DFT calculations. There are also a substantial number of hydroxy-indolenine natural 
products which bear a close structural similarity to the major product of this reaction ent-261 
(Scheme 128). We propose that their biosynthesis mirrors the chemical synthesis of 
hydroxy-indolenine ent-261 and we are in the process of planning biomimetic syntheses of these 














1H NMR spectra were recorded at 600 MHz on a Bruker 600 spectrometer with a AVANCE 3HD 
console, at 500MHz on Ascend 500 spectrometers with AVANCE 3 and AVANCE 3HD consoles, 
and at 400MHz on a Bruker 400 spectrometer with AVANCE 3 console. Residual solvent peaks 
were used as an internal reference for 1H NMR spectra (CDCl3 δ 7.26 ppm, CD3OD δ 3.31 ppm, 
CD2Cl2 δ 5.32 ppm, CD3CN δ 1.94 ppm and (CD3)2SO δ 2.50 ppm). Coupling constants (J) are 
quoted to the nearest 0.1 Hz. 13C NMR spectra were recorded at 151 MHz on a Bruker 600 
spectrometer with an AVANCE 3HD console, 126 MHz on Ascend 500 spectrometers with 
AVANCE 3 and AVANCE 3HD consoles, and at 101 MHz on a Bruker 400 spectrometer with 
AVANCE 3 console. Solvent peaks were used as an internal reference for 13C NMR spectra 
(CDCl3 δ 77.16 ppm, CD3OD δ 49.00 ppm, CD2Cl2 δ 54.00 ppm, CD3CN δ 1.32 ppm and (CD3)2SO 





IR spectra were recorded as neat samples on a Shimadzu IR affinity-1 FTIR spectrometer fitted 




EI mass spectra were recorded on a MAT 900 XP double focussing high resolution sector, run at 
70 eV. ESI spectra were recorded on a Bruker microTOF, calibrated with sodium formate clusters, 




TLC analyses were performed on Merck silica plates coated with silica gel 60 F254 (0.2mm) and 
were visualised with UV light and by staining with p-anisaldehyde or KMnO4 standard TLC stain 




Flash chromatography was performed using Merck silica gel 60 (40–63 µm) for routine 
separations and Fluorochem silica gel 60 (20–45 µm) for more challenging separations. 
Neutralised silica refers to columns packed with solvent containing 1% NEt3 and rinsed with 




Optical rotations were recorded using a Bellingham Stanley ADP450 polarimeter with a 






Analytical chiral HPLC was conducted using a modular Shimadzu system using a LC-20AD pump, 
DGU-20A5R degassing unit, SIL-20A HT autosampler, CTO-20A column oven, SPD-20A UV/Vis 
detector and CDM-20A communications module. 
 
Experimental Procedures, Reagents and Solvents 
 
Unless stated otherwise, reactions were performed under a positive pressure of dry nitrogen. For 
reactions performed under anhydrous reaction conditions, reaction vessels were dried with a heat 
gun under vacuum prior to use, and anhydrous solvents were used throughout. Commercially 
available chemicals were used as received, unless specified otherwise. Solvents and reagents dried 
over 4 Å molecular sieves were dried for at least 24 h before use. Dry NEt3 refers to NEt3 dried 
over activated 4 Å molecular sieves. Distillates were collected in flasks cooled with a dry 




Total Synthesis of Brevianamide A (1) and B (2) 
 
Experimental Procedure for Compound 143 
 
Compound 143 was prepared based on conditions reported by Vederas and co-workers.82 
 
To a stirred suspension of L-tryptophan methyl ester hydrochloride (25.0 g, 98.2 mmol) and 
phthalic anhydride (14.5 g, 98.2 mmol) in toluene (1000 mL) was added NEt3 (27.4 mL, 196 mmol) 
and the mixture heated at reflux for 18 h. The reaction was allowed to cool to room temperature 
and a mixture of saturated aq. NH4Cl (150 mL) and water (150 mL) was added. The organic phase 
was separated, washed with brine (300 mL), dried (Na2SO4) and concentrated under reduced 
pressure to yield crude 143 (33.6 g, 98% crude mass recovery) which was used without further 
purification in the next step. 
 
Compound 143 had previously been prepared by a different procedure (see page 157) and purified 
by flash chromatography (2:3 EtOAc/petroleum spirit) to give compound 143 as a pale-yellow 




Rf 0.24 (2:3 EtOAc/petroleum spirit) 
 
1H NMR (500 MHz, CDCl3) δ 7.97 (br. s, 1H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 7.65 (dd, J = 5.5, 
3.0 Hz, 2H), 7.60 (app. dt, J = 7.9, 0.9 Hz, 1H), 7.25 (app. dt, J = 7.3, 0.9, 0.9 Hz, 1H), 7.12 (ddd, 
J = 8.1, 7.0, 1.2 Hz, 1H), 7.05 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.99 (d, J = 2.3 Hz, 1H), 5.28 (dd, J 
= 9.9, 6.1 Hz, 1H), 3.79 (s, 3H), 3.78 – 3.70 (m, 2H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 169.8, 167.7, 136.2, 134.1, 131.8, 127.3, 123.5, 122.7, 122.2, 
119.6, 118.6, 111.2, 111.2, 53.0, 52.7, 24.9 ppm; 
 
IR (film, cm−1) 3404, 3057, 3013, 2953, 2924, 2849, 1775, 1740, 1705, 1612, 1555; 
 




𝟐𝟑.𝟑 −201.1 (c 1.07, CHCl3)  
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Compound 145 was prepared under anhydrous conditions, based on a procedure reported by 
Danishefsky and co-workers.4g 
 
A solution of crude compound 143 (25.0 g) and dry NEt3 (12.0 mL, 86.1 mmol) in THF (250 mL) 
was cooled to −78 °C, and the lights in the vicinity of the reaction were turned off. t-BuOCl (9.7 
mL, 86.1 mmol) was added dropwise and the reaction stirred for 30 minutes at −78 °C. A solution 
of B-Prenyl-9-BBN 144 (360 mL, 180 mmol, 0.5 M in THF, see page 154 for preparation) was 
added dropwise at −78 °C, over 50 min. After stirring for 1 h at −78 °C the cooling bath was 
removed and the reaction slowly allowed to warm to room temperature. Reaction progress was 
monitored by TLC analysis, following the disappearance of starting material 143, Rf 0.24 (1:1 
EtOAc/petroleum spirit) and appearance of an intermediate with Rf 0.63 (1:1 EtOAc/petroleum 
spirit). After stirring for 2 h saturated aq. K2CO3 (75 mL) was added. The layers were separated 
and the aqueous layer extracted with EtOAc (3 × 125 mL). The combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure. The crude product was filtered through 
silica with CH2Cl2, concentrated and purified by flash chromatography (1:9 to 1:3 
EtOAc/petroleum spirit) to give compound 145 (21.1 g, 50.7 mmol, 69% over 2 steps) as a pale-




Rf 0.55 (1:1 EtOAc/petroleum spirit), 0.24 (1:4 EtOAc/petroleum spirit); 
 
1H NMR (600 MHz, CDCl3) δ 7.86 (br. s, 1H), 7.69 (dd, J = 5.5, 3.0 Hz, 2H), 7.62 (dd, J = 5.5, 
3.0 Hz, 2H), 7.28 (app. dt, J = 7.9, 0.9 Hz, 1H), 7.13 (app. dt, J = 8.0, 0.8 Hz, 1H), 6.90 (ddd, J = 
8.1, 7.0, 1.1 Hz, 1H), 6.71 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.19 (dd, J = 17.5, 10.5 Hz, 1H), 5.23 – 
5.17 (m, 2H), 5.15 (dd, J = 10.5, 1.0 Hz, 1H), 3.86 (dd, J = 15.4, 3.9 Hz, 1H), 3.78 (s, 3H), 3.67 
(dd, J = 15.4, 11.3 Hz, 1H), 1.58 (s, 3H), 1.57 (s, 3H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 169.7, 167.8, 146.0, 140.3, 134.0, 134.0, 132.0, 129.9, 123.3, 
121.3, 119.3, 117.9, 112.3, 110.3, 106.4, 53.6, 52.9, 39.3, 27.8, 27.7, 24.6 ppm; 
 
[𝛂]𝑫
𝟐𝟑.𝟕 −221.6 (c 3.97, CHCl3), literature: [𝛂]𝑫
𝟐𝟓 −180.8 (c 3.9, CHCl3).4g 
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Experimental Procedure for Compound 164 
 
 
The synthesis of compound 164 was inspired by the work of Hell,128,129 and Fisher.75 
 
Compound 145 (24.6 g, 59.0 mmol) and LiCl (50.0 g, 1180 mmol) were suspended in DMF (125 
mL) and the resulting mixture heated at 160 °C under a flow of nitrogen for 21 h. The thick brown 
suspension was diluted with CH2Cl2 (300 mL), sonicated for 30 minutes and the solid removed by 
filtration. The residual solid was broken up, suspended in CH2Cl2 (300 mL), stirred for 30 minutes 
and filtered. The combined filtrates were concentrated under reduced pressure, then dried at 160 °C 
under reduced pressure. The crude product was re-dissolved in CH2Cl2, filtered and concentrated 
twice to remove any residual LiCl solid, before being dried at 160 °C under reduced pressure to 





1H NMR (500 MHz, CD3OD) δ 7.62 (app. s, 4H), 7.21 (app. dt, J = 8.1, 0.9 Hz, 1H), 7.11 (app. t, 
J = 8.0, 0.9 Hz, 1H), 6.75 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.53 (ddd, J = 8.0, 7.0, 1.0 Hz 1H), 6.26 
(dd, J = 17.4, 10.6 Hz, 1H), 5.13 (dd, J = 17.4, 1.2 Hz, 1H), 5.04 (dd, J = 10.6, 1.2 Hz, 1H), 4.95 
(dd, J = 12.0, 3.3 Hz, 1H), 3.84 (dd, J = 15.3, 3.3 Hz, 1H), 3.58 (dd, J = 15.2, 12.0 Hz, 1H), 1.59 
(s, 3H), 1.54 (s, 3H) ppm; 
 
13C NMR (126 MHz, CD3OD) δ 176.1, 170.1, 147.8, 141.3, 136.2, 134.6, 133.7, 131.1, 123.5, 
121.2, 118.9, 118.6, 111.7, 111.2, 108.5, 57.8, 40.4, 28.6, 28.3, 26.0 ppm; 
 
IR (film, cm−1) 2924, 2365, 1773, 1701, 1611, 1466, 1396, 1350; 
 
HRMS (ESI−) m/z 401.1476 (calculated [M − Li]− 401.1507);  
 
[𝛂]𝑫
𝟐𝟐.𝟗 −226.0 (c 0.20, MeOH). 
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Compound 148 was prepared under anhydrous conditions, inspired by the work of Schmalz68 and 
Soai.70 
 
To a solution of oxalyl chloride (6.24 mL, 73.8 mmol) in CH2Cl2 (200 mL) at 0 °C was added 
dropwise DMF (1.90 mL, 24.6 mmol). A suspension of crude compound 164 (20.1 g) in CH2Cl2 
(200 mL) was added dropwise over 30 minutes at 0 °C. The residual compound 164 was washed 
into the reaction with CH2Cl2 (2 × 50 mL) and the resulting mixture was stirred at 0 °C for 30 min. 
A solution of compound 147 (5.84 mL, 49.2 mmol, see page 152 for preparation) and NEt3 (10.3 
mL, 73.8 mmol) in CH2Cl2 (200 mL) was added dropwise over 20 minutes at 0 °C. The cooling 
bath was then removed and the reaction stirred for 21 h at room temperature. The reaction was 
quenched by the addition of 1 M aq. HCl (80 mL). The phases were separated and the aqueous 
layer extracted with CH2Cl2 (3 × 50 mL). The combined organics were washed with saturated aq. 
NaHCO3 (80 mL) and the aqueous layer was then back extracted with CH2Cl2 (50 mL). The 
combined organics were washed with brine (120 mL), dried (Na2SO4) and concentrated under 
reduced pressure to give compound 148 (23.9 g) which was used without further purification in 
the next step. A small sample was purified by flash chromatography (1:1 EtOAc/petroleum spirit) 






Rf 0.28 (1:1 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CD2Cl2) δ 7.95 (s, 1H), 7.64 (app. s, 4H), 7.17 – 7.13 (m, 2H), 6.86 (dd, J = 
8.2, 7.1 Hz, 1H), 6.61 (app. t, J = 7.4 Hz, 1H), 6.20 (dd, J = 17.4, 10.5 Hz, 1H), 5.87 (dd, J = 3.5, 
2.5 Hz, 1H), 5.24 (dd, J = 10.4, 4.4 Hz, 1H), 5.20 (dd, J = 17.5, 1.1 Hz, 1H), 5.13 (dd, J = 10.6, 
1.1 Hz, 1H), 3.94 (br. s, 1H), 3.83 (dd, J = 15.4, 4.4 Hz, 1H), 3.72 (s, 3H), 3.62 (app. q, J = 10.5 
Hz, 1H), 3.46 (dd, J = 15.4, 10.4 Hz, 1H), 2.62 (dtd, J = 17.6, 10.0, 2.5 Hz, 1H), 2.39 (ddt, J = 
17.5, 10.6, 3.4 Hz, 1H), 1.55 (s, 3H), 1.55 (s, 3H) ppm; 
 
13C NMR (151 MHz, CD2Cl2) δ 167.8, 167.7, 162.1, 146.6, 140.9, 137.0, 134.5, 134.5, 131.9, 
130.3, 123.6, 123.5, 121.5, 119.4, 118.1, 112.3, 110.6, 106.6, 54.2 (beneath residual solvent peak), 
52.6, 50.4 (br.), 39.7, 29.6, 27.9, 27.9, 25.4 ppm; 
 
IR (film, cm−1) 1775, 1713, 1655, 1639, 1611, 1437, 1381; 
 












The crude product 148 (23.9 g) from Step (4) was dissolved in a solution of NH3 in MeOH (7 M, 
1200 mL) and stirred at room temperature for 18 h. The crude reaction mixture was concentrated 
under reduced pressure. Flash chromatography on neutralised silica (7:3 to 8:2 EtOAc/petroleum 
spirit) gave dehydrodeoxy-brevianamide E (9) (8.51 g, 24.4 mmol, 49% over 3 steps) as a 





Rf 0.19 (8:2 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CDCl3) δ 8.08 (br. s, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.32 (dt, J = 8.1, 0.9 Hz, 
1H), 7.17 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.11 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 6.14 (t, J = 3.1 Hz, 
1H), 6.12 (dd, J = 17.2, 10.4 Hz, 1H), 5.66 (br. s, 1H), 5.20 – 5.15 (m, 2H), 4.52 (ddd, J = 11.3, 
3.5, 1.8 Hz, 1H), 4.14 – 4.02 (m, 2H), 3.73 (dd, J = 14.7, 3.7 Hz, 1H), 3.23 (dd, J = 14.6, 11.3 Hz, 
1H), 2.78 (td, J = 9.1, 3.1 Hz, 2H), 1.55 (s, 3H), 1.55 (s, 3H);  
 
13C NMR (126 MHz, CDCl3) δ 162.7, 156.6, 145.8, 141.8, 134.4, 133.2, 128.9, 122.3, 120.2, 118.9, 
118.3, 112.6, 110.9, 104.6, 57.6, 45.7, 39.2, 30.9, 28.1, 28.0, 27.9. 
 
IR (film, cm−1) 3331, 2967, 2926, 1672, 1639, 1435;  
 




𝟐𝟑.𝟏 −33.2 (c 1.30, CHCl3), literature: [𝛂]𝑫
𝟐𝟐 −38 (c 1.3, CHCl3).7b  
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Experimental Procedure for Dehydro-brevianamide E (71) and Compounds 
dia-71 and 254 
 
 
The synthesis of dehydro-brevianamide E (71) was inspired by the work of Kametani4a and 
Wolff.120 
 
To a rapidly stirred solution of dehydrodeoxy-brevianamide E (9) (4.00 g, 11.5 mmol) in CHCl3 
(80 mL) at room temperature was added dropwise over 4 h a solution of m-CPBA in CHCl3 (0.29 
M, 40 mL, 11.7 mmol).* The reaction was stirred for 2 h at room temperature and quenched by 
the addition of saturated aq. Na2S2O3 (20 mL) and saturated aq. NaHCO3 (20 mL). The reaction 
mixture was diluted with EtOAc (200 mL) and CHCl3 (150 mL) and the phases separated. The 
aqueous phase was back-extracted with CHCl3 (50 mL) and the combined organics washed with 
saturated aq. NaHCO3 (80 mL), brine (80 mL), dried (Na2S2O4) and concentrated under reduced 
pressure. 
 
Flash column chromatography (1.5:7:3 petroleum spirit/CH2Cl2/i-Pr2O to 7:3 CH2Cl2/i-Pr2O to 
EtOAc to i-PrOH) of the crude reaction product gave dehydro-brevianamide E (71) (1.43 g, 3.91 
mmol, 34%) as a white foam, a fraction containing mixed dehydro-brevianamide E (71) and 
compound dia-71 (1.37 g, 18:82 71/dia-71, 3.75 mmol, 33%) as a cream foam, alongside 
recovered starting material dehydrodeoxy-brevianamide E (9) (270 mg, 0.774 mmol, 7%) as a 
cream foam and a fraction containing mixed compounds 254/113 (0.414 g, 254/153, 0.585 
mmol/0.521 mmol, 5%/5%) as a brown foam. Overall, 71/dia-71 (2.80 g, 60:40, 7.67 mmol, 67%) 
 
A second round of chromatography on the mixed dehydro-brevianamide E (71) and compound 
dia-71 fraction gave additional pure dehydro-brevianamide E (71) (0.108 g, 0.296 mmol, 3%) as 
a cream glass and pure minor diastereomer dia-71 (0.454 g, 1.24 mmol, 11%) as a white foam. At 
this point, further chromatography was deemed unnecessary since 92% of the major diastereomer 




* m-CPBA (69% w/w by iodometric titration, 4.38 g, 17.5 mmol) was added to CHCl3 (60 mL) 




Rf 0.15 (7:3 CH2Cl2/i-Pr2O); 
 
1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 7.5, 1.2 Hz, 1H), 7.18 (td, J = 7.7, 1.3 Hz, 1H), 6.81 
(td, J = 7.4, 1.0 Hz, 1H), 6.74 (dt, J = 7.9, 0.8 Hz, 1H), 6.40 – 6.34 (m, 2H), 6.16 (app. t, J = 3.1 
Hz, 1H), 5.15 (dd, J = 17.7, 1.4 Hz, 1H), 5.07 (dd, J = 10.9, 1.3 Hz, 1H), 4.06 (ddd, J = 12.0, 8.7, 
7.3 Hz, 1H), 3.93 – 3.83 (m, 1H), 3.81 (dd, J = 11.5, 7.3 Hz, 1H), 2.79 – 2.69 (m, 4H), 2.43 (br. s, 
1H), 1.34 (s, 3H), 1.27 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 163.7, 162.1, 149.4, 144.7, 136.4, 131.0, 129.8, 123.8, 120.6, 
120.2, 113.4, 111.2, 91.5, 89.3, 60.3, 45.8, 45.0, 36.7, 29.0, 27.6, 23.2 ppm; 
 
IR (film, cm−1) 3362, 2967, 2926, 1670, 1634, 1609, 1485, 1468, 1437, 1393, 1360;  
 










Rf 0.09 (7:3 CH2Cl2/i-Pr2O); 
 
1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 7.5 Hz, 1H), 7.13 (td, J = 7.7, 1.3 Hz, 1H), 6.76 (td, J 
= 7.4, 0.9 Hz, 1H), 6.62 (dt, J = 7.9, 0.8 Hz, 1H), 6.47 (br. s, 1H), 6.34 (dd, J = 17.7, 10.8 Hz, 1H), 
6.06 (app. t, J = 3.0 Hz, 1H), 5.22 (dd, J = 17.7, 1.3 Hz, 1H), 5.10 (dd, J = 10.9, 1.3 Hz, 1H), 4.73 
(app. t, J = 8.8 Hz, 1H), 4.00 (ddd, J = 12.4, 11.1, 6.1 Hz 1H), 3.82 (dddd, J = 12.3, 11.4, 8.3, 0.8 
Hz, 1H), 2.86 (ddd, J = 13.6, 8.6, 0.7 Hz, 1H), 2.80 – 2.62 (m, 3H), 2.57 (br. s 1H), 1.45 (s, 3H), 
1.35 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 161.9, 156.2, 147.0, 144.8, 134.7, 131.5, 130.4, 123.8, 119.5, 
119.3, 114.1, 109.9, 95.3, 89.6, 60.5, 46.6, 45.4, 43.4, 28.2, 27.2, 22.5 ppm; 
 
IR (film, cm−1) 3360, 2965, 2924, 2854, 1665, 1632, 1611, 1487, 1466, 1439, 1414, 1371;  
 










An analytically pure sample of compound 254 had previously been purified by flash 
chromatography (1:9 MeOH/EtOAc). 
 
Rf 0.10 (EtOAc); 
 
1H NMR (601 MHz, CDCl3) δ 11.49 (br. s, 1H), 8.81 (dd, J = 8.6, 1.1 Hz, 1H), 7.84 (dd, J = 8.1, 
1.6 Hz, 1H), 7.58 (ddd, J = 8.7, 7.2, 1.6 Hz, 1H), 7.10 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.49 (br. s, 
1H), 6.24 (app. t, J = 3.0 Hz, 1H), 6.11 (dd, J = 17.4, 10.6 Hz, 1H), 5.36 (dd, J = 17.5, 0.8 Hz, 1H), 
5.32 (dd, J = 10.6, 0.8 Hz, 1H), 4.68 (d, J = 10.2 Hz, 1H), 4.08 (app. t, J = 9.2 Hz, 2H), 4.00 (dd, 
J = 18.3, 2.2 Hz, 1H), 3.44 (dd, J = 18.3, 10.1 Hz, 1H), 2.86 – 2.80 (m, 2H), 1.43 (s, 3H), 1.42 (s, 
3H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 201.2, 176.1, 161.7, 156.5, 142.3, 141.6, 136.0, 132.7, 130.6, 
122.4, 121.1, 120.8, 119.7, 115.0, 53.6, 46.9, 45.8, 44.9, 27.9, 24.7, 24.7 ppm; 
 
IR (cm−1) 3694, 3680, 3238, 2967, 2922, 2866, 2845, 1680, 1645; 
 










The synthesis of (+)-brevianamide A (1) was carried out under aerobic conditions, inspired by the 
work of Kishi98 and Williams.42e Effort was made to limit the exposure of the material to light 
once the reaction was complete, to prevent photolysis of brevianamide A (1) to brevianamide C 
(3) and D (4).6b 
 
To a solution of dehydro-brevianamide E (71) (1.30 g, 3.56 mmol) was added a 1 M solution of 
aq. LiOH (450 mL) and the reaction stirred rapidly, with vigorous manual shaking every 2–3 
minutes to facilitate gradual dissolution of the starting material. After 30 minutes the reaction 
mixture was extracted with CH2Cl2 (2 × 450 mL, 2 × 200 mL), and the combined organics dried 
(Na2SO4). Flash column chromatography (2:8 to 3:7 to 1:1 THF/CHCl3 to 25:25:1 THF/CHCl3/i-
PrOH) gave (+)-brevianamide A (1) (905 mg, 16.2% CHCl3 w/w, 2.07 mmol, 58%)* as a yellow 
amorphous solid, (+)-brevianamide B (2) (59.8 mg, 0.164 mmol, 5%) as a yellow crystalline solid 
and compound 272 (60.6 mg, 0.279 mmol, 8%) as a white crystalline solid. 
  
A sample of (+)-brevianamide A (1) was crystallised from CHCl3 by slow vapour diffusion with 
Et2O. See page 199 for X-ray crystal structure of brevianamide A·CHCl3. 
 
*In Birch’s original isolation paper brevianamide A ‘crystallized from CHCl3 in needles 
containing one molecule of solvent of crystallisation’.6a The reported crystal structure for 
5-bromo-brevianamide A also showed co-crystallisation with one molecule of acetone.8 Consistent 
with these observations, we found that a certain portion of solvent could not be removed from 
brevianamide A under high vacuum. Proteo-solvent was replaced with deutero-solvent to record 






Spectroscopic data matched literature values reported by Zhu Weiming (朱伟明 ) and 
co-workers.130 Subtle differences in 1H NMR data are attributed to concentration effects in CDCl3 
(see page 214). 
 
Rf 0.21 (3:7 THF/CHCl3); 
 
MP 173–179 °C, literature: 175–180 °C ‘with loss of solvent’6a;  
 
1H NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 7.7, 1.2 Hz, 1H), 7.44 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 
6.84 – 6.78 (m, 2H), 6.62 (br. s, 1H), 4.98 (br. s, 1H), 3.52 – 3.41 (m, 2H), 2.81 – 2.74 (m, 2H), 
2.40 (ddd, J = 9.8, 7.3, 1.1 Hz, 1H), 2.35 (d, J = 15.6 Hz, 1H), 2.04 (pd, J = 6.8, 1.6 Hz, 2H), 1.96 
– 1.81 (m, 3H), 1.12 (s, 3H), 0.93 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 202.2, 172.4, 169.8, 160.2, 137.8, 124.8, 121.2, 119.3, 112.1, 78.9, 
69.5, 67.8, 55.7, 48.4, 44.1, 37.4, 29.2, 29.0, 25.1, 24.1, 19.9 ppm; 
 
1H NMR (500 MHz, (CD3)2SO) δ 8.65 (br. s, 1H), 7.84 (br. s, 1H), 7.41 (ddd, J = 8.3, 7.0, 1.4 Hz, 
1H), 7.37 (d, J = 7.7 Hz, 1H), 6.81 (dd, J = 8.2, 0.8 Hz, 1H), 6.64 (ddd, J = 7.8, 7.0, 0.8 Hz, 1H), 
3.34 – 3.23 (m, 2H), 2.55 (ddd, J = 10.1, 7.5, 1.1 Hz, 1H), 2.49 – 2.44 (m, 2H), 2.39 (d, J = 15.1 
Hz, 1H), 2.01 – 1.91 (m, 1H), 1.90 – 1.77 (m, 3H), 1.68 (dd, J = 13.1, 7.6 Hz, 1H), 0.98 (s, 3H), 
0.68 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 199.9, 172.1, 169.5, 160.5, 137.2, 123.6, 119.4, 116.7, 111.1, 
79.0, 68.5, 66.4, 53.1, 48.3, 43.2, 39.5, 28.4, 27.2, 24.6, 21.2, 17.7 ppm; 
 
IR (film, cm−1) 3314, 3229, 2938, 2876, 1667, 1618, 1491, 1466, 1395; 
 
HRMS (ESI+) m/z 366.1818 (calculated [M + H]+ 366.1812); 
 
[𝛂]𝑫
𝟐𝟑.𝟓 +316 (c 0.12, EtOH), literature: [𝛂]𝑫
𝟐𝟓 +413 (EtOH);6a 
 
e.r. 93:7, after crystallisation 99:1 (Chiralpak IA, 1:1 i-PrOH/hexane, 1 mL min-1, λ 254 nm) tRminor 






Brevianamide B was only sparingly soluble in CDCl3, consistent with the observation in Birch’s 
original isolation paper that brevianamide B ‘was insoluble in most solvents except hot DMSO and 
CF3CO2H, the latter causing decomposition’.
6b 1H and 13C NMR spectra could be recorded using 
a saturated sample in CDCl3, to enable comparison to literature data,
4e, 42g however 2D NMR 
spectra were unobtainable. High quality 1D and 2D NMR spectra were instead recorded in 
(CD3)2SO. 
 
Rf 0.08 (3:7 THF/CHCl3); 
 
MP 286–290 °C (decomposition), literature: 324–328 °C (decomposition);6b  
 
1H NMR (500 MHz, CDCl3) δ 7.56 (ddt, J = 7.6, 1.3, 0.7 Hz, 1H), 7.43 (ddd, J = 8.4, 7.1, 1.4 Hz, 
1H), 6.84 – 6.78 (m, 2H), 5.78 (br. s, 1H), 4.73 (br. s, 1H), 3.50 – 3.44 (m, 2H), 3.31 (ddd, J = 
10.3, 7.4, 1.3 Hz, 1H), 3.27 (d, J = 15.6 Hz, 1H), 2.74 (ddd, J = 13.1, 7.0, 6.1 Hz, 1H), 2.06 – 1.93 
(m, 3H), 1.90 – 1.77 (m, 2H), 1.70 (d, J = 15.7, 1H), 1.14 (s, 3H), 0.83 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 203.9, 173.4, 169.2, 160.3, 137.5, 125.2, 120.1, 119.2, 111.5, 77.7, 
68.9, 66.5, 49.7, 46.6, 44.0, 36.8, 29.3, 28.6, 25.1, 22.6, 20.5 ppm; 
 
1H NMR (500 MHz, (CD3)2SO) δ 8.64 (br. s, 1H), 7.41 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 7.33 (d, J 
= 7.7 Hz, 1H), 7.27 (br. s, 1H), 6.89 (dt, J = 8.3, 0.9 Hz, 1H), 6.64 (ddd, J = 7.8, 7.0, 0.9 Hz, 1H), 
3.35 – 3.24 (m, 2H), 3.01 (ddd, J = 10.3, 7.5, 1.1 Hz, 1H), 2.67 (d, J = 15.1 Hz, 1H), 2.46 (dd, J = 
11.9, 6.1 Hz, 1H), 2.02 – 1.90 (m, 3H), 1.85 – 1.74 (m, 2H), 1.63 (dd, J = 13.0, 7.5 Hz, 1H), 1.05 
(s, 3H), 0.63 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 204.7, 172.6, 169.2, 161.3, 137.2, 123.8, 118.1, 116.9, 111.4, 
77.5, 68.1, 65.2, 48.8, 46.0, 43.3, 33.4, 28.4, 27.5, 24.4, 21.9, 19.7 ppm; 
 
IR (film, cm−1) 3348, 3231, 2949, 2878, 1705, 1664, 1653, 1616, 1587, 1495, 1468; 
 
HRMS (ESI+) m/z 366.1796 (calculated [M + H]+ 366.1812); 
 
[𝛂]𝑫
𝟐𝟒.𝟕 +136 (c 0.23, 2.5% HCO2H in CH2Cl2), literature (enantiomer): [𝛂]𝑫
𝟐𝟓 −147 (c 0.23, 2.5% 
HCO2H in CH2Cl2),
42g [𝛂]𝑫
𝟐𝟓 −124 (c 0.81, 2.5% HCO2H in CH2Cl2);
4e 
 
e.r. 93:7 (Chiralpak IA, 1:3 EtOH/hexane, 1 mL min-1, λ 254 nm) tRminor = 13.99 min, tRmajor = 







Spectroscopic data matched literature values.131  
 
Rf 0.42 (3:7 THF/CHCl3); 
 
1H NMR (500 MHz, (CD3)2SO) δ 10.12 (br. s, 1H), 7.20 (dd, J = 7.6, 1.2 Hz, 1H), 7.17 (td, J = 
7.6, 1.3 Hz, 1H), 6.89 (td, J = 7.5, 1.1 Hz, 1H), 6.73 (dt, J = 7.7, 0.8 Hz, 1H), 6.01 (dd, J = 17.6, 
10.9 Hz, 1H), 5.78 (s, 1H), 4.95 (dd, J = 10.8, 1.5 Hz, 1H), 4.84 (dd, J = 17.6, 1.6 Hz, 1H), 1.13 
(s, 3H), 0.96 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 178.8, 143.0, 142.1, 131.0, 128.6, 125.7, 120.6, 112.6, 108.9, 





Experimental Procedure for (–)-brevianamide A (1) and B (2) 
 
 
The synthesis of (–)-brevianamide A was carried out under aerobic conditions, inspired by the 
work of Kishi98 and Williams.42e 
 
To a solution of compound dia-71 (234 mg, 0.640 mmol) was added a 1 M solution of aq. LiOH 
(80 mL) and the reaction stirred rapidly, with vigorous manual shaking every 2–3 minutes to 
facilitate gradual dissolution of the starting material. After 30 minutes the reaction mixture was 
extracted with CH2Cl2 (4 × 100 mL), and the combined organics dried (Na2SO4). Flash column 
chromatography (2:8 to 3:7 to 1:1 THF/CHCl3 to 25:25:1 THF/CHCl3/i-PrOH) gave 
(–)-brevianamide A (1) (155 mg, 17.5% CHCl3 w/w, 0.350 mmol, 55%)* as a yellow amorphous 
solid, (–)-brevianamide B (2) (11.6 mg, 0.0317 mmol, 5%) as a yellow crystalline solid and 272 
(10.7 mg, 0.049 mmol, 8%) as a white crystalline solid. 
 
*In Birch’s original isolation paper brevianamide A ‘crystallized from CHCl3 in needles 
containing one molecule of solvent of crystallisation’.6a The reported crystal structure for 
5-bromo-brevianamide A also showed co-crystallisation with one molecule of acetone.8 Consistent 
with these observations, we found that a certain portion of solvent could not be removed from 
brevianamide A under high vacuum. Proteo-solvent was replaced with deutero-solvent to record 





𝟐𝟒.𝟕 −281 (c 0.12, EtOH), literature (enantiomer): [𝛂]𝑫
𝟐𝟓 +413 (EtOH);6a 
 
e.r. 95:5 (Chiralpak IA, 1:1 i-PrOH/hexane, 1 mL min-1, λ 254 nm) tRmajor = 5.38 min, tRminor = 





𝟐𝟓.𝟏 −119 (c 0.23, 2.5% HCO2H in CH2Cl2), literature: [𝛂]𝑫
𝟐𝟓 −147 (c 0.23, 2.5% HCO2H in 
CH2Cl2),
42g [𝛂]𝑫
𝟐𝟓 −124 (c 0.81, 2.5% HCO2H in CH2Cl2);
4e 
 
e.r. 92:8 (Chiralpak IA, 1:3 EtOH/hexane, 1 mL min-1, λ 254 nm) tRmajor = 13.86 min, tRminor = 
26.14 min. See Appendix 2, Page 193 for chiral HPLC traces. 
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Experimental Procedures for Reagents 
 




Compound 147 was prepared under anhydrous conditions, based on a procedure reported by 
Schmalz and co-workers.68 
 
To a rapidly stirred suspension of L-proline methyl ester hydrochloride 155 (25.0 g, 151 mmol) 
and NEt3 (48.3 mL, 347 mmol) in CH2Cl2 (450 mL) at 0 °C was added slowly, portion-wise, solid 
NCS (22.2 g, 166 mmol). The mixture was stirred at room temperature for 3 h and then diluted 
with Et2O (350 mL). A mixture of saturated aq. NH4Cl (150 mL) and water (150 mL) was added, 
the organic phase was separated and the aqueous phase was back-extracted with CH2Cl2 
(2 × 150 mL). The combined organics were washed with a mixture of saturated aq. NH4Cl (100 
mL) and water (100 mL), saturated aq. NaHCO3 (150 mL), brine (150 mL), dried (Na2SO4) and 
concentrated under reduced pressure. Vacuum distillation under reduced pressure (5 mbar) gave 
imine 147 (15.1 g, 119 mmol, 79%) as a pale-yellow liquid. All spectroscopic data matched 
literature values.67 
 
BP 60–64 °C (5 mbar); 
 
1H NMR (500 MHz, CDCl3) δ 4.04 (app. tt, J = 7.6, 2.6 Hz, 2H), 3.80 (s, 3H), 2.76 (app. ddt, J = 
8.5, 7.6, 2.6 Hz, 2H), 1.96 – 1.89 (m, 2H) ppm; 
 




Experimental Procedure for 1,1-Dimethylallene 152 
 
 
1,1-Dimethylallene 152 is a commercially available reagent, but was prepared on large scale based 
on a procedure reported by Pfeffer and co-workers.65 
 
Step (1) - Anhydrous CaCl2 (229 g, 2.06 mol) was added in portions to a stirred mixture of 
concentrated hydrochloric acid (800 mL), 2-methyl-3-butyn-2-ol 150 (200 mL, 2.06 mol) and 
hydroquinone (1.82 g, 16.5 mmol) at 0 °C over 7 minutes and the reaction was stirred for 1 h at 
room temperature. The top organic layer was seperated and solid K2CO3 added cautiously to 
the organic phase until effervescence ceased. The organic phase was then distilled under 
reduced pressure, collected up to 50 °C at 147 mbar. The crude distilate was redistilled under 
reduced pressure (147 mbar) to give 3-chloro-3-methyl-1-butyne 151 (103 g, 1.00 mol, 49%) as 
a colourless oil. All spectroscopic data matched a comercially available sample. 
 
 
BP 32–36 °C (147 mbar); 
 
1H NMR (500 MHz, CDCl3) δ 2.62 (s, 1H), 1.87 (s, 6H) ppm; 
 
13C NMR (101 MHz, CDCl3) δ 86.7, 72.0, 57.1, 34.7 ppm. 
 
Step (2) - Zinc powder (52.0 g, 760 mmol) was washed with 3% aq. HCl (4 × 40 mL), 
2% aq. CuSO4 (2 × 60 mL), ethanol (2 × 60 mL) and n-butanol (2 × 60 mL). The treated zinc was 
suspended in n-butanol (110 mL) in a 3 neck RBF with a dropping funnel, magnetic stirrer bar and 
a distillation head fitted with a 30 cm Vigreux column.  3-Chloro-3-methyl-1-butyne 151 (44.4 
mL, 390 mmol) was placed in the dropping funnel along with 1,2-dibromoethane (2.50 mL, 
29.0 mmol). A portion of the alkyne mixture (3 mL) was added to the zinc butanol slurry along 
with a few crystals of iodine and 1,2-dibromoethane (2.50 mL, 29.0 mmol). The mixture was then 
heated cautiously (using a heat gun) with stirring until the reaction had clearly commenced. Slow 
addition of the remaining alkyne mixture followed, with external heating applied to maintain the 
reaction. The crude product was collected by distillation from the reaction mixture during the 
course of the reaction, and external heat applied to continue collection up to a temperature of 44 °C. 
The crude distillate was redistilled to give 1,1-dimethylallene 152 (17.5 g, 257 mmol, 66%) as a 
colourless liquid. All spectroscopic data matched literature values.132 
 
 
BP 40–42 °C; 
 
1H NMR (500 MHz, CDCl3) δ 4.52 (hept, J = 3.1 Hz, 2H), 1.69 (t, J = 3.2 Hz, 6H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 206.8, 94.2, 72.7, 20.3 ppm.  
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A solution of B-Prenyl-9-BBN 155 was prepared under anhydrous conditions, based on a 
procedure reported by Trauner and co-workers.66 
 
A solution of 9-BBN 153 in THF (360 mL, 179 mmol, 0.5 M in THF) was cooled to 0 °C. Once 
the solution was observed to go cloudy, 1,1-dimethylallene 152 (20.5 mL, 208 mmol) was added 
dropwise over 30 minutes with stirring. The reaction was warmed to room temperature and stirred 
for 18 h before being used directly in the reverse prenylation procedure described on page 138. 
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t-BuOCl was prepared based on a procedure reported by Mintz and co-workers.64 For safety 
reasons exposure of the reaction and product to light was minimised. 
 
An aqueous solution of bleach (500 mL, 0.767 M, 384 mmol)* was cooled below 10 °C with 
stirring. A solution of t-BuOH (43.3 mL, 383 mmol) and glacial acetic acid (24.1 mL, 421 mmol) 
was added in a single portion to the rapidly stirred bleach and the stirring continued for 3 min. The 
entire reaction mixture was transferred to a separating funnel, the aqueous layer discarded, the 
yellow organic layer washed with 10% aq. Na2CO3 (50 mL) and water (50 mL). The product was 
dried (CaCl2 approximately 3g) and decanted into its final container via pipette. The t-BuOCl 
(16.4 g, 151 mmol, 39%) was stored in a fridge over CaCl2 in an amber glass bottle as a yellow 
liquid. 
 
*Bleach solution was titrated to a concentration of 0.767 M by iodometric titration using sodium 
thiosulfate prior to use. 
 
1H NMR (500 MHz, CDCl3) δ 1.33 (s, 9H) ppm; 
 





Experimental Procedures for Other Compounds 
 
Experimental Procedure for Compound 149 
 
Compound 149 was prepared based on a procedure reported by Evano and co-workers63a. 
 
Phthalic anhydride (18.1 g, 122 mmol) was added to a solution of L-tryptophan (25.0 g, 122 mmol) 
in pyridine (200 mL) and the mixture stirred at reflux overnight. The crude reaction mixture was 
concentrated under reduced pressure to approximately 60 mL and the residue was added slowly to 
a rapidly stirred solution of 6 M aq. HCl (500 mL) at 0 °C. The resulting suspension was stirred at 
0 °C for a further 2 h. The precipitate was collected by filtration, washed with water, dissolved in 
EtOAc, washed with 1 M aq. HCl and brine, dried (MgSO4) and concentrated under reduced 
pressure. The resulting expansive yellow foam was re-dissolved in CHCl3 (500 mL) and 
concentrated under reduced pressure to give crude acid 149 as a yellow solid (39.1 g, 117 mmol) 
which was used without further purification. All spectroscopic data matched literature values.63a 
 
1H NMR (400 MHz, (CD3)2SO) δ 13.29 (br. s, 1H), 10.72 (br. s, J = 2.5 Hz, 1H), 7.81 (app. s, 
4H), 7.47 (dq, J = 7.9, 0.9 Hz, 1H), 7.25 (dt, J = 8.1, 0.9 Hz, 1H), 7.03 – 6.96 (m, 2H), 6.89 (ddd, 
J = 8.0, 7.0z, 1.0 Hz, 1H), 5.10 (dd, J = 9.7, 6.3 Hz, 1H), 3.61 – 3.50 (m, 2H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 170.3, 167.1, 136.0, 134.8, 130.8, 126.9, 123.3, 123.3, 120.9, 
118.3, 117.8, 111.4, 109.7, 52.6, 24.0 ppm; 
 









Compound 143 was prepared under anhydrous conditions based on a procedure reported by Perrin 
and co-workers.4h Compound 143 was prepared by a different procedure as part of the synthesis 
of brevianamide A (1) (see page 137). 
 
Acetyl chloride (5.1 mL, 71 mmol) was added drop wise to MeOH (30 mL) at 0 °C under an inert 
atmosphere. After 5 minutes, solid crude acid 149 (6.80 g, 23.8 mmol) was added and the solution 
stirred at reflux for 2 h. After cooling, most of the solvent was evaporated under reduced pressure 
and the residue suspended in water (50 mL). Saturated aq. NaHCO3 (120 mL) was added slowly, 
with caution and the mixture extracted with CH2Cl2 (3 × 70 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. Flash 
chromatography (2:3 EtOAc/petroleum spirit) gave protected tryptophan 143 as a pale-yellow 
foam (5.95 g, 19.8 mmol, 80% over 2 steps). All data for compound 143 matched literature values.1  
 
Rf 0.24 (2:3 EtOAc/petroleum spirit) 
 
1H NMR (500 MHz, CDCl3) δ 7.97 (br. s, 1H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 7.65 (dd, J = 5.5, 
3.0 Hz, 2H), 7.60 (app. dt, J = 7.9, 0.9 Hz, 1H), 7.25 (app. dt, J = 7.3, 0.9, 0.9 Hz, 1H), 7.12 (ddd, 
J = 8.1, 7.0, 1.2 Hz, 1H), 7.05 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.99 (d, J = 2.3 Hz, 1H), 5.28 (dd, J 
= 9.9, 6.1 Hz, 1H), 3.79 (s, 3H), 3.78 – 3.70 (m, 2H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 169.8, 167.7, 136.2, 134.1, 131.8, 127.3, 123.5, 122.7, 122.2, 
119.6, 118.6, 111.2, 111.2, 53.0, 52.7, 24.9 ppm; 
 
IR (film, cm−1) 3404, 3057, 3013, 2953, 2924, 2849, 1775, 1740, 1705, 1612, 1555; 
 




𝟐𝟑.𝟑 −201.1 (c 1.07, CHCl3)  
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Compound 156 was prepared under anhydrous conditions according to a procedure reported by 
Schmalz and co-workers.68 
 
Solid NCS (0.49 g, 3.6 mmol) was added portion-wise to a solution of L-proline methyl ester 
hydrochloride 155 (500 mg, 3.0 mmol) and NEt3 (1.1 mL, 7.6 mmol) in CH2Cl2 (10 mL) at 0 °C. 
The resulting mixture was stirred at room temperature for 2 h. Pyridine (0.62 mL, 7.6 mmol) was 
added dropwise and the mixture cooled to −20 °C. Methyl chloroformate (0.56 mL, 7.3 mmol) 
was added slowly and the mixture stirred for 4 days at room temperature. The reaction mixture 
was diluted with ether (10 mL) and 1 M aq. HCl (4 mL) was added. The organic layer was washed 
with 1 M aq. HCl (4 mL), saturated aq. NaHCO3 (5 mL), brine (5 mL), dried (Na2SO4) and 
concentrated under reduced pressure. Flash chromatography (1:1 EtOAc/petroleum spirit) gave 
carbamate 156 as a pale-yellow liquid (180 mg, 0.97 mmol, 32%). All spectroscopic data matched 
literature values.68 
 
Rf 0.32 (1:1 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CDCl3) δ 5.85 (t, J = 2.9 Hz, 1H), 3.96 (t, J = 9.0 Hz, 2H), 3.82 (s, 3H), 3.73 
(s, 3H), 2.70 – 2.62 (m, 2H) ppm; 
 










Compounds 158 and 159 were prepared under anhydrous conditions, inspired by procedures 
reported by Soai70 and Schmalz.68 
 
To a stirred suspension of crude acid 149 (1.00 g, 2.99 mmol) in CH2Cl2 (50 mL) at 0 °C was 
added oxalyl chloride (250 µL, 2.99 mmol) followed by DMF (93 µL, 1.2 mmol). The reaction 
was allowed to slowly warm to room temperature within 2 h. The reaction was cooled to −20 °C 
and a solution of imine 147 (355 µL, 2.99 mmol) and pyridine (730 µL, 9.97 mmol) in CH2Cl2 
(5 mL) was added over 2 h. The reaction was allowed to slowly warm to room temperature and 
stirred at room temperature overnight. The reaction was diluted with EtOAc (100 mL) and 
quenched by addition of 1 M aq. HCl (50 mL). The phases were separated and the organic phase 
was washed with saturated aq. NaHCO3 (20 mL), brine (20 mL), dried (MgSO4) and concentrated 
under reduced pressure. Flash chromatography (8:2 EtOAc/petroleum spirit) gave N-acyl enamine 
159 contaminated with a minor impurity in a 5:1 ratio (297 mg) and spiro-indolenine 158 (167 mg, 




Rf  0.42 (8:2 EtOAc/petroleum spirit), 0.26 (1:9 EtOAc/CH2Cl2) 
 
IR (film, cm−1) 3374, 2953, 2924, 1775, 1709, 1659, 1614, 1381; 
 





NMR provided below are the peaks corresponding to compound 159 in the isolated mixture (see 
page 229 for spectra). 
 
Environment 1H NMR Peaks 
(500 MHz, CDCl3) 
13C NMR Peaks 
(126 MHz, CDCl3) 
1  167.54 
2 5.35 (dd, J = 8.7, 6.3 Hz, 1H) 53.5 
3 3.78 – 3.74 (m, 1H), 3.65 (dd, J = 
15.2, 8.7 Hz, 1H) 
25.4 
4  111.1 
5 7.08 (d, J = 2.5 Hz, 1H) 123.7 
6 8.01 (s, 1H)  
7  136.1 
8 7.28 (d, J = 8.2 Hz, 1H) 111.2 
9 7.08 (d, J = 1.5 Hz, 1H) 122.1 
10 7.01 (t, J = 7.5 Hz, 1H) 119.6 
11 7.57 (d, J = 7.9 Hz, 1H) 118.5 
12  127.5 
13  167.48 
14  131.7 
15 7.74 (dd, J = 5.4, 3.0 Hz, 2H) 123.50 
16 7.66 (dd, J = 5.6, 3.1 Hz, 2H) 134.2 
17 3.79 (s, 3H) 52.4 
18  161.8 
19  136.7 
20 5.96 (app. t, J = 2.9 Hz, 1H) 123.46 
21 2.71 – 2.59 (m, 1H), 2.52 (m, 1H) 29.3 
22 4.02 (m, 1H), 3.86 (app. td, J = 
10.5, 8.5 Hz, 1H) 
49.8 
 











Rf 0.23 (8:2 EtOAc/petroleum spirit); 
 
1H NMR (600 MHz, CDCl3) δ 8.65 (s, 1H), 7.88 – 7.83 (m, 1H), 7.83 – 7.79 (m, 1H), 7.72 – 7.68 
(m, 2H), 7.65 (d, J = 7.7 Hz, 1H), 7.40 (td, J = 7.6, 1.2 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.16 (d, 
J = 7.5 Hz, 1H), 5.53 (dd, J = 11.7, 4.5 Hz, 1H), 3.93 (s, 3H), 3.77 (ddd, J = 12.1, 9.2, 7.3 Hz, 1H), 
3.66 (ddd, J = 11.8, 8.4, 3.1 Hz, 1H), 3.02 (dd, J = 14.9, 11.7 Hz, 1H), 2.19 (ddd, J = 13.4, 7.0, 2.7 
Hz, 1H), 1.95 (dd, J = 14.9, 4.5 Hz, 1H), 1.87 (dtt, J = 13.3, 7.5, 2.9 Hz, 1H), 1.75 (ddtd, J = 13.1, 
11.1, 9.0, 7.0 Hz, 1H), 1.42 (ddd, J = 13.3, 11.0, 7.7 Hz, 1H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 174.9, 171.2, 167.9, 167.6, 165.8, 156.1, 136.3, 134.3, 134.2, 
132.1, 132.0, 129.6, 126.8, 123.8, 123.7, 123.6, 121.9, 71.3, 61.2, 53.3, 47.2, 46.4, 32.7, 32.3, 22.0 
ppm; 
 
IR (film, cm−1) 1775, 1734, 1709, 1667, 1449, 1427, 1387, 1350; 
 
HRMS (ESI+) m/z 444.1519 ([M + H]+ 444.1554), 466.1323 ([M + Na]+ 466.1373). 
 
[𝛂]𝑫









Compound 161 was prepared based on conditions reported by Ley and co-workers.61b 
 
To a solution of compound 145 (67 mg, 0.16 mmol) in 1:1 THF/H2O (2 mL) was added solid 
LiOH (19 mg, 0.79 mmol) and the solution stirred at room temperature for 3 h. The solution was 
neutralised with 1 M aq. HCl and extracted with Et2O (3 × 5 mL). The combined organics were 
washed with H2O (2 × 2.5 mL), brine (2.5 mL), dried (Na2SO4) and concentrated under reduced 
pressure to give crude di-carboxylic acid 161 (62 mg, 0.15 mmol, 94% crude mass recovery) as a 
yellow foam which was deemed sufficiently pure for characterisation purposes. 
 
1H NMR (500 MHz, CD3OD) δ 7.91 (dd, J = 7.6, 1.6 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.46 (app. 
td, J = 7.6, 1.6 Hz, 1H), 7.42 (app. td, J = 7.5, 1.6 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.04 (ddd, J 
= 8.1, 6.9, 1.2 Hz, 1H), 6.98 – 6.93 (m, 1H), 6.89 (dd, J = 7.4, 1.5 Hz, 1H), 6.26 (dd, J = 17.5, 10.6 
Hz, 1H), 5.17 (dd, J = 17.4, 1.3 Hz, 1H), 5.11 (dd, J = 10.5, 1.2 Hz, 1H), 4.98 (app. t, J = 7.8 Hz, 
1H), 3.51 (dd, J = 14.5, 7.7 Hz, 1H), 3.27 (dd, J = 14.5, 7.9 Hz, 1H), 1.59 (s, 3H), 1.59 (s, 3H) 
ppm; 
 
13C NMR (126 MHz, CD3OD) δ 175.3, 172.2, 169.2, 147.6, 142.1, 139.4, 136.4, 132.9, 131.2, 
131.1, 130.5, 130.4, 129.0, 121.7, 119.6, 119.3, 112.1, 111.6, 106.6, 55.6, 40.4, 28.9, 28.5, 28.4 
ppm; 
 
IR (film, cm−1) 3000, 1771, 1694, 1597, 1525, 1462, 1389; 
 
HRMS (EI+) m/z 420.16655 (calculated [M]+ : 420.16797); 
 
[𝛂]𝑫










Compound 182 was tentatively assigned as the major product of the reaction, which was carried 
out under anhydrous conditions, inspired by a procedure reported by Kobayashi and co-workers.88 
 
To a stirred solution of Cu(OTf)2 (103 mg, 0.286 mmol) in MeCN (1 mL) at 0 °C was added solid 
dehydrodeoxy-brevianamide E (9) (50 mg, 0.143 mmol). The reaction was stirred at 0 °C for 40 
minutes. Water (1 mL) and EtOAc (1 mL) were added to the stirred reaction mixture, and the 
mixture was diluted with water (5 mL) and EtOAc (5 mL). The phases were separated and the 
aqueous phase extracted with EtOAc (2 × 5 mL). To the combined organics was added saturated 
aq. NaHCO3 (5 mL), and the resultant precipitate removed by filtration. The phases of the filtrate 
were separated and the organic phase was dried (Na2SO4) and concentrated under reduced pressure. 
Flash column chromatography (2:3 to 1:1 Acetone/EtOAc) gave an impure mixture containing 
dimer 182 as the major product (18 mg) as a cream amorphous solid. 
 
The structure of dimer 182 was tentatively assigned by careful analysis of the 2D NMR data of the 
impure mixture. 
 
Rf (mixture) 0.18 (2:3 Acetone/EtOAC); 
 
IR (mixture) (film, cm−1) 3372, 2970, 1678, 1645, 1443; 
 





NMR see page 233 for 1D and 2D spectra of the mixture; 
 
 
Figure 15: Tentative assignment of 1H and 13C NMR signals, with selected HMBC and COSY 
correlations. See page 233 for 1D and 2D spectra of the mixture. 
 
1H NMR (601 MHz, CDCl3) δ 9.05 (br. s, 1H, A), 7.61 (app. dt, J = 7.9, 0.9 Hz, 1H, B), 7.43 (app. 
td, J = 7.6, 1.2 Hz, 1H, C), 7.25 (d, J = 8.3 Hz, 1H, D), 7.21 (app. td, J = 7.5, 1.1 Hz, 1H, E), 7.17 
(br. s, 1H, F), 6.99 (app. dt, J = 7.3, 1.0 Hz, 1H, G), 6.42 (br. s, 1H, H), 6.14 (dd, J = 17.5, 10.6 
Hz, 1H, I), 6.08 (br. s, 1H, J), 6.01 (dd, J = 17.4, 10.7 Hz, 1H, K), 5.87 – 5.83 (m, 2H, L), 5.13 
(dd, J = 17.5, 1.1 Hz, 1H, M), 5.09 (dd, J = 10.5, 1.1 Hz, 1H, N), 5.01 (dd, J = 17.4, 1.1 Hz, 1H, 
O), 4.92 (dd, J = 10.7, 1.1 Hz, 1H, P), 4.31 (br. s, 1H, Q), 4.29 – 4.25 (m, 1H, R), 3.87 – 3.77 (m, 
4H, S), 3.72 (dd, J = 14.1, 2.3 Hz, 1H, T), 3.68 (d, J = 8.7 Hz, 1H, U), 3.45 (app. dt, J = 14.6, 4.1 
Hz, 1H, V), 3.15 (dd, J = 14.7, 9.0 Hz, 1H, W), 2.97 (dd, J = 14.1, 8.8 Hz, 1H, X), 2.64 – 2.58 (m, 
4H, Y), 1.49 (app. s, 6H, Z), 1.41 (s, 3H, A1), 1.23 (s, 3H, B1) ppm; 
 
13C NMR (126 MHz, CDCl3) - where possible, 
13C peaks were tentatively assigned (Figure 15) 
based on 2D spectroscopic data. We were unable to observe HMBC signals strong enough to allow 











The synthesis of compound 194 was inspired by procedures reported by Sodeoka93 and Sorensen.94 
 
Solid dehydrodeoxy-brevianamide E (9) (10 mg, 0.029 mmol) and DMAP (~0.35 mg, 2.9 µmol) 
in an NMR tube were dissolved in anhydrous* CD3CN (0.6 mL). Boc2O (10 mg, 0.046 mmol) was 
added and the reaction left for 8 days at room temperature. 
 
NMR analysis indicated clean protection of the amide within 30 minutes, with no evidence of 
protection of the indole. 
 
Boc2O (31 mg, 0.14 mmol) and DMAP (3.5 mg, 0.029 mg) were added and the reaction heated at 
70 °C for 1.5 h. The reaction was left at room temperature for 48 days, and the sample concentrated 
under reduced pressure. Flash chromatography was carried out after combination with the crude 
from experiment 2. 
 
NMR analysis still indicated clean protection of the amide after 46 days, with no evidence of 
protection of the indole. 
 






The synthesis of compound 194 was inspired by a procedure reported by Martin and co-workers.95 
 
Solid dehydrodeoxy-brevianamide E (9) (10 mg, 0.0286 mmol) and NaH (1.9 mg, 60% dispersion 
in mineral oil, 0.0475 mmol) were covered in DMF (0.5 mL) at 0 °C and the mixture stirred at 
0 °C for 1 h and 45 minutes. Boc2O (9.4 mg, 0.043 mmol) and DMAP (appx. 0.7 mg, 0.006 mmol) 
were added to the yellow solution at 0 °C and the reaction was left to stir at room temperature 
overnight. The reaction mixture was diluted with EtOAc (2 mL) and water (2 mL), the phases 
separated and the aqueous phase extracted with EtOAc (3 × 2 mL). The combined organics were 
washed with brine (6 mL), dried (Na2SO4) and concentrated under reduced pressure. Flash 




The crude for the reaction showed clean protection of the amide, with no evidence of protection 
of the indole. 
 
The combined crudes from experiment 1 & 2 were purified by flash column chromatography on 
neutralised silica (1:1 EtOAc/petroleum spirit) to give compound 194 (12.7 mg, 0.0287 mmol, 




Rf 0.25 (1:1 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CD3CN) δ 8.93 (br. s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.28 (dt, J = 8.1, 1.0 Hz, 
1H), 7.07 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.98 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.11 (dd, J = 17.5, 
10.6 Hz, 1H), 5.91 (t, J = 3.2 Hz, 1H), 5.09 (dd, J = 17.4, 1.2 Hz, 1H), 5.06 (dd, J = 10.5, 1.1 Hz, 
1H), 5.00 (t, J = 5.7 Hz, 1H), 3.81 (td, J = 11.5, 4.4 Hz, 1H), 3.60 (td, J = 11.6, 9.2 Hz, 1H), 3.49 
(dd, J = 14.9, 6.0 Hz, 1H), 3.35 (dd, J = 14.9, 5.5 Hz, 1H), 2.50 – 2.41 (m, 1H), 2.11 – 2.08 (m, 
1H), 1.47 (s, 3H), 1.47 (s, 3H), 1.34 (s, 9H) ppm; 
 
13C NMR (126 MHz, CD3CN) δ 164.1, 157.5, 151.8, 147.1, 142.9, 136.0, 134.8, 130.8, 122.7, 
122.1, 119.6, 119.4, 112.0, 111.3, 105.2, 84.3, 61.9, 46.2, 40.3, 30.9, 28.9, 28.2, 28.1, 28.0 ppm; 
 
IR (film, cm−1) 3370, 2976, 2926, 2847, 1767, 1721, 1674, 1636, 1493,1454, 1447; 
 








The synthesis of compound 206 was inspired by a procedure reported by Kaiser and Wiegrebe.99a 
 
To a solution of compound 147 (93 µL, 100 mg, 0.787 mmol) in THF (0.5 mL) at 0 °C was added 
n-BuLi (346 µL, 2.5 M in Hexanes, 0.910 mmol) and the reaction stirred for 1 h at 0 °C. A solution 
of iodine (240 mg, 0.944 mmol) in THF (1 mL) was added dropwise at 0 °C. After 3 minutes, 
saturated aq. NH4Cl (1.5 mL) was added, the reaction diluted with EtOAc (10 mL). The organic 
phase was separated and washed with saturated aq. Na2S2O3 (2 × 1.5 mL), brine (5 mL), dried 
(Na2SO4) and concentrated under reduced pressure. Flash column chromatography (1:9 to 2:8 
EtOAc/petroleum spirit to EtOAc to 1:9 MeOH/EtOAc) to give alcohol 206 (8.8 mg, 0.042 mmol, 
5%) as a yellow oil. 
 
Rf 0.30 (1:4 EtOAc/petroleum spirit) 
 
1H NMR (500 MHz, CDCl3) δ 4.24 (br. s, 1H), 3.85 – 3.81 (m, 2H), 2.42 (tt, J = 8.4, 1.8 Hz, 2H), 
2.01 (app. p, J = 7.7 Hz, 2H), 1.65 (ddd, J = 13.5, 12.1, 4.4 Hz, 2H), 1.54 (ddd, J = 13.4, 11.8, 4.5 
Hz, 2H), 1.48 – 1.37 (m, 2H), 1.28 (dddd, J = 15.9, 14.5, 8.1, 4.3 Hz, 4H), 0.98 – 0.90 (m, 2H), 
0.87 (t, J = 7.4 Hz, 6H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 182.6, 75.9, 59.5, 39.5, 33.4, 25.5, 24.3, 23.2, 14.2 ppm; 
 
IR (film, cm−1) 3447, 2955, 2932, 2860, 1703, 1639, 1458; 
 








Compound 207 was prepared under anhydrous conditions. LDA was prepared and used based on 
conditions reported by Bookser.100 
 
To a stirred solution of diisoproylamine (130 µL, 0.928 mmol) in THF (3 mL) at −78 °C was added 
n-BuLi (350 µL, 2.45 M in hexanes, 0.858 mmol). The mixture was stirred for 1 minute at −78 °C. 
Compound 147 (93 µL, 0.787 mmol) was added slowly, dropwise and the mixture was stirred at 
−78 °C for 15 min. Solid I2 (120 mg, 0.472 mmol) was added portionwise and the reaction was 
stirred at −78 °C for 15 minutes. The reaction was stirred at 0 °C for 1 h and then diluted with a 
mixture of saturated aq. NH4Cl (5 mL) and water (5 mL). The reaction mixture was extracted with 
EtOAc (20 mL). The organic layer was washed with saturated aq. Na2S2O3 (10 mL), brine (10 mL), 
dried (Na2SO4) and concentrated under reduced pressure. Flash column chromatography on 
neutralised silica (7:3 EtOAc/petroleum spirit to EtOAc to 1:9 MeOH/EtOAc) gave dimer 207 
(5.3 mg, 0.0210 mmol, 5%) as a yellow oil. 
 
Rf 0.20 (1:9 MeOH/EtOAc); 
 
1H NMR (601 MHz, CHCl3) δ 7.68 (d, J = 1.2 Hz, 1H), 5.03 – 4.90 (m, 1H), 3.84 (s, 3H), 3.79 (s, 
3H), 2.91 – 2.84 (m, 1H), 2.80 – 2.72 (m, 1H), 2.72 – 2.66 (m, 1H), 2.66 – 2.59 (m, 1H), 2.53 (ddd, 
J = 13.2, 9.8, 4.7 Hz, 1H), 2.10 (dddd, J = 17.7, 16.7, 8.4, 4.7 Hz, 3H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 174.0, 171.1, 169.9, 163.2, 86.7, 79.9, 52.8, 52.7, 38.2, 36.6, 29.6, 
24.5 ppm; 
 
IR (film, cm−1) 2954, 1724, 1634, 1616, 1493, 1443; 
 










To a stirred solution of NCS (20 mg, 0.15 mmol) in CDCl3 (1.2 mL) was added compound 147 
(20 µL, 0.15 mmol). The reaction mixture was heated at 60 °C for 2 h and then stored at room 
temperature overnight. The reaction was heated at 60 °C for a further 6 h and the reaction stored 
at room temperature for 2 days. Additional NCS (4.0 mg, 0.030 mmol) was added, the reaction 
heated at 60 °C for 2 h and stored at room temperature overnight. The reaction mixture was diluted 
with Et2O (10 mL) and concentrated to a small volume under reduced pressure. Petroleum spirit 
(10 mL) was added, the resultant precipitate was removed by filtration. The filtrate concentrated 
under reduced pressure and purified by flash column chromatography (1:4 EtOAc/petroleum spirit) 
to give compound 212 (14 mg, 0.086 mmol, 57%) as a colourless oil. 
 
Rf 0.25 (1:4 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CDCl3) δ 5.10 (ddt, J = 7.8, 1.9, 1.0 Hz, 1H), 4.32 – 4.20 (m, 2H), 3.93 (s, 
3H), 2.46 (dq, J = 14.6, 7.9 Hz, 1H), 2.31 (dddd, J = 14.7, 6.3, 2.7, 1.8 Hz, 1H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 165.8, 161.5, 60.9, 58.7, 53.2, 34.8 ppm; 
 
IR (film, cm−1) 2955, 1730, 1626, 1439, 1350; 
 





Experimental Procedure for Compound 213 
 
 
Compound 213 was prepared by Dr. Nick Green, inspired by conditions reported by Yasuaki and 
co-workers.103 
 
To a stirred solution of dehydrodeoxy-brevianamide E (9) (50 mg, 0.14 mmol) in CH2Cl2 (4.0 mL) 
at was added solid K2CO3 (71 mg, 0.52 mmol) and the reaction stirred for 5 minutes at 0 °C. Solid 
NBS (31 mg, 0.17 mmol) was added and the reaction stirred for 5 minutes at 0 °C. The cooling 
bath was removed and the reaction was left to stir for 16 h at room temperature. The reaction was 
diluted with CH2Cl2 (10 mL) and 10% aq. Na2SO3 (10 mL). The phases were separated and the 
aqueous phase back-extracted with CH2Cl2 (10 mL). The combined organic extracts were washed 
with brine, dried (Na2SO4) and a drop of NEt3 was added before the crude was concentrated under 
reduced pressure. Flash column chromatography (1:99 NEt3/EtOAc to 10:1:99 MeOH/ 
NEt3/EtOAc) yielded the bromo-indolenines 213 as a 9:2 mixture of diastereomers (34 mg, 57%). 
Whilst the diastereomers appeared to co-elute, careful chromatography allowed separation of a 
small sample of the major diastereomer suitable for characterisation. 
 
Characterisation data for major diastereomer: 
 
Rf 0.20 (EtOAc); 
 
1H NMR (601 MHz, CDCl3) δ 8.21 (br. s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.29 (dd, J = 7.7, 1.2 Hz, 
1H), 7.25 (d, J = 7.7 Hz, 1H), 7.05 (dd, J = 7.5, 1.0 Hz, 1H), 6.49 (dd, J = 3.2, 3.2 Hz, 1H), 6.08 
(dd, J = 17.4, 10.7 Hz, 1H), 5.30 (dd, J = 10.4, 6.4 Hz, 1H), 5.19 (d, J = 17.4 Hz, 1H), 5.13 (d, J 
= 10.7 Hz, 1H), 4.11 (ddd, J = 12.4, 10.8, 5.3 Hz, 1H), 3.85 (ddd, J = 11.8, 11.8, 9.0 Hz, 1H), 2.93 
(dd, J = 13.4, 6.5 Hz, 1H), 2.90 – 2.79 (m, 2H), 2.15 (dd, J = 13.4, 10.5 Hz, 1H), 1.21 (s, 3H), 0.70 
(s, 3H) ppm; 
 
13C NMR (151 MHz, CDCl3) δ 181.0, 162.2, 159.2, 153.3, 144.1, 139.2, 134.3, 129.0, 123.7, 
123.6, 123.5, 120.4, 115.0, 66.9, 66.4, 45.6, 43.3, 31.5, 28.8, 24.1, 21.6 ppm; 
 
IR (film, cm−1) 2970, 2930, 2855, 1697, 1674, 1636, 1570; 
 








Compound 227 was prepared under anhydrous conditions, based on a procedure developed by 
Dr Nick Green. After the addition of I2, effort was made to limit exposure of the material to light. 
 
To a stirred solution of dehydrodeoxy-brevianamide E (9) (250 mg, 0.715 mmol) in anhydrous 
DMF* (12.5 mL) was added a solution of a TFA* (1.6 µL, 0.021 mmol) in anhydrous DMF 
(500 µL). The reaction mixture was cooled to 0 °C and NIS* (161 mg, 0.715 mmol) was added in 
a single portion. The reaction was stirred at 0 °C for 5 minutes, the cooling bath was removed and 
the reaction was stirred at room temperature for 1 h. The reaction was cooled to 0 °C and NEt3 
(750 µL, 5.38 mmol) was added. The reaction mixture was poured onto a stirred mixture of EtOAc 
(100 mL) and 10% aq. Na2S2O3 (50 mL). The organic layer was separated, washed with brine 
(5 × 100 mL) and concentrated under reduced pressure. Flash column chromatography (7:13 to 
13:7 EtOAc/petroleum spirit) gave compound 227 (227 mg, 0.478 mmol, 67%) as a cream foam. 
 
*Anhydrous DMF was dried over activated 4 Å molecular sieves. Commercial TFA was distilled 
under inert atmosphere before use. NIS was recrystallised from dioxane/ether. 
 
Rf 0.50 (70% EtOAc)  
 
1H NMR (500 MHz, CDCl3) δ 8.16 (br. s, 1H), 7.50 (d, J = 7.9z Hz, 1H), 7.31 (dd, J = 8.0, 1.0 
Hz, 1H), 7.15 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.09 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.13 (dd, J = 
17.5, 10.6 Hz, 1H), 5.79 (br. s, 1H), 5.19 – 5.14 (m, 2H), 4.46 (ddd, J = 10.7, 3.5, 2.1 Hz, 1H), 
4.07 – 3.93 (m, 2H), 3.69 (dd, J = 14.6, 3.6 Hz, 1H), 3.23 (dd, J = 14.6, 10.8 Hz, 1H), 3.05 – 2.89 
(m, 2H), 1.55 (s, 3H), 1.54 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 162.0, 156.0, 145.9, 141.9, 134.4, 130.8, 128.9, 122.2, 120.1, 118.3, 
112.5, 110.9, 104.4, 80.3, 57.7, 45.8, 40.3, 39.2, 30.9, 28.1, 27.9 ppm; 
 
IR (film, cm−1) 3340, 2967, 2924, 1654, 1620; 
 








Experimental Procedure for Compound 131 
 
Compound 131 was prepared under anhydrous conditions, based on conditions developed by 
Dr Nick Green and inspired by Liebeskind and co-workers.113 
 
To a stirred solution of compound 227 (20 mg, 0.042 mmol) in NMP (0.4 mL) at 70 °C was added 
copper(I) thiophene-2-carboyxlate (32 mg, 0.17 mmol). After 50 minutes the reaction was cooled 
to room temperature. The reaction mixture was diluted with EtOAc, washed through a small plug 
of neutralised silica with EtOAc and the filtrate was concentrated under reduced pressure. Flash 
chromatography on neutralised silica (EtOAc to 6:100 MeOH/EtOAc) gave dimer 131 (4.5 mg, 




Rf 0.20 (1:40 MeOH/EtOAc); 
 
MP 158–162 °C; 
 
1H NMR (500 MHz, CDCl3) δ 8.04 (br. s, 2H), 7.52 (d, J = 7.8 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 
7.16 (dd, J = 7.3 Hz, 2H), 7.11 (dd, J = 7.4 Hz, 2H), 6.11 (dd, J = 17.4, 10.6 Hz, 2H), 5.62 (br. s, 
2H), 5.28 – 5.06 (m, 4H), 4.45 (dt, J = 10.9, 2.9 Hz, 2H), 4.06 – 3.97 (m, 4H), 3.72 (dd, J = 14.6, 
3.5 Hz, 2H), 3.22 (dd, J = 14.6, 11.0 Hz, 2H), 3.03 (app. t, J = 9.4 Hz, 4H), 1.54 (s, 6H), 1.53 (s, 
6H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 162.7, 156.4, 145.8, 141.8, 134.5, 129.0, 128.0, 127.1, 122.2, 
120.2, 118.4, 112.6, 110.9, 104.7, 57.2, 44.2, 39.2, 31.5, 30.7, 28.1, 28.0 ppm; 
 
 IR (cm−1); 3360, 2968, 2926, 1653; 
 





Experimental Procedure for Brevianamide K (10) 
 
 
Brevianamide K (10) was prepared under anhydrous conditions, inspired by the work of 
Matsuo110a and Mukaiyama.107 
 
To a solution of dehydrodeoxy-brevianamide E (9) (100 mg, 0.286 mmol) in CH2Cl2 (5 mL) was 
added 2-t-butyl-1,1,3,3-tetramethylguanidine 221 (115 µL, 0.572 mmol) and the reaction cooled 
to −78 °C with stirring. A solution of N-t-butylbenzenesulfinimidoyl chloride 216* (123 mg, 0.572 
mmol) in CH2Cl2 (4.1 mL) was added dropwise over 5 minutes at −78 °C. After stirring for 6 
minutes at −78 °C the reaction was quenched by the addition of saturated aq. NaHCO3 (15 mL) 
and the reaction was left to warm to room temperature. The phases were separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 15 mL). The combined organics were washed with brine (15 
mL), dried (Na2SO4) and concentrated under reduced pressure. Flash column chromatography (3:7 
to 1:1 EtOAc/petroleum spirit to EtOAc) gave brevianamide K (10) (55.2 mg, 0.159 mmol, 56%) 
as a pale brown glass. Spectroscopic data matched literature values.3c 
 
*Mukaiyama’s N-t-butylbenzenesulfinimidoyl chloride reagent 216107a was prepared according to 
a procedure reported by Trost and co-workers.133 For optimum yield, a pressure >200 mbar was 
maintained when concentrating solutions of the t-BuNCl2 intermediate during this synthesis.
107b 
 
Rf 0.13 (1:1 EtOAc/petroleum spirit); 
 
1H NMR (500 MHz, CHCl3) δ 8.47 (br. s, 1H), 7.58 (br. s, 1H), 7.35 (dt, J = 8.0, 1.0 Hz, 1H), 
7.28 (d, J = 7.8 Hz, 1H), 7.20 (s, 1H), 7.21 – 7.14 (m, 1H), 7.13 (td, J = 7.5, 1.2 Hz, 1H), 6.23 (t, 
J = 3.2 Hz, 1H), 6.05 (dd, J = 17.4, 10.6 Hz, 1H), 5.20 (dd, J = 10.7, 1.1 Hz, 1H), 5.17 (dd, J = 
17.5, 0.9 Hz, 1H), 4.19 (dd, J = 9.8, 8.6 Hz, 2H), 2.93 – 2.82 (m, 2H), 1.51 (s, 6H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 155.2, 154.4, 144.4, 144.0, 134.5, 134.0, 126.4, 126.1, 122.5, 
121.2, 119.8, 119.1, 113.5, 111.4, 111.2, 103.3, 45.9, 39.4, 28.3, 27.5 ppm; 
 
IR (film, cm−1) 3312 br., 2963, 2922, 2853, 1668, 1636, 1616, 1409, 1350; 
 









Compound 239 was prepared under anhydrous conditions, inspired by the work of Matsuo110a and 
Mukaiyama.107 
 
To a solution of compound 227 (20 mg, 0.0421 mmol) in CH2Cl2 (1 mL) was added 2-t-butyl-
1,1,3,3-tetramethylguanidine 221 (17.0 µL, 0.0842 mmol) and the reaction cooled to −78 °C with 
stirring. A solution of N-t-butylbenzenesulfinimidoyl chloride 216* (18.2 mg, 0.842 mmol) in 
CH2Cl2 (0.44 mL) was added dropwise over 4 minutes at −78 °C. After stirring for 11 minutes at 
−78 °C the reaction was quenched by the addition of saturated aq. NaHCO3 (3 mL) and the reaction 
was left to warm to room temperature. The reaction mixture was diluted with water (5 mL) and 
CH2Cl2 (5 mL). The phases were separated and the aqueous layer was back-extracted with CH2Cl2 
(3 × 5 mL). The combined organics were dried (Na2SO4) and concentrated under reduced pressure. 
Two rounds of flash column chromatography (3:7 to 1:1 EtOAc/petroleum spirit) then (1:4 to 2:3 
EtOAc/petroleum spirit) gave 239 contaminated with N-(phenylsulfinyl)-N-(tert-butyl)amine 
227.134 Flash column chromatography (CH2Cl2 to 1:9 EtOAC/CH2Cl2) gave compound 239 
(2.6 mg, 0.00549 mmol, 13%) as a yellow glass. 
 
*Mukaiyama’s N-t-butylbenzenesulfinimidoyl chloride reagent 216107a was prepared according to 
a procedure reported by Trost and co-workers.133 For optimum yield, a pressure >200 mbar was 
maintained when concentrating solutions of the t-BuNCl2 intermediate during this synthesis.
107b 
 
Rf 0.33 (1:9 EtOAc/ CH2Cl2); 
 
1H NMR (500 MHz, CDCl3) δ 8.30 (br. s, 1H), 7.61 (br. s, 1H), 7.36 (dt, J = 8.0, 0.9 Hz, 1H), 
7.28 (ddt, J = 7.9, 1.6, 0.8 Hz, 1H), 7.20 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 7.19 (s, 1H), 7.15 (ddd, J 
= 8.1, 7.1, 1.2 Hz, 1H), 6.07 (dd, J = 17.4, 10.6 Hz, 1H), 5.23 (dd, J = 10.5, 0.9 Hz, 1H), 5.19 (dd, 
J = 17.5, 0.9 Hz, 1H), 4.17 (dd, J = 10.1, 8.6 Hz, 2H), 3.15 (dd, J = 10.0, 8.7 Hz, 2H), 1.52 (s, 6H) 
ppm; 
 
13C NMR (126 MHz, CDCl3) δ 154.5, 153.6, 144.3, 144.1, 134.4, 131.9, 126.1, 126.0, 122.6, 
121.4, 119.2, 113.6, 111.4, 111.3, 103.4, 81.4, 46.1, 40.6, 39.4, 27.5 ppm; 
 
IR (film, cm−1) 3333, 2963, 2924, 1661, 1624, 1612, 1410; 
 









Compounds 56 and 109 were prepared based on a procedure reported by Williams and 
co-workers.42e 
 
To a solution of dehydrodeoxy-brevianamide E (9) (250 mg, 0.715 mmol) in MeOH (54.3 mL) 
was added 3.56 M aq. KOH (13.6 mL) and the reaction stirred at 40 °C overnight. The reaction 
was cooled to room temperature, quenched with saturated aq. NH4Cl (25 mL) and extracted with 
CH2Cl2 (5 × 50 mL) and CHCl3 (2 × 50 mL). The combined extracts were dried (Na2SO4) and 
concentrated under reduced pressure. Flash column chromatography (1:9 to 2:8 MeCN/CHCl3) 
gave compound 109 (77.7 mg, 0.222 mmol, 31%) as a white foam and compound 56 (57.2 mg, 




Rf 0.14 (2:8 MeCN/CHCl3); 
 
1H NMR (500 MHz, CDCl3) δ 7.79 (br. s, 1H), 7.53 (d, J = 7.8  1H), 7.33 (dt, J = 7.9, 0.9 Hz, 1H), 
7.19 (ddd, J = 8.1, 7.1, 1.3 Hz, 1H), 7.13 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 5.65 (br. s, 1H), 3.95 (d, 
J = 17.9 Hz, 1H), 3.56 (td, J = 7.1, 1.6 Hz, 2H), 2.92 (d, J = 17.9 Hz, 1H), 2.84 (ddd, J = 13.2, 7.1, 
6.2 Hz, 1H), 2.37 (ddd, J = 9.9, 4.2, 0.9 Hz, 1H), 2.17 (dd, J = 13.5, 9.9 Hz, 1H), 2.10 (dd, J = 
13.6, 4.2 Hz, 1H), 2.09 – 1.99 (m, 2H), 1.88 (dt, J = 13.1, 7.5 Hz, 1H), 1.34 (s, 3H), 1.31 (s, 3H) 
ppm; 
 
13C NMR (126 MHz, CDCl3) δ 172.6, 169.0, 139.6, 136.4, 127.2, 122.2, 119.8, 118.4, 110.7, 
103.6, 67.1, 61.7, 45.8, 44.2, 34.5, 32.7, 29.2, 29.1, 25.4, 24.5, 24.0 ppm; 
 
IR (film, cm−1) 3447, 3217, 2955, 2911, 2359, 1697, 1655, 1460, 1435; 
 








Rf 0.08 (2:8 MeCN/CHCl3); 
 
1H NMR (500 MHz, CDCl3) δ 7.74 (br. s, 1H), 7.51 (ddt, J = 7.7, 1.4, 0.7 Hz, 1H), 7.29 (dt, J = 
8.0, 0.9 Hz, 1H), 7.16 (ddd, J = 8.1, 7.1, 1.3 Hz, 1H), 7.11 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.93 (br. 
s, 1H), 3.90 (d, J = 15.2 Hz, 1H), 3.57 (dt, J = 11.4, 6.4 Hz, 1H), 3.41 (dt, J = 11.4, 7.2 Hz, 1H), 
2.83 (dt, J = 13.1, 6.6 Hz, 1H), 2.64 (d, J = 15.3 Hz, 1H), 2.61 (dd, J = 10.4, 4.9 Hz, 1H), 2.26 (dd, 
J = 13.5, 10.3 Hz, 1H), 2.04 (app. p, J = 7.1 Hz, 2H), 1.97 (dd, J = 13.5, 4.9 Hz, 1H), 1.89 (dt, J = 
13.0, 7.6 Hz, 1H), 1.32 (s, 3H), 1.13 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 173.3, 168.6, 139.6, 136.6, 127.1, 122.1, 119.7, 118.6, 110.7, 
104.8, 66.7, 60.6, 49.7, 44.3, 34.8, 31.2, 29.6, 28.5, 25.5, 24.7, 22.5 ppm; 
 
IR (film, cm−1) 3287, 3163, 3119, 3055, 2968, 2889, 2864, 1680, 1661, 1458, 1429, 1416, 1395, 
1375; 
 












Brevianamide X (16) was prepared under anhydrous conditions, inspired by the work of Williams 
and co-workers.4e, 42f 
 
Step (1) - To a solution of compound 109 (32.9 mg, 0.0942 mmol) in THF (5.7 mL) was added a 
solution of solution of m-CPBA in THF (0.021 M, 5.7 mL, 0.12 mmol).* The reaction mixture was 
stirred at room temperature for 18 h before being quenched with DMS (50 µL) and concentrated 
under reduced pressure. The crude material was used directly in the next step. 
 
Step (2) - The crude product from the first step was dissolved in CH2Cl2 (5.7 mL), 2 M aq. HCl 
(5.7 mL) was added and the reaction stirred rapidly at room temperature for 22 h. The reaction 
mixture was diluted with brine (5 mL), extracted with CH2Cl2 (4 × 10 mL) and the combined 
organics concentrated under reduced pressure. Column chromatography (EtOAc) followed by 
preparative TLC (2:3 MeCN/CHCl3) gave brevianamide X (16) (17.3 mg, 0.0473 mmol, 50%) as 
an amorphous white solid. Spectroscopic data matched literature values.13 
 
*m-CPBA (69% w/w by iodometric titration, 107 mg, 0.429 mmol) was added to THF (20 mL) 




Rf 0.11 (2:3 MeCN/CHCl3); 
 
1H NMR (500 MHz, (CD3)2SO) δ 10.34 (br. s, 1H), 9.09 (br. s, 1H), 7.23 (dd, J = 7.6, 1.2 Hz, 1H), 
7.18 (td, J = 7.7, 1.2 Hz, 1H), 6.97 (td, J = 7.6, 1.1 Hz, 1H), 6.82 (dd, J = 7.8, 1.0 Hz, 1H), 3.45 – 
3.34 (m, 2H), 3.22 (dd, J = 10.3, 8.2 Hz, 1H), 2.85 (d, J = 14.2 Hz, 1H), 2.55 – 2.51 (m, 1H), 2.19 
(d, J = 14.2 Hz, 1H), 2.05 – 1.98 (m, 1H), 1.94 (dd, J = 13.0, 10.3 Hz, 1H), 1.85 – 1.72 (m, 3H), 
0.74 (s, 3H), 0.71 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 182.3, 173.0, 169.4, 142.3, 130.5, 128.0, 125.9, 121.0, 109.2, 
68.1, 65.6, 61.4, 55.4, 45.1, 43.4, 33.1, 29.4, 29.0, 24.3, 23.2, 19.7 ppm; 
 
IR (film, cm−1) 3155, 3088, 2951, 2880, 1699, 1661, 1616, 1471, 1398; 
 





Experimental Procedure for ‘Depyrano-sclerotiamide’ (235) 
 
To a solution of compound (±)-109 (5.0 mg, 0.0143 mmol) in CDCl3 (0.5 mL) was added (−)-(8,8-
dichlorocamphorsulfonyl)oxaziridine (3.8 mg, 0.143 mmol) and the reaction was stirred at room 
temperature for 20 minutes. TFA (2.0 µL, 0.0261 mmol) was added and the reaction stirred at 
room temperature for 3 days. The reaction mixture was neutralised with saturated aq. NaHCO3 
(0.5 mL), quenched with saturated aq. Na2S2O3 (0.5 mL) extracted with CH2Cl2 (3 × 5 mL) and 
concentrated under reduced pressure. Preparative TLC (EtOAc) gave recovered starting material 
(±)-109 (0.6 mg, 0.0017 mmol, 12%) as a white glass and (±)-‘depyrano-sclerotiamide’ (235) (0.5 
mg, 0.0013 mmol, 9%) as a white glass. 
 
 
e.r. 49.4:50.6 (Chiralpak IA, 1:1 i-PrOH/hexane, 1 mL min-1, λ 254 nm) tR1 = 4.71 min, tR2 = 5.81 
min. 
 
 Rf 0.13 (EtOAC); 
 
1H NMR (500 MHz, CDCl3) δ 7.70 (br. s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.26 (td, J = 7.6, 1.2 Hz, 
1H), 7.09 (td, J = 7.6, 1.1 Hz, 1H), 6.90 (br. s, 1H), 6.89 (dt, J = 8.0, 0.8 Hz, 1H), 5.42 (d, J = 11.3 
Hz, 1H), 3.64 (ddd, J = 11.8, 7.5, 4.5 Hz, 1H), 3.58 (d, J = 11.3 Hz, 1H), 3.56 (dd, J = 10.1, 8.2 
Hz, 1H), 3.48 (ddd, J = 11.3, 8.2, 7.0 Hz, 1H), 2.82 (ddd, J = 13.1, 7.2, 4.8 Hz, 1H), 2.13 (dd, J = 
12.8, 10.1 Hz, 1H), 2.10 – 1.98 (m, 2H), 1.84 (ddd, J = 13.1, 8.8, 7.5 Hz, 1H), 1.73 (dd, J = 12.8, 
8.2 Hz, 1H), 0.89 (s, 3H), 0.89 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 179.4, 173.0, 169.2, 140.9, 129.6, 128.7, 127.1, 123.0, 109.8, 73.5, 
69.3, 69.2, 66.5, 55.0, 44.8, 44.0, 30.4, 29.6, 25.1, 24.2, 20.2 ppm; 
 
IR (film, cm−1) 3348, 3327, 2920, 1686, 1665, 1618, 1472; 
 




𝟐𝟑.𝟎 0 (c 0.07, MeOH).  
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To a solution of dehydrodeoxy-brevianamide E (9) (100 mg, 0.286 mmol) in MeOH (6 mL) at 
0 °C was added a solution of TFA (0.44 µL, 0.00572 mmol) in water (26 µL) with stirring, 
followed by addition of NCS (40.1 mg, 0.300 mmol). The reaction was allowed to warm slowly 
to room temperature and stirred for 3 days. The entire mixture was concentrated under reduced 
pressure. Flash column chromatography (2:8 to 13:7 MeCN/CHCl3) gave oxindole 113 (50.1 mg, 






Rf 0.11 (1:1 MeCN/CHCl3); 
 
1H NMR (500 MHz, CDCl3) δ 10.94 (br. s, 1H), 8.75 (br. s, 1H), 7.18 (dd, J = 7.6, 1.2 Hz, 1H), 
7.11 (td, J = 7.7, 1.2 Hz, 1H), 6.94 – 6.85 (m, 2H), 6.08 (dd, J = 17.4, 10.8 Hz, 1H), 5.55 (app. t, 
J = 3.0 Hz, 1H), 5.10 (dd, J = 10.9, 1.2 Hz, 1H), 4.97 (dd, J = 17.4, 1.2 Hz, 1H), 4.31 (d, J = 7.2 
Hz, 1H), 3.71 (app. t, J = 9.1 Hz, 2H), 3.03 (dd, J = 14.8, 1.5 Hz, 1H), 2.75 (dd, J = 14.8, 7.4 Hz, 
1H), 2.51 – 2.43 (m, 2H), 1.11 (s, 3H), 0.97 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 183.1, 162.6, 157.6, 143.1, 143.1, 132.1, 128.4, 128.0, 127.9, 
120.5, 118.3, 114.2, 111.1, 56.3, 55.8, 45.2, 42.6, 33.7, 27.5, 22.2, 21.6 ppm; 
 
IR (film, cm−1) 3200, 3084, 2963, 2930, 1676, 1643, 1618, 1470, 1449; 
 













Rf 0.25 (1:1 MeCN/CHCl3); 
 
1H NMR (500 MHz, CDCl3) δ 10.42 (br. s, 1H), 7.58 (br. d, J = 3.7 Hz, 1H), 7.29 – 7.22 (m, 2H), 
7.05 (td, J = 7.6, 1.1 Hz, 1H), 6.97 (dd, J = 8.2, 1.1 Hz, 1H), 6.06 (dd, J = 17.5, 10.8 Hz, 1H), 5.95 
(app. t, J = 3.0 Hz, 1H), 5.13 (dd, J = 10.7, 1.1 Hz, 1H), 5.02 (dd, J = 17.4, 1.2 Hz, 1H), 4.05 (ddd, 
J = 12.3, 11.2, 5.4 Hz, 1H), 3.83 (ddd, J = 11.9, 11.8, 8.3 Hz, 1H), 3.56 (dt, J = 11.3, 3.2 Hz, 1H), 
2.80 (dddd, J = 18.4, 11.2, 8.3, 2.8 Hz, 1H), 2.72 – 2.61 (m, 2H), 2.41 (dd, J = 14.0, 11.7 Hz, 1H), 
1.15 (s, 3H), 1.05 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 182.9, 163.6, 157.9, 142.7, 142.3, 133.3, 128.2, 127.9, 126.3, 
121.9, 119.0, 114.6, 112.0, 56.7, 55.9, 45.7, 42.6, 38.9, 28.0, 22.0, 21.9 ppm; 
 
IR (film, cm−1) 3211, 2957, 2926, 1703, 1676, 1643, 1618, 1470, 1441; 
 








Experimental Procedure for Brevianamide Y (17) 
 
 
The synthesis of brevianamide Y (17) was inspired by the work of Williams and co-workers.42e, 53 
 
To a solution of oxindole 113 (36.2 mg, 0.0991 mmol) in MeOH (7.6 mL) at 0 °C was added 3.56 
M aq. KOH (2.0 mL), the reaction allowed to slowly warm to room temperature and stirred for 18 
h. The reaction was quenched with saturated aq. NH4Cl (8 mL) and extracted with CH2Cl2 (3 × 20 
mL) and EtOAc (2 × 20 mL). The combined organics were dried (Na2SO4) and concentrated under 
reduced pressure. Preparative TLC (2:3 1,2-dimethoxyethane/MTBE) gave compound 253 (4.7 
mg, 0.013 mmol, 13%) as a white amorphous solid. A second round of preparative TLC (3:7 




Spectroscopic data matched literature values.13 
 
Rf 0.15 (2:3 1,2-dimethoxyethane/MTBE), 0.22 (3:7 THF/CH2Cl2); 
 
1H NMR (601 MHz, (CD3)2SO) δ 10.30 (br. s, 1H), 8.79 (br. s, 1H), 7.42 (dd, J = 7.6, 1.2 Hz, 1H), 
7.19 (td, J = 7.7, 1.2 Hz, 1H), 6.98 (td, J = 7.6, 1.1 Hz, 1H), 6.81 (dd, J = 7.7, 1.0 Hz, 1H), 3.36 – 
3.22 (m, 2H), 3.17 (dd, J = 10.4, 7.2 Hz, 1H), 2.82 (d, J = 15.1 Hz, 1H), 2.46 (dd, J = 12.3, 6.6 Hz, 
1H), 2.13 (d, J = 15.2 Hz, 1H), 2.02 – 1.96 (m, 1H), 1.93 (dd, J = 13.1, 10.4 Hz, 1H), 1.85 – 1.75 
(m, 2H), 1.65* (dd, J = 13.0, 7.2 Hz, 1H), 0.99 (s, 3H), 0.69 (d, J = 2.1 Hz, 3H) ppm; 
 
*A literature table of NMR data doesn’t report this peak. However a printout of the literature 1H 
NMR spectrum shows a peak at δ = 1.639, which integrates for 1.11, appears to be a dd and wasn’t 
reported in the table. Instead the table reports ‘δ = 2.47, dd (6.4, 12.1)’ twice, which is presumably 
an error. 
 
13C NMR (126 MHz, (CD3)2SO) δ 181.8, 172.5, 169.0, 142.4, 129.8, 128.1, 126.3, 120.8, 109.0, 
68.6, 67.1, 62.1, 50.0, 46.8, 43.2, 33.6, 28.4, 28.0, 24.4, 23.0, 20.4 ppm; 
 
IR (film, cm−1) 3225, 2970, 2928, 2872, 2359, 2324, 1719, 1694, 1668, 1595, 1470, 1445, 1404;  
 
HRMS (ESI+) m/z 366.1813 (calculated [M + H]+ 366.1812), 388.1624  (calculated [M + Na]+ 
388.1632); 
 
[𝛂]𝑫  more material required for accurate measurement, literature [𝛂]𝑫






Rf 0.26 (2:3 1,2-dimethoxyethane/MTBE); 
 
1H NMR (500 MHz, (CD3)2SO) δ 10.27 (br. s, 1H), 8.69 (br. s, 1H), 7.17 (td, J = 7.6, 1.2 Hz, 1H), 
7.06 (d, J = 7.4 Hz, 1H), 6.93 (td, J = 7.6, 1.1 Hz, 1H), 6.81 (dd, J = 7.7, 1.1 Hz, 1H), 3.40 (dt, J 
= 10.7, 6.8 Hz, 1H), 3.30 – 3.22 (m, 1H), 2.63 (dd, J = 10.1, 7.5 Hz, 1H), 2.59 (d, J = 14.9 Hz, 
1H), 2.49 – 2.43 (m, 2H), 2.05 – 1.98 (m, 1H), 1.94 (dd, J = 13.0, 10.1 Hz, 1H), 1.89 – 1.75 (m, 
2H), 1.66 (dd, J = 13.0, 7.4 Hz, 1H), 1.05 (s, 3H), 0.41 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 178.6, 172.2, 169.4, 141.5, 134.3, 127.8, 124.0, 121.0, 109.1, 
68.5, 67.5, 62.4, 53.0, 47.7, 43.3, 33.1, 28.4, 27.3, 24.4, 23.1, 19.5 ppm; 
 
IR (film, cm−1) 3235, 2961, 2930, 2880, 1686, 1678, 1618, 1470, 1395; 
 
HRMS (ESI+) m/z 366.1832 (calculated [M + H]+ 366.1812). 
 
[𝛂]𝑫  more material required for accurate measurement  
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To a solution of compound dia-71 (20 mg, 0.0547 mmol) in MeOH (1 mL) was added a solution 
of 1.45 M K2CO3 (1 mL) and the reaction stirred at room temperature overnight. The reaction was 
acidified with 1 M aq. HCl (3 mL), extracted with CH2Cl2 (3 × 5 mL), dried (Na2SO4) and 
concentrated under reduced pressure. Preparative TLC (1:9 i-PrOH/CHCl3) gave ent-261 (8.2 mg, 




Rf 0.33 (1:9 i-PrOH/CHCl3), 0.32 (3:7 THF/CHCl3); 
 
1H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 7.6 Hz, 1H), 7.43 (dd, J = 7.5, 1.3 Hz, 1H), 7.37 (td, J 
= 7.6, 1.3 Hz, 1H), 7.23 (td, J = 7.4, 0.9 Hz, 1H), 7.14 (br. s, 1H), 3.67 (br. s, 1H), 3.42 (app. t, J 
= 6.9 Hz, 2H), 2.83 (d, J = 15.7 Hz, 1H), 2.74 (dt, J = 13.5, 6.9 Hz, 1H), 2.10 – 1.94 (m, 6H), 1.83 
(dt, J = 13.1, 7.3 Hz, 1H), 1.44 (s, 3H), 1.33 (s, 3H) ppm; 
 
13C NMR (126 MHz, CDCl3) δ 188.2, 172.6, 168.4, 152.1, 140.6, 130.3, 126.7, 122.4, 121.2, 82.5, 
67.3, 62.1, 50.5, 44.2, 40.6, 38.0, 32.7, 29.2, 27.5, 24.5, 20.2 ppm; 
 
IR (film, cm−1) 3362, 2968, 2882, 1674, 1580, 1458, 1390; 
 








Rf 0.29 (1:9 i-PrOH/CHCl3); 
 
1H NMR (500 MHz, (CD3)2SO) δ 8.24 (br. s, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.43 (dd, J = 7.6, 0.9 
Hz, 1H), 7.33 (td, J = 7.6, 1.3 Hz, 1H), 7.21 (td, J = 7.4, 1.0 Hz, 1H), 5.88 (d, J = 1.6 Hz, 1H), 
3.55 (d, J = 15.0 Hz, 1H), 3.39 (dt, J = 10.6, 6.9 Hz, 1H), 3.35 – 3.28 (m, 1H), 3.21 (dd, J = 10.4, 
5.6 Hz, 1H), 2.54 – 2.47 (m, 1H), 2.17 (dd, J = 13.3, 10.5 Hz, 1H), 2.04 – 1.95 (m, 1H), 1.86 – 
1.76 (m, 3H), 1.30 (dd, J = 15.0, 1.7 Hz, 1H), 1.27 (s, 3H), 1.25 (s, 3H) ppm; 
 
13C NMR (126 MHz, (CD3)2SO) δ 191.6, 172.5, 168.7, 153.3, 141.5, 128.9, 125.6, 122.5, 119.9, 
81.2, 66.3, 59.5, 43.8, 42.3, 38.4, 33.1, 30.2, 28.8, 28.5, 24.0, 22.4 ppm; 
 
IR (film, cm−1) 3269, 2970, 2879, 1694, 1674, 1578, 1456, 1404; 
 








Appendix 1: Previous Syntheses of Brevianamide B (2)  
 
Williams’ synthesis of (−)-brevianamide B (2) (1988) 
 
 
Scheme 129: Williams’ synthesis of (−)-brevianamide B (2) (1988)4d, 4e, 42a  
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Williams’ first biomimetic synthesis of (±)-brevianamide B (2) (1998) 
 
 




Williams’ synthesis of (±)-brevianamide B (2) (2006) 
 
 




Williams’ second biomimetic synthesis of (±)-brevianamide B (2) (2007) 
 
 








Simpkins’ synthesis of (–)-brevianamide B (2) (2009) 
 
 
Scheme 134: Simpkins’ synthesis of (−)-brevianamide B (2) (2009).42g, 42h 
 
Starting material - Scheerer (2013)50  
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Scheerer’s first formal synthesis of (±)-brevianamide B (2) (2016) 
 
Scheme 135: Scheerer’s first formal synthesis of (±)-brevianamide B (2) (2016).49 
 
Starting material - Scheerer (2013)50  
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Scheerer’s second formal synthesis of (±)-brevianamide B (2) (2017) 
 
 
Scheme 136: Scheerer’s 2017 formal synthesis of (±)-brevianamide B (2).42e, 42i 
 




Appendix 2: Chiral HPLC Chromatograms 
 
 










e.r. 99:1 after crystallisation (Chiralpak IA, 1:1 i-PrOH/hexane, 1 mL min-1, λ 254 nm) tRminor = 
5.51 min, tRmajor = 6.84 min. 
 






Mixed Run (Chiralpak IA, 1:3 EtOH/hexane, 1 mL min-1, λ 254 nm) tR1 = 13.86 min, tR2 = 26.03 
min. 
 













Racemic starting material (Chiralpak IA, 1:1 i-PrOH/hexane, 1 mL min-1, λ 254 nm) tR1 = 4.71 





Recovered starting material from kinetic resolution attempt 









Appendix 3: X-ray Crystal Structure (+)-Brevianamide A 
(1) 
 
Solved by: Dr. Gary S Nichol 
 
Crystal Data and Experimental 
 
 
Experimental. Single yellow plate-shaped crystals of 
AL19001 were recrystallised from a mixture of 
chloroform and diethyl ether by vapour diffusion. A 
suitable crystal 0.24×0.09×0.05  mm3 was selected and 
mounted on a MITIGEN holder in Paratone oil on an Rigaku 
Oxford Diffraction SuperNova diffractometer. The crystal 
was kept at a steady T = 120.0 K during data collection. The 
structure was solved with the ShelXT (Sheldrick, 2015) 
structure solution program using the Intrinsic Phasing 
solution method and by using Olex2 (Dolomanov et al., 
2009) as the graphical interface. The model was refined 
with version 2018/3 of ShelXL (Sheldrick, 2015) using 
Least Squares minimisation. 
Crystal Data. C22H24Cl3N3O3, Mr = 484.79, monoclinic, I2 
(No. 5), a = 13.2441(2) Å, b = 8.65980(10) Å, c = 
20.3280(2) Å,  = 104.2140(10)°,  =  = 90°, V = 
2260.07(5) Å3, T = 120.0 K, Z = 4, Z' = 1, (CuK) = 3.919, 
22429 reflections measured, 4696 unique (Rint = 0.0715) 
which were used in all calculations. The final wR2 was 
0.1135 (all data) and R1 was 0.0434 (I > 2(I)). 
Compound  AL19001  
    
Formula  C22H24Cl3N3O3  
Dcalc./ g cm-3  1.425  
/mm-1  3.919  
Formula Weight  484.79  
Colour  yellow  
Shape  plate  
Size/mm3  0.24×0.09×0.05  
T/K  120.0  
Crystal System  monoclinic  
Flack Parameter  -0.007(8)  
Hooft Parameter  -0.004(5)  
Space Group  I2  
a/Å  13.2441(2)  
b/Å  8.65980(10)  
c/Å  20.3280(2)  
/°  90  
/°  104.2140(10)  
/°  90  
V/Å3  2260.07(5)  
Z  4  
Z'  1  
Wavelength/Å  1.54184  
Radiation type  CuK  
min/°  3.618  
max/°  76.076  
Measured Refl.  22429  
Independent Refl.  4696  
Reflections with I > 
2(I)  
4622  
Rint  0.0715  
Parameters  301  
Restraints  12  
Largest Peak  0.283  
Deepest Hole  -0.377  
GooF  1.040  
wR2 (all data)  0.1135  
wR2  0.1130  
R1 (all data)  0.0437  




Figure 16: The asymmetric unit of AL19001. Displacement ellipsoids are at the 50% probability level. Disorder 








Separating the diastereomeric hydroxy-pyrroloindoles 71 and dia-71 proved particularly 
challenging and required extensive optimisation. A table of Rf values for the two diastereomers is 
included for reference. 
 
Solvent system Rf (71) Rf (dia-71) 
EtOAc 0.51 0.48 
70% EtOAc/petroleum spirits 0.29 0.23 
50% THF/petroleum spirits 0.30 0.29 
DCM 0.08 0.05 
30% MeCN/petroleum spirits 0.15 0.15 
Et2O 0.26 0.2 
90% Et2O/petroleum spirits 0.21 0.16 
1,2-dimethoxyethane 0.64 0.64 
MTBE 0.36 0.30 
77% MTBE/petroleum spirits 0.15 0.12 
i-Pr2O 0.03 0.01 
40% Acetone/petroleum spirits 0.28 0.26 
10% MeCN/CHCl3 0.18 0.15 
20% MeCN/CHCl3 0.36 0.32 
30% MeCN/CHCl3 0.42 0.37 
50% EtOAc/DCM 0.37 0.31 
50% EtOAc/CHCl3 0.33 0.27 
10% i-PrOH/Toluene 0.42 0.42 
70% EtOAc/petroleum spirits 
+1% NEt3 
0.31 0.26 
60% EtOAc/Toluene 0.32 0.27 
70% Et2O/CHCl3 0.26 0.19 
60% Et2O/Toluene 0.23 0.19 
202 
 
30% EtOAc/i-Pr2O 0.12 0.08 
40% EtOAc/i-Pr2O 0.18 0.13 
i-Pr2O 0.03 0.01 
20% CH2Cl2/i-Pr2O 0.06 0.03 
30% CH2Cl2/i-Pr2O 0.08 0.06 
40% CH2Cl2/i-Pr2O 0.11 0.07 
50% CH2Cl2/i-Pr2O 0.10 0.06 
60% CH2Cl2/i-Pr2O 0.12 0.08 
70% CH2Cl2/i-Pr2O 0.15 0.09 
80% CH2Cl2/i-Pr2O 0.12 0.09 





Appendix 5: NMR Spectra 
 
1H NMR of Compound 143 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 145 (600 MHz, CDCl3) 
 
 




1H NMR of Compound 164 (500 MHz, CD3OD) 
 
 




1H NMR of Compound 148 (500 MHz, CD2Cl2) 
 
 




1H NMR of Dehydrodeoxy-brevianamide E (9) (500 MHz, CDCl3) 
 
 




1H NMR of Dehydro-brevianamide E (71) (500 MHz, CDCl3) 
 
 




1H NMR of Compound dia-71 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 254 (601 MHz, CDCl3) 
 
 




1H NMR of Brevianamide A (1) (500 MHz, CDCl3, ~3.0 mg/mL) 
 
 




1H-1H COSY of Brevianamide A (1) (CDCl3) 
 
 




1H-13C HMBC of Brevianamide A (1) (CDCl3) 
 
 










1H NMR of Brevianamide A (1) (500 MHz, (CD3)2SO) 
 
 





1H-1H COSY of Brevianamide A (1) ((CD3)2SO) 
 
 




1H-13C HMBC of Brevianamide A (1) ((CD3)2SO) 
 
 




1H NMR of Brevianamide B (2) (500 MHz, CDCl3) 
 
 




1H NMR of Brevianamide B (2) (500 MHz, (CD3)2SO) 
 
 




1H-1H COSY of Brevianamide B (2) ((CD3)2SO) 
 
 




1H-13C HMBC of Brevianamide B (2) ((CD3)2SO) 
 
 




1H NMR of Compound 272 (500 MHz, (CD3)2SO) 
 
 




1H NMR of Compound 147 (500 MHz, CDCl3) 
 
 




1H NMR of 3-Chloro-3-methyl-1-butyne 151 (500 MHz, CDCl3) 
 
 




1H NMR of 1,1-Dimethylallene 152 (500 MHz, CDCl3) 
 
 




1H NMR of t-BuOCl (500 MHz, CDCl3) 
 
 




1H NMR of Compound 149 (400 MHz, (CD3)2SO) 
 
 




1H NMR of Compound 156 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 159 as a Major Constituent (500 MHz, CDCl3) 
 
 





1H-1H COSY of Compound 159 as a Major Constituent ((CD3)2SO) 
 
 










1H NMR of Compound 158 (600 MHz, CDCl3) 
 





1H NMR of Compound 161 (500 MHz, CD3OD) 
 
 




1H NMR of Compound 182 (600 MHz, CD3CN) 
 
 




1H-1H COSY of Compound 182 (CD3CN) 
 
 









1H NMR of Compound 194 (500 MHz, CD3CN) 
 
 




1H NMR of Compound 206 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 207  (601 MHz, CHCl3) 
 
 




1H NMR of Compound 212 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 213 (601 MHz, CDCl3) 
 
 




1H NMR of Compound 227 (500 MHz, CDCl3) 
 
 




1H NMR of Compound 131 (500 MHz, CDCl3) 
 
 




1H NMR of Brevianamide K (10) (500 MHz, CDCl3)  
 
 




1H NMR of Compound 239 (500 MHz, CDCl3)  
 
 




1H NMR of Compound 56 (500 MHz, CDCl3)  
 
 




1H NMR of Compound 109 (500 MHz, CDCl3)  
 
 




1H NMR of Brevianamide X (16) (500 MHz, (CD3)2SO)  
 
 




1H-1H COSY of Brevianamide X (16) ((CD3)2SO) 
 
 




1H-13C HMBC of Brevianamide X (16) ((CD3)2SO) 
 
 




1H NMR of Depyrano-sclerotiamide’ (235) (500 MHz, CDCl3)  
 
 




1H NMR of Compound 113 (500 MHz, CDCl3) 
 
 




1H NMR of Compound dia-113 (500 MHz, CDCl3) 
 
 




1H NMR of Brevianamide Y (17) (601 MHz, (CD3)2SO) 
 
 




1H-1H COSY of Brevianamide Y (17) ((CD3)2SO) 
 
 




1H-13C HMBC of Brevianamide Y (17) ((CD3)2SO) 
 
 




1H NMR of Compound 253 (500 MHz, (CD3)2SO) 
 
 




1H-1H COSY of Compound 253 ((CD3)2SO) 
 
 




1H-13C HMBC of Compound 253 ((CD3)2SO) 
 
 




1H NMR of Compound ent-261 (500 MHz, CDCl3) 
 
 




1H NMR of Compound ent-74 (500 MHz, (CD3)2SO) 
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